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Abstract 
Currently, the field of mammalian membrane protein structural biology is in its 
infancy. Existing technologies and experiences have shown that it is possible to 
obtain  the  structures  of  mammalian  membrane proteins if sufficient work and 
thought has been invested. However, there is still an urgent need to develop new 
methodologies and approaches to improve all aspects of this important area of 
biological research. Here, a series of novel technologies for the overproduction, 
purification and crystallisation of human membrane proteins are described which 
have  been  tested  with  a  representative  member  from  each  of  the  G-protein 
coupled receptor (adenosine 2a receptor (A2aR)) and membrane enzyme (sterol 
isomerase (SI)) superfamilies. 
The  methylotrophic  yeast  Pichia  pastoris  is  an  excellent  host  cell  for  the 
overproduction  of  recombinant  proteins  including  membrane  proteins  of 
mammalian origin. However, the commercially available expression vectors are 
far from what is required to maximise the production levels as well as simplify 
the detergent extraction and purification of human membrane proteins. Here, a 
series  of  related  expression  constructs  were  made  that  had  different 
combinations of tags at both ends of the recombinant protein. The final optimised 
expression vectors had a C3 protease-iLOV-biotin acceptor-His10 (CLBH) tag fused 
to the C-terminus of the recombinant protein. The -CLBH vectors gave high level 
production of both test proteins (one Nin – hSI; one Nout – hA2aR) that could be 
rapidly  purified  to  homogeneity  using  a  generic  protocol.  The  position  of  the 
His10  tag  did  not  affect  the  expression  level  of  the  recombinant  protein.  In 
contrast,  fusion  of  the  biotin  acceptor  domain  to  the  C-terminus  of  the 
recombinant  protein  increased  its  expression  by  a  factor  of  between  2-4.  The 
biotin  acceptor  domain  could  also  be  fully  biotinylated  in  vitro  using 
recombinantly expressed biotin ligase allowing purification/immobilisation of the 
target protein with streptavidin beads. Removal of the expression/ purification 
tags from the recombinant proteins with C3 protease occurred more efficiently 
than when TEV protease was used.      iv 
An optimised protocol was developed that gave maximal production of our target 
proteins  in  fermenter  culture  at  an  induction  temperature  of  22°C.  Care  was 
taken  to  find  a  methanol  feed  rate  that  gave  the  highest  levels  of  protein 
production without causing the accumulation of excess methanol in the culture 
(which is known to be toxic to the yeast). Using this protocol it was possible to 
make both hSI and hA2aR with a production level >10 mg of recombinant protein 
per litre of culture. 
As most MPs are colourless, target protein identification is usually performed by 
methods  such  as  radioligand  binding  and/or  Western  blotting.  However,  these 
techniques  can  be  time-consuming,  use  a  lot  of  protein  and  do  not  give  any 
information  on  the  aggregation  state  of  the  protein  in  detergent  solution. 
Previously,  it  has  been  shown  that  the  processes  of  identifying  and  analysing 
membrane proteins in detergent solution can be accelerated by attaching green-
fluorescent protein to the C-terminus of the recombinant MP. Here, the potential 
of  the  recently  described  iLOV  fluorescence  tag  for  membrane  protein 
applications was assessed. iLOV was shown to be an useful tool for optimising 
processes such as yeast clonal selection, protein production in fermenter culture, 
detergent and construct screening as well as tracking recombinant MPs through 
the purification process. Of note, the iLOV tag allowed a direct assessment of the 
stability  and  dispersity  state  of  both  target  MPs  in  a  range  of  detergents  by 
fluorescence size exclusion chromatography (FSEC). Using this approach, it was 
shown  that  wild-type  hA2aR  solubilised  using  a  combination  of  dodecyl-βD-
maltoside  (DDM)  and  cholesteryl-hemisuccinate  (CHS)  aggregated  during 
purification on a Ni
2+ column. Furthermore, it was shown that the hA2aR agonist-
conformationally-fixed mutant Rag23 is stable in DDM without any CHS present. 
Moreover,  Rag23  was  found  to  be  monodisperse  in  a  series  of  short-chain 
detergents  (decyl-βD-maltoside,  nonyl-βD-maltoside  (NM)  and  β-octylglucoside) 
suggesting that this mutant is well-suited to structural studies. SI was remarkably 
robust in short chain detergents demonstrating a reasonable level of stability in 
the short chain detergent NM. The FSEC experiments showed that wild-type SI has 
considerably  higher  intrinsic  stability  than  native  hA2aR  suggesting  that     v 
membrane enzymes will prove to be more amenable to structural analysis than 
GPCRs.  
Rag23 and SI were both purified to homogeneity in a simple four-step procedure: 
i) Ni
2+ purification, ii) cleavage with C3 protease, iii) reverse Ni
2+ purification and 
iv) gel-filtration chromatography. A buffer/salt screen was devised that allowed 
those conditions where SI had maximal thermostability in detergent-solution to be 
identified. SI was found to have greatest stability in sodium phosphate buffer at 
acidic pH. Using this information, it was possible to purify monodisperse SI in DM 
suggesting  that  this  protein  may  make  an  excellent  candidate  for  structural 
studies too. 
Crystallisation  trials  with  SI  were  performed  using  the  commercially  available 
sparse  matrix  screen  MemSys/MemStart.  In  addition,  a  lipidic-sponge  phase 
sparse-matrix  crystallisation  screen  that  was  developed  in  collaboration  with 
Prof.  Richard  Neutze  (University  of  Chalmers,  Sweden)  was  tested  using  SI. 
Cholesterol could be incorporated into all of the sponges that make up the screen 
upto  a  concentration  of  10%.  (This  is  important  as  the  activity  of  many 
mammalian membrane proteins is cholesterol-dependent). To date, no diffracting 
crystals of SI have been obtained with either the conventional or lipidic-sponge 
phase crystallisation approaches. 
In short, a series of novel technologies/methodologies have been developed that 
will act as a platform for future efforts to solve the structures of a wide-range of 
human membrane proteins.     vi 
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1  Membrane protein structural biology 
1.1 Biological membranes 
Membranes  are  an  essential  component  of  all  cells  where  they  function  as 
selectively-permeable barriers. They consist of a rich mixture of lipid molecules 
and proteins (Figure 1.1). In mammalian cells, the plasma membrane physically 
separates  the  intracellular  components  from  the  extracellular  environment 
(Brown,  1998).  Moreover,  intracellular  membranes  are  used  to  form  distinct 
compartments  within  the  cell  that  perform  highly-specialised  functions  (e.g. 
mitochondria  –  oxidative  phosphorylation;  lysosome  –  protein  degradation) 
(Brown, 1998). All biological membranes are primarily composed of a thin layer 
of  amphipathic  molecules  called  phospholipids  (which  have  polar  hydrophilic 
head groups and hydrophobic tails) (Singer and Nicolson, 1972). In an aqueous 
environment the phospholipids spontaneously form bilayers with the hydrophobic 
tails sandwiched between the two hydrophilic headgroups (Figure 1.1) (Singer 
and Nicolson, 1972; Rietveld and Simons, 1998). 
 
Figure 1.1 Schematic representation of a mammalian plasma membrane 
Higher-eukaryotic membranes are a rich mixture of lipid molecules and proteins. Both peripheral 
and  integral  membrane  proteins  are  located  at  and  in  the  phospholipid  bilayer,  respectively. 
Mammalian membranes are distinct from those found in bacteria, lower eukaryotes and plants in 
that they contain cholesterol (which gives the membrane increased rigidity).   
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Although mammalian cell membranes are primarily composed of phospholipids, 
they also contain sphingolipids, glycolipids and cholesterol (Figure 1.2) (Rietveld 
and Simons, 1998). In their simplest form, phospholipids consist of a glycerol 
backbone  to  which  two  fatty  acids  and  a  phosphate  group  are  connected. 
Mammalian cells make a range of related phospholipids (phosphatidyl-choline, -
ethanolamine, -serine, -glycerol and -inositol) by attaching different headgroups 
to the core phosphate moiety (Figure 1.2). Many different fatty acids (including 
both  saturated  and  unsaturated  versions)  can  be  added  to  the  glycerol 
backbone.  The  biophysical  properties  of  the  fatty  acid  that  are  attached 
influence  both  the  thickness  and  fluidity  of  the  membrane  (Becher  and 
McIlhinney, 2005). Sphingolipids have a similar overall structure to phospholipids 
except  that  they  have  a  sphingosine  rather  than  a  glycerol  spine.  Certain 
phospho-  and  sphingo-lipids  located  on  the  extracellular  face  of  the  plasma 
membrane  have  short  carbohydrate  chains  attached  to  them  and  are  called 
glycolipids  (Figure  1.2).  Cholesterol  (Figure  1.2)  is  a  major  component  of 
mammalian  membranes  and  is  exclusively  found  in  higher  eukaryotes. 
Cholesterol  brings  rigidity  to  membranes  by  restricting  the  movement  of  the 
fatty acids in neighbouring phospholipids through its bulky four-ring structure 
(Brown and London, 1998; Chini and Parenti, 2009).  
Membranes  are  dynamic,  and  can  be  described  as  a  “fluid  mosaic”  as  they 
behave like a two-dimensional liquid in which all the lipid and protein molecules 
diffuse  to  a  greater  or  lesser  extent  (Singer  and  Nicolson,  1972).  There  are 
regions  in  mammalian  membranes  that  have  high  local  concentrations  of 
cholesterol and sphingolipids called lipid rafts (Brown and London, 1998; Brown, 
1998). Rafts are more ordered and tightly packed than the surrounding bilayer 
and  float  freely  in  the  membrane.  Rafts  function  as  specialised  membrane 
microdomains that enable certain signalling and trafficking events at the cell’s 
surface  to  be  compartmentalised  (Rietveld  and  Simons,  1998;  Simons  and 
Ikonen, 2000; Becher and McIlhinney, 2005; Epand, 2006).  
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Figure 1.2 Chemical structures of selected lipids found in mammalian membranes 
Higher-eukaryotic  membranes  contain  four  different  kinds  of  lipid  namely  phospholipids  (for 
example - phosphatidylcholine), sphingolipids (sphingomyelin), glycolipids (glucocereboside) and 
cholesterol.   
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1.2 Membrane proteins 
Proteins found on/in membranes can be classed either as peripheral or integral 
membrane  proteins  according  to  the  way  that  they  attach  to  the  membrane 
(Singer and Nicolson, 1972) (Figure 1.1). Peripheral membrane proteins (MPs) are 
located at the surface of membranes where they are anchored to them either 
directly by interacting with the lipid bilayer or indirectly via contact with an 
integral  membrane  protein.  Peripheral  MPs  can  usually  be  released  from  the 
membrane by washing with buffer of high ionic strength. In contrast, integral 
MPs  (as  their  name  suggests)  span  the  entire  membrane,  and  consist  of  two 
hydrophilic regions (that are exposed on either side of the membrane) separated 
by  a  hydrophobic  region  (that  is  buried  within  the  membrane  core).  These 
proteins can only be released from the lipid bilayer by treating the membrane 
with detergent. As integral MPs need to be coated with detergent at all times in 
aqueous  solution,  they  are  considerably  harder  to  work  compared  to  either 
soluble  of  peripheral  MPs.  As  even  mild  detergents  are  denaturants  when 
integral  MPs  are  removed  from  the  membrane  for  structural  studies  it  is  not 
uncommon for the protein to lose its functional activity (Seddon et al., 2004). 
1.3 Membrane proteins and secondary structure 
Following translation, proteins fold first into a series of defined small secondary 
structures from which a 3-dimensional shape is eventually formed. There are 
two main types of secondary structure found in all proteins called α-helix and β-
sheet, both of which are formed by hydrogen bonding between the carbonyl and 
amine groups of the protein backbone (Figure 1.3) (Kennedy, 1978). α-helices 
are more common than β-sheet, and have a right-handed coiled conformation. In 
an α-helix, every backbone N-H group donates a hydrogen bond to the backbone 
C=O group of the amino acid four residues previous (Kabsch and Sander, 1983). 
There  are  ca.  3.6  amino  acids  per  turn  of  helix  (Pauling  and  Corey,  1951a; 
Pauling et al., 1951). The other main type of secondary structure is β-sheet, and 
it  consists  of  neighbouring  β-strands  (stretches  of  polypeptide  where  the 
backbone has an almost fully-extended conformation) that are hydrogen bonded  
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to each other (Figure 1.3) (Kabsch and Sander, 1983). Where the β-strands all 
have a similar orientation the β-sheet that is formed is denoted parallel. Where 
the β-strands have alternating orientations, the β-sheet is described as being 
anti-parallel (Pauling and Corey, 1951b).  
The most common secondary structure found in integral MPs is the α-helix with a 
minimum of 17-20 residues required to span the bilayer (Kennedy, 1978; Nyholm 
et al., 2007; McLuskey et al., 2010). α-helices are energetically stable in the 
membrane as the amine and carbonyl groups of the peptide bonds are involved 
in hydrogen-bonding within the helix. The majority of the amino acids that occur 
within membrane-spanning helices tend to be hydrophobic in nature (Nyholm et 
al., 2007). The presence of proline and/or glycine residues in a helix can cause it 
to kink (as was observed in the structure of rhodopsin) (Palczewski et al., 2000). 
The  number  and  orientation  of  the  helices  traversing  the  membrane,  in 
combination with the variation of the connecting loop regions, creates a diverse 
range of membrane proteins including transporters, ion channels and receptors.  
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(B) 
 
 
 
Figure 1.3 Representation of the two main types of protein secondary structure 
(A) is an α-helix in which every backbone N-H group donates a hydrogen bond to the backbone 
C=O group of the amino acid four residues previous. There are ca. 3.6 amino acids per turn of  
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helix. (B) shows an anti-parallel β-sheet with hydrogen bond “bridges” between neighbouring β- 
strands. Hydrogen bonds are shown as black broken lines. 
Alternatively, the plasma membrane can be traversed by a large β-sheet that has 
been twisted and coiled to form a closed structure called a β-barrel (Schulz, 
2000). β-strands in β-barrels are arranged in an anti-parallel fashion with the 
first strand hydrogen bonded to the last (Kennedy, 1978; Cowan et al., 1992; 
Buchanan, 1999). Unlike transmembrane α-helices that are largely composed of 
aliphatic amino acids, the β-sheets that make up β-barrels do not have obvious 
long  hydrophobic  regions  which  makes  their  identification  from  primary 
sequence analysis alone difficult (Schulz, 2000). Furthermore, whereas α-helical 
containing integral MPs have a ubiquitous distribution, proteins that have a β-
barrel  structure  are  only  found  in  the  outer  membranes  of  gram-negative 
bacteria as well as mitochondria and chloroplasts (Schulz, 2000). 
 
1.4 History of membrane protein structural biology 
The PDB currently contains nearly 60,000 entries of which 700 are structures of 
integral membrane proteins. Of these, however, only 200-250 are regarded as 
unique structures (White, 2009; McLuskey et al., 2010). The number of integral 
membrane  protein  structures  solved  to  date  does  not  reflect  either  their 
importance in biology or indeed their natural abundance (with 30% of the genes 
in a typical genome encoding MPs) (Arora and Tamm, 2001). The slow rate at 
which MPs have had their structures determined reflects the many challenges 
that have to be overcome before crystals that diffract to high resolution are 
obtained.  These  include  the  difficulties  of  making  membrane  proteins  in  a 
heterologous  system  on  a  milligram  scale,  preventing  the  protein  from 
aggregating once it has been removed from its membrane environment as well as 
trying to find the optimal detergent for crystallisation. Furthermore, mammalian 
MPs have proved to be even more difficult to work with than bacterial MPs as 
they  are  harder  to  make  in  large  amounts  as  well  as  being  less  stable  in 
detergent  solution.  This  is  reflected  in  the  PDB  where  there  are  <20  unique  
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mammalian membrane protein structures (White, 2009; McLuskey et al., 2010). 
Having  said  this,  membrane  protein  crystallisation  is  no  longer  considered  as 
difficult, and with considerable advances in technology, ca. 30-40 new integral 
MP  structures  are  being  deposited  each  year  in  the  PDB  (Figure  1.4)  (White, 
2009).  Here,  a  brief  overview  of  the  history  of  membrane  protein  structural 
biology is presented.  
 
Figure 1.4 Progress in determining membrane protein structures 
(A) The number of new structures reported each year since 1985. (B) A plot of the cumulative 
number of membrane protein structures solved (y-axis) versus the number of years since the first 
integral  MP  structure  was  solved  (x-axis).  The  number  of  new  membrane  protein  structures  is 
increasing exponentially on a yearly basis. Figure adapted from (White, 2009). 
In  1975,  bacteriorhodopsin  became  the  first  membrane  protein  to  have  its 
structure  elucidated.  Using  low-resolution  (7  Å)  electron  microscopy  data 
Richard  Henderson  and  Nigel  Unwin  were  able  to  unequivocally  show  that 
bacteriorhodopsin consisted of seven transmembrane α-helices (Henderson and 
Unwin, 1975). However, at this resolution, it was not possible to visualise the 
molecular  details  of  bacteriorhodopsin’s  structure.  It  was  another  ten  years 
before the first membrane protein structure at atomic resolution was obtained 
when  Johann  Deisenhoffer  and  Hartmut  Michel  solved  the  structure  of  the 
reaction  centre  (RC)  from  the  purple  photosynthetic  bacteria  
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Rhodopseudomonas viridis to a resolution of 3 Å (Figure 1.5) (Deisenhofer et al., 
1984;  Deisenhofer  et  al.,  1985).  This  landmark  achievement  was  recognised 
when Michel, Deisenhoffer and Huber were awarded the Nobel Science prize for 
Chemistry  in  1988.  The  RC  is  a  protein-pigment  complex  of  ca.  145  kDa 
consisting of three different sub-units (H, L, and M). The L and M subunits form 
the core of the RC and have five transmembrane α helices each (Michel, 1982). 
The H sub-unit has just one transmembrane helix which interacts with both L 
and M, and its globular domain is located in the bacteria’s cytoplasm. The RC 
was solved in complex with a cytochrome that interacted with the periplasmic 
side of the core formed from the L and M sub-units (Deisenhofer and Michel, 
1989).  The  protein  acts  as  a  scaffold  holding  the  pigments  at  the  correct 
geometry to allow efficient charge separation and electron transfer. 
 
Figure 1.5 The first high-resolution structure of a membrane protein  
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The photosynthetic reaction centre from the purple bacteria Rhodopseudomonas viridis (accession 
code 1PRC) was the first membrane protein to have its structure solved to atomic resolution by X-
ray  crystallography  (Deisenhofer  et  al.,  1984;  Deisenhofer  et  al.,  1985).  The  heavy  chain  is 
coloured black, medium chains are red, light chains are yellow and the globular domain is coloured 
green. 
Since this RC structure, several other photosynthetic integral MP complexes from 
purple bacteria have had their structures determined including the RC from Rb. 
sphaeroides  (Yeates  et  al.,  1987;  Stowell  et  al.,  1997),  light  harvesting 
complexes from Rps. acidophila (McDermott et al., 1995; McLuskey et al., 2001) 
and Rs. molischianum (Koepke et al., 1996), as well as the “core” complex from 
Rps. palustris (Roszak et al., 2003). In addition, structures of photosystem (PS) II 
(Zouni  et  al.,  2001;  Kamiya  and  Shen,  2003;  Ferreira  et  al.,  2004)  and  PSI 
(Krauss et al., 1996; Schubert et al., 1997) from cyanobacteria, as well as PSI 
(Ben-Shem  et  al.,  2003;  Amunts  et  al.,  2007)  and  light-harvesting  complex  II 
(LHCII)  (Liu  et  al.,  2004;  Standfuss  et  al.,  2005)  from  plants  (all  integral 
membrane proteins) have been determined to atomic resolution. The structures 
of  these  photosynthetic  complexes  have  given  detailed  insights  into  the 
molecular mechanisms of light capture, charge separation and water-splitting 
which occur in nature.  
Arguably, the most important process that occurs within cells is the production 
of  adenosine  triphosphate  (ATP)  by  oxidative  phosphorylation.  This  process 
occurs in and across the inner mitochondrial membrane (IMM) (where both the 
electron carriers and ATP synthase are located). Electrons are transferred from 
either NADH or FADH2 to molecular oxygen which is reduced to water. Electron 
transport  through  complexes  I  (NADH  dehydrogenase),  III  (Cytochrome  bc1 
complex) and IV (Cytochrome oxidase) results in H
+ pumping across the IMM. The 
proton-gradient  which  results  is  used  to  drive  the  formation  of  adenosine-
triphosphate (ATP) from inorganic phosphate and adenosine diphosphate (ADP) 
via  the  integral  membrane  protein  ATP  synthase.  The  structures  of  all  four 
electron transfer complexes (I-IV) (Iwata et al., 1995; Tsukihara et al., 1996; 
Iwata, 1998; Iwata et al., 1998; Yankovskaya et al., 2003; Hunte et al., 2010) 
and ATP synthase (Abrahams et al., 1994; Stock et al., 1999) (Figure 1.6) have  
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all been solved to atomic resolution. The structure of ATP synthase was solved 
by John Walker and co-workers, for which he was awarded the Nobel Prize for 
Chemistry in 1997. ATP synthase has three distinct domains:  the transmembrane 
rotor domain, a globular catalytic domain and a rod subunit (comprising of two 
anti-parallel  alpha  helices)  that  connects  the  transmembrane  and  catalytic 
regions  (Stock  et  al.,  1999).  Proton  translocation  through  the  rotor  domain 
causes the catalytic region to turn, which drives the formation of ATP. 
 
Figure 1.6 The 3-dimensional structure of F1-ATP synthase 
ATP synthase (accession code 2XOK) is composed of a number of subunits forming the proton 
translocating transmembrane domain (coloured black) and the catalytic portion which is comprised 
of α (red), β (green), γ (blue) and ε (yellow/orange) subunits (Stock et al., 1999).  
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β-barrel containing proteins are found in the outer membranes of gram-negative 
bacteria, mitochondria and chloroplasts where they have functions as diverse as 
ion  transport,  passive  nutrient  uptake,  membrane  anchors,  membrane-bound 
enzymes  as  well  as  defense  against  attack  proteins  (Buchanan,  1999;  Schulz, 
2000). Membrane protein β-barrels contain between 8 and 22 strands, and the 
overall pore size depends on the number of β-strands that make up the barrel 
(Buchanan,  1999;  Schulz,  2000).  The  first  membrane  protein  with  a  β-barrel 
motif to have its structure solved was porin from Rb. capsulatus (Figure 1.7) 
(Weiss and Schulz, 1992). Porin is a 16-stranded β-barrel that associates to form 
homo-trimers, and carries out passive diffusion of small (ca. 600 Da) molecules. 
OmpA and OmpX both contain eight stranded barrels (Figure 1.7) (Pautsch and 
Schulz, 1998; Vogt and Schulz, 1999). These proteins are not thought to have any 
channel activity but rather function as transmembrane anchors. The structures 
of  other  bacterial  β-barrel  containing  MPs  are  discussed  in  (Buchanan,  1999; 
Schulz,  2000).  Recently,  structures  of  the  voltage-dependent  anion  channel 
(VDAC) (the major pathway for entry and exit of metabolites across the outer 
mitochondrial  membrane)  from  human  (Bayrhuber  et  al.,  2008)  and  mouse 
(Ujwal et al., 2008) have been solved to atomic resolution. The VDACs contain a 
19-stranded β-barrel.  
Although membrane proteins that contain β-barrel structures are relatively rare, 
there are a large variety of protein families that have transmembrane α-helical 
domains. These include transporters, water and ion channels, enzymes as well as 
G-protein coupled receptors.  
The  major  facilitator  superfamily  (MFS)  is  the  largest  family  of  active 
transporters,  comprising  one  quarter  of  all  transport  proteins  (Saier  et  al., 
1999). These proteins overcome the thermodynamically unfavourable process of 
transporting a substrate across the membrane against a concentration gradient 
by either utilising the free energy stored in an electrochemical ion (e.g. Na
+, H
+) 
gradient or coupling the primary transport event to the movement of a second 
substrate down a concentration gradient. There are three main types of MFS 
protein : i) uniporters - that translocate a single substrate across the membrane,  
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ii) symporters – that transport two or more substrates across the membrane in 
the same direction (e.g. the lactose/H
+ symporter LacY), and iii) antiporters – 
that transfer two or more substrates across the membrane in opposing directions 
(e.g.  the  inorganic  phosphate/glycerol-3-phosphate  antiporter  GlpT))  (Law  et 
al., 2008).  
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(A) 
 
(B) 
 
(C) 
 
Figure 1.7 Examples of membrane proteins with a β-barrel type structure 
(A) porin (2OMF), (B) OmpA (1BXW), and (C) OmpX (1QJ8). ( Weiss and Schulz, 1992; Pautsch 
and Schulz, 1998; Vogt and Schulz, 1999)   
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The first member of the MFS family to have its structure solved was LacY from E. 
coli (to a resolution of 3.5 Å) (Figure 1.8(A)) (Abramson et al., 2003 a,b). Since 
then,  numerous  bacterial  MFS  transporters  have  had  their  structures  solved 
including GlpT (Huang et al., 2003), the multidrug transporters EmrD (Yin et al., 
2006) and EmrE (Chen et al., 2007), the Na
+/H
+ antiporter NhaA (Figure 1.8 (B)) 
(Hunte  et  al.,  2005),  the  sodium-dependent  glutamate  transporter  GltPh 
(Yernool et al., 2004), the leucine transporter LeuT (Yamashita et al., 2005) and 
the  zinc  transporter  YiiP  (Lu  and  Fu,  2007).  As  yet,  no  mammalian  MFS 
transporter has had its structure solved. 
 (A) 
 
(B) 
 
Figure 1.8 Structures of bacterial members of the MFS family 
(A) the lactose/H
+ symporter, LacY (1PV7) has a large internal hydrophilic cavity which opens to 
the cytoplasm (Abramson et al., 2003 a,b) and (B) the Na
+/H
+ antiporter, NhaA (1BL8) has a water 
pore on the outer side (Hunte et al., 2005). 
ATP-binding  cassette  (ABC)  transporters  use  the  energy  released  on  ATP 
hydrolysis  to  transport  specific  substrates  across  the  membrane.  All  ABC 
transporters  have  a  four-domain  structure  in  common  consisting  of  two 
nucleotide binding domains (NBD), that hydrolyse ATP and drive the transport 
reaction,  and  two  transmembrane  domains  (TMD)  that  form  the  translocation 
pathway (Higgins, 1992; Rees et al., 2009). The first ABC transporter to have its  
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structure determined was the vitamin B12 importer from E. coli (BtuCD) to a 
resolution of 3.2 Å (Figure 1.9) (Locher et al., 2002). Since then, a further five 
bacterial  (including  the  multidrug  resistance  protein  Sav1866)  (Dawson  and 
Locher, 2006; Hollenstein et al., 2007 ; Oldham et al., 2007; Pinkett et al., 
2007; Ward et al., 2007) and one mammalian (P-glycoprotein) (Aller et al., 2009) 
ABC transporters have had their structures solved. 
 
Figure  1.9  The  bacterial  ABC  transporter  that  transfers  vitamin  B12  across  the  inner 
cytoplasmic membrane 
The α helices (coloured blue through green) create the transmembrane region of BtuC domains 
while the BtuD regions (coloured yellow through red) are involved in ATP-binding. In combination 
these four domains complete the BtuCD structure (accession code 1L7V) (Locher et al., 2002). 
Aquaporins  are  water-specific  membrane  channels  that  allow  water  to  move 
freely  and  bi-directionally  across  the  membrane  (Meinild  et  al.,  1998). 
Structures for bacterial (GlpF, AqzP) (Fu et al., 2000; Savage et al., 2003), plant 
(Tornroth-Horsefield et al., 2006) and mammalian (AQP1, 4 and 5) (Murata et 
al., 2000; Horsefield et al., 2008; Ho et al., 2009) aquaporins are known (Figure 
1.10).  
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Ion  channels  allow  the  selective  passage  of  particular  ions  (e.g  Na
+,  K
+,  Cl
-) 
across membranes in response to signals such as ligand-binding (e.g. glutamate, 
GABA)  or  changes  in  transmembrane  voltage.  All  ion  channels  have  a  similar 
architecture with multiple sub-units arranged around a central pore (where the 
ion conduction pathway is located). The first ion channel to have its structure 
determined was the K
+ channel from the bacteria S. lividans (KcsA) (Doyle et al., 
1998). Since this ground-breaking achievement, a plethora of other bacterial ion 
channels have had their structures solved including the Ca
2+-gated K
+ channel 
from  M.  thermoautotrophicum  (MthK)  (Jiang  et  al.,  2002a),  the  Kv  from  A. 
pernix  (KvAP)  (Jiang  et  al.,  2002b),  the  inward-rectifying  K
+  channel  from 
Burkholeria pseudomallei (KirBac1.1) (Kuo et al., 2003), the non-selective cation 
channel (Shi et al., 2006), the large and small mechanosensitive channels from 
M. tuberculosis (MscL) (Chang et al., 1998) and E. coli (MscS) (Bass et al., 2002), 
respectively as well as the ClC Cl
- channels from S. enterica and E. coli (Dutzler 
et al., 2002; Dutzler et al., 2003). Several ion channels of mammalian origin 
have  also  been  determined  including  rat  Kv1.2  (a  member  of  the  K
+  Shaker 
channel family) (Long et al., 2005), chicken Kir2.2 (Tao et al., 2009), the human 
high-conductance voltage and Ca
2+-activated (BK) channel (Yuan et al., 2010), 
the chicken acid sensing ion channel (Jasti et al., 2007), the zebrafish ATP-gated 
P2X(4) ion channel (Kawate et al., 2009) and the rat AMPA-sensitive ionotropic 
glutamate  receptor  (GluA2)  (Sobolevsky  et  al.,  2009).  The  abundance  of  ion 
channel structures in the PDB suggests that they are considerably more tractable 
to work with than most other membrane protein superfamilies.  
The  major  mammalian  G-protein  coupled  receptor  superfamily  has  proved 
remarkably resistant to crystallisation. However, several GPCR structures have 
recently been solved and deposited in the PDB. These include bovine rhodopsin 
(Palczewski et al., 2000), the human β2-adrenergic receptor (Cherezov et al., 
2007;  Rasmussen  et  al.,  2007),  turkey  β1  adrenergic  receptor  (Warne  et  al., 
2008) as well as the human adenosine 2a receptor (Jaakola et al., 2008). These 
are discussed in more detail in Section 2.  
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In short, there are now a substantial (several hundred), and increasing, number 
of  bacterial  membrane  proteins  in  the  PDB  with  rather  few  (several  tens)  of 
mammalian origin. This reflects the extra difficulties in obtaining high quality, 
diffracting crystals of membrane proteins from mammalian cells as compared to 
those from bacteria.  
(A) 
 
(B) 
 
(C) 
 
(D) 
 
Figure  1.10  Structures  of  selected  water  and  ion  channels  showing  the  ways  that  the 
aqueous pore can be organised  
The human water channels (A) aquaporin 1, AQP1 (accession code 1FQY) and (B) aquaporin 5, 
AQP5 (3D9S) (Murata et al., 2000; Ho et al., 2009). (C) The potassium channel from Streptomyces  
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lividans,  KcsA  (1BL8)  (Doyle  et  al.,  1998).  (D)  The  E.  coli  mechanosensitive  channel  of  small 
conductance, MscS (2OAU) (Bass et al., 2002). 
1.5 The problems associated with solving the structures 
of mammalian membrane proteins 
Before  the  structure  of  any  mammalian  membrane  protein  can  be  solved, 
several major obstacles need to be overcome. Firstly, milligram quantities of the 
protein of interest are required for either crystallographic or nuclear magnetic 
resonance  experiments  (Sarramegna  et  al.,  2003).  In  certain  instances, 
mammalian membrane proteins exist in native tissues at sufficiently high levels 
to allow their purification to homogeneity e.g. rhodopsin. However, this is not 
the case for the vast majority of mammalian membrane proteins which need to 
be overexpressed in an appropriate host cell system before they can be purified 
(Seddon et al., 2004). Secondly, the mammalian MP needs to be isolated from its 
native  membrane  environment  by  detergent  solubilisation.  The  choice  of 
detergent  is  critical  as  mammalian  MPs  are  very  unstable  and  are  readily 
denatured by detergent (Lacapere et al., 2007). Thirdly, the protein has to be 
purified  to  homogeneity  prior  to  structural  analysis  in  a  monodisperse  state 
keeping its activity intact. However, given their poor stability, many mammalian 
membrane proteins tend to aggregate during the purification process (Gutmann 
et  al.,  2007).  Finally,  mammalian  membrane  proteins  (like  all  membrane 
proteins)  have  relatively  small  exposed  polar  surface  areas  making  them 
considerably harder to crystallise than soluble proteins.  
 
1.6 Engineering membrane proteins for crystallisation  
Given that membrane proteins are so difficult to crystallise, mammalian ones in 
particular, it is imperative that the protein to be used in the crystallisation trials 
is  largely  rigid,  thermostable,  homogenous  and  has  sufficient  polar  surface 
exposed  to  allow  the  formation  of  crystal  contacts.  As  most  wild-type 
mammalian  membrane  proteins  do  not  fulfil  all  of  these  criteria,  it  is  often  
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necessary  to  engineer  the  target  protein  to  increase  the  probability  of  it 
crystallising. There are a variety of techniques that can be employed to increase 
the stability and rigidity of target proteins as well as their homogeneity. These 
include  using  deglycosylated  mutants  (Fraser,  2006),  removing  disordered 
regions  from  the  protein  (Cherezov  et  al.,  2007),  introducing  single  point 
mutations  to  increase  its  stability  (Standfuss  et  al.,  2007)  as  well  as  adding 
binding  partners  to  “lock”  the  target  protein  into  a  particular  conformation 
(often  increasing  the  available  polar  surface  area  for  lattice  contacts) 
(Palczewski et al., 2000; Rasmussen et al., 2007). With all of these strategies, 
however,  it  is  possible  to  engineer  mutants  that  have  non-physiological 
properties.  Therefore,  care  must  be  taken  when  trying  to  create  modified 
proteins better suited to crystallisation trials so that they retain their biological 
activity also. 
 
1.6.1 Removing regions predicted to be disordered 
It is not uncommon for proteins involved in signalling (eg p53, GPCRs) to have 
large regions that are intrinsically disordered. Well-ordered crystals cannot be 
obtained for proteins that have extensive flexible regions (Warne et al., 2009). 
Utilising disorder predictor programs such as RONN (University of Oxford) likely 
site(s) of disorder within the target protein can be identified and removed by 
mutagenesis  (Yang  et  al.,  2005).  For  example,  the  C-terminal  tails  of  most 
GPCRs are highly disordered and are routinely removed by researchers trying to 
make a crystallisable construct (Warne et al., 2003; Fraser, 2006; Rasmussen et 
al.,  2007;  Rosenbaum  et  al.,  2007;  Magnani  et  al.,  2008).  Not  unexpectedly, 
removal of disordered regions from a target protein can improve its expression 
by reducing the number of protease sensitive sites within it (Warne et al., 2003).   
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1.6.2 Increasing  the  thermostability  and  therefore  the 
crystallisability of membrane proteins     
Most  mammalian  membrane  proteins  that  function  at  the  cell  surface  are 
glycosylated.  Although  not  necessarily  an  impediment  to  crystallisation,  it  is 
often desirable to remove the glycosylation site(s) from the target protein by 
mutagenesis  to  ensure  that  the  final  purified  sample  has  negligible 
heterogeneity. Although many glycosylation-deficient mutants retain wild-type 
properties (Fraser, 2006), this is not always the case (Tate, 2001).  
The contribution that individual amino acids make to the thermostability of a 
membrane  protein  can  be  readily  determined  by  combining  alanine-scanning 
mutagenesis  with  an  appropriate  activity  assay  following  partial  heat-
denaturation of the Ala mutants (for example DAG kinase (Gorzelle et al., 1999), 
the  β1-adrenergic  (Serrano-Vega  et  al.,  2008)  and  adenosine  2a  receptors 
(Magnani et al., 2008)). Once the amino acids that are critical for stability have 
been  identified,  it  is  possible  to  combine  several  mutations  to  make  a 
temperature-  and  detergent-resistant  mutant  suitable  for  crystallisation 
(Standfuss  et  al.,  2007).  Proteins  can  also  be  selectively  engineered  to  have 
increased  stability,  through  the  introduction  of  cysteine  residues  that  form 
disulphide bonds fixing the protein’s conformation (Blois and Bowie, 2009).  
An  alternative  way  that  the  thermostability  of  a  membrane  protein  can  be 
increased  is  through  the  addition  of  a  specific  ligand  (eg  inhibitor,  agonist, 
antagonist).  Indeed,  the  recent  structures  of  the  β1-,  β2-adrenergic  and 
adenosine 2a receptors were all solved in the presence of a high-affinity (pico- 
to nano-molar) inverse agonist (Cherezov et al., 2007; Rasmussen et al., 2007; 
Rosenbaum et al., 2007; Hanson et al., 2008; Jaakola et al., 2008). One of the 
reasons that rhodopsin has proved considerably more tractable to crystallisation 
than ligand-activated GPCRs is that in the ground state its ligand, 11-cis-retinol, 
is  covalently  bound  to  it  making  rhodopsin  substantially  more  thermostable 
compared to other GPCRs (Standfuss et al., 2007).  
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To  increase  the  probability  of  getting  a  membrane  protein  to  crystallise 
strategies  for  increasing  their  polar  surface  area  have  been  developed.  For 
example, cytochrome oxidase (Hunte and Michel, 2002) and the β2 adrenoceptor 
(Rasmussen et al., 2007) have been successfully crystallised in complex with an 
antibody  binding  fragment  (FAb)  (Figure  1.11  (coloured  red)).  The  rationale 
behind this approach is that when the FAb binds to the target protein it creates a 
complex with a large polar surface area that can readily form lattice contacts 
(Hunte and Michel, 2002). Although this approach has been successfully used to 
obtain  crystal  structures  of  selected  membrane  proteins  it  is  not  widely 
practiced as generating FAb is both expensive and time-consuming.  
A related approach has recently been developed by Stevens and co-workers (The 
Scripps Research Institute, California) where, to improve the crystallisability of 
GPCRs, they largely replaced the receptor’s third intracellular loop (IL3) with 
T4-lysozyme. This GPCR-fusion protein has a large hydrophilic domain useful for 
forming crystal contacts. This approach has been used to solve the structures of 
the β2-adrenoceptor (Figure 1.11 (coloured blue)) (Cherezov et al., 2007) and 
the adenosine 2a receptor (Jaakola et al., 2008) to atomic resolution.  
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Figure  1.11  Overlay  of  the  two  structures  of  the  ligand-activated  GPCR,  β2-adrenergic 
receptor, that have been solved using strategies to increase their polar surface area 
Displayed in red is a complex of the human β2-adrenergic receptor in complex with a Fab that binds 
to IL3 (accession code 2R4R); while blue shows a chimera consisting of the human β2-adrenergic 
receptor with T4-lysozyme instead of IL3 (accession code 2RH1). 
1.7 Heterologous production of mammalian membrane 
proteins 
Mammalian membrane protein expression can be performed in a variety of host 
cells  [reviewed  in  (Sarramegna  et  al.,  2003)]  including  bacteria  (Weiss  and 
Grisshammer,  2002),  yeast  (Reilander  and  Weiss,  1998;  Jahic  et  al.,  2006), 
insect  (Cherezov  et  al.,  2007;  Rasmussen  et  al.,  2007)  and  mammalian  cells 
(Mize et al., 2008). For any given protein, the choice of system will depend on a 
number of factors including the availability of specialised expression vectors and  
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strains,  budget  as  well  as  any  post-translational  modifications  required  for 
maintaining the protein’s functionality (Sarramegna et al., 2003).  
Although  bacterial  expression  systems  are  routinely  used  to  make  soluble 
mammalian proteins their use with membrane proteins from higher-eukaryotes is 
rather more restricted. This is not surprising given that bacteria cannot perform 
many of the post-translational modifications that occur in mammalian cells (e.g. 
glycosylation,  palmitylation)  that  are  often  required  for  full  activity  of  the 
membrane  protein.  Furthermore,  as  the  lipid  composition  of  bacterial 
membranes is very different from that in higher eukaryotic cells it is not possible 
to functionally produce those mammalian membrane proteins that have specific 
lipid requirements in bacteria. This said, however, E. coli has been used to make 
both  integral  (including  GPCRS)  (Tucker  and  Grisshammer,  1996;  Weiss  and 
Grisshammer, 2002) and peripheral mammalian membrane proteins (e.g. 11β-
hydroxylase) (Zollner et al., 2008) in milligram amounts. The main advantages of 
making mammalian membrane proteins in bacteria are the short (ca. 20 min) 
doubling-time of the host cell and the use of cheap media (Sarramegna et al., 
2003).  
Yeasts  (in  particular  Saccharomyces  cerevisiae  and  Pichia  pastoris)  are 
commonly used to make mammalian membrane proteins as they combine a short 
generation time (ca. 2 h) on cheap growth media with their ability to perform 
many  of  the  post-translational  modifications  that  occur  in  higher  eukaryotes 
(Reilander  and  Weiss,  1998).  The  methylotrophic  yeast  P.  pastoris  has  been 
shown to be particularly useful for making a wide-range of human membrane 
proteins including GPCRs, ion channels, transporters and pumps (Weiss et al., 
1995; Weiss et al., 1998; Grunewald et al., 2004; Andre et al., 2006; Fraser, 
2006; Shukla et al., 2007; Horsefield et al., 2008 ; Aller et al., 2009 ; Ho et al., 
2009; Tao et al., 2009). The main advantages of using P. pastoris are that it has 
a very strong, methanol-inducible promoter (Alcohol Oxidase 1 (AOX1)) which 
drives the production of high levels of recombinant protein (Hartner and Glieder, 
2006; Jahic et al., 2006) as well as its ability to grow to high cell densities in 
fermenter culture (>10
9 cells/ml) (Fantoni et al., 2007). One drawback of using 
yeast, however, is that its membranes contain ergosterol (the principal fungal  
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sterol) instead of the mammalian one, cholesterol. This lack of cholesterol is 
thought  to  have  prevented  the  functional  expression  of  certain  human 
membrane proteins in yeast including the serotonin transporter (Tate, 2001) and 
the µ-opioid receptor (Lagane et al., 2000). 
Insect cells that have been infected with recombinant baculovirus are useful for 
expressing  a  number  of  mammalian  membrane  proteins.  Indeed,  all  of  the 
ligand-activated GPCRs that have been crystallised to date have been made in 
insect cells (Cherezov et al., 2007; Rasmussen et al., 2007; Jaakola et al., 2008; 
Warne et al., 2008). Other advantages of this system are that they perform a 
simple  form  of  glycosylation  as  well  as  growing  to  cell  densities  of  10
7-10
8 
cells/ml  in  spinner  flasks  (Sarramegna  et  al.,  2003).  Although  the  media  for 
growing  insect  cells  costs  substantially  more  than  that  for  either  bacteria  or 
yeast, it is also significantly less expensive than that for mammalian cells. 
In  many  respects,  mammalian  cells  are  the  ideal  host  system  for  making 
mammalian  membrane  proteins  as  the  lipid  composition  of  the  membrane  is 
exactly what the recombinant proteins require as well as the cells having all of 
the machinery to perform post-translational modifications to the target protein. 
However, mammalian cells have several drawbacks including a long generation 
time (>24h), they grow to low cell density in bioreactors (10
6-10
7 cells/ml) and 
the media can be prohibitively expensive (Sarramegna et al., 2003; Tate et al., 
2003). 
As there is a wide-range of expression systems available, each with their own 
advantages and disadvantages, the particular host cell chosen for heterologous 
expression will largely be determined by the particular mammalian membrane 
protein being over-expressed. Whichever system is chosen, it must deliver high 
yields of functional protein (Tate et al., 2003).  
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1.8 Detergent solubilisation 
Prior  to  their  purification,  membrane  proteins  are  extracted  from  the  lipid 
bilayer  by  adding  an  amphipathic  substance  usually  detergent.  Although 
detergents come in many shapes and forms they all have a hydrophilic head-
group connected to a hydrophobic domain. The nature of the headgroup defines 
the class of detergent: anionic detergents have a negatively charged headgroup 
whereas cationic detergents are positively charged. Detergents with headgroups 
that have both positive and negative charges are termed zwitterionic whereas 
those  detergents  without  a  charged  headgroup  are  classified  as  non-ionic 
(Seddon et al., 2004).  
The choice of detergent used for solubilisation is critical and the chosen one 
must retain the protein’s stability and functionality in solution. Although strong 
ionic detergents (e.g. LDAO) are excellent at solubilising membranes they can 
also  remove  essential  lipids  from  a  protein’s  surface  rendering  it  useless  for 
structural studies (Johansson et al., 2009). Therefore, mild non-ionic detergents 
(e.g.  DDM)  are  commonly  used  for  solubilisation  as  they  often  yield  stable, 
active protein in aqueous solution (Misquitta and Caffrey, 2003). 
The concentration at which discrete detergent monomers spontaneously forms 
micelles is known as the critical micelle concentration (CMC). Membranes can be 
readily solubilised by adding detergents at a concentration significantly (10 – 20 
times)  greater  than  their  CMC.  The  detergent  molecules  replace  the  lipids 
surrounding the MP resulting in the formation of discrete MP-containing micelles 
(Figure 1.12). Following solubilisation, the target protein can be purified using 
conventional  chromatographic  techniques  for  crystallisation  trials  (Weiss  and 
Grisshammer, 2002; Krueger-Koplin et al., 2004). To prevent membrane proteins 
precipitating  out  of  solution,  however,  all  purification  buffers  must  contain 
detergent with a concentration greater than the CMC. 
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Figure 1.12 Schematic diagram showing solubilisation of an integral membrane protein with 
detergent 
Following the addition of detergent at levels 10-20 fold greater than its critical micelle concentration 
(CMC), the lipids surrounding the membrane protein are stripped away and replaced by detergent. 
This results in the formation of discrete protein-detergent micelle complexes. If the solubilisation 
detergent is harsh all of the native lipids may be stripped away. When milder detergents are used, 
those lipids that bind tightly to the surface of the protein are often retained. If a second detergent or 
lipid is included within the solubilisation mixture mixed micelles will result. 
When  working  with  membrane  proteins  the  particular  detergent  used  in  the 
crystallisation trials is often a critical determinant of whether or not any crystals 
are  obtained.  Large  detergent  micelles  (e.g.  DDM)  can  mask  the  hydrophilic 
(non-transmembrane) regions of membrane proteins, preventing the formation 
of protein-protein interactions necessary for crystal formation (Kobilka, 2007). In 
contrast, as short chain detergents have small micelles they are better suited to 
membrane  protein  crystallisation.  However,  this  factor  has  to  be  weighed 
against the effect of the detergents’ tail length on its ability to stabilise the 
target membrane protein (Prive, 2007). In general, detergents with long (C=12) 
alkyl chains tend to be stabilising whereas those with short (C=8) tails are not.  
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Therefore,  for  the  vast  majority  of  mammalian  membrane  proteins  the 
detergents best suited for crystallisation can not be used because they are too 
destabilising (Gutmann et al., 2007; Prive, 2007). One way in which this problem 
can be overcome is by engineering thermostable mutants of the target protein 
that retain their structure in short chain detergents. For example, considerable 
effort was invested by Tate and co-workers to make a thermostable mutant of 
the  turkey  β1-adrenergic  receptor  which  was  stable  in  a  wider  range  of 
detergents than the wild type protein (Serrano-Vega et al., 2008; Warne et al., 
2008) (Figure 1.13). Using their most thermostable mutant, it was possible to 
grow diffracting crystals of the β1AR in the detergent octyl-thioglucoside from 
which a structure to atomic resolution has been obtained (Warne et al., 2008).  
While modifications of protein sequence can aid protein stability in detergent 
solution,  it  is  becoming  increasingly  apparent  that  the  activities  of  many 
mammalian membrane proteins are influenced by specific lipids, in particular by 
cholesterol  (Epand,  2006).  By  including  specific  lipids  in  the  solubilisation 
mixture as well as the purification buffers it is possible to increase the stability 
of  the  target  protein  in  solution  (Lacapere  et  al.,  2007).  For  example,  the 
cholesterol  derivative  cholesterol  hemisuccinate  (CHS)  is  essential  to  obtain 
radioligand binding by the human adenosine 2a receptor in detergent solution 
(Weiss and Grisshammer, 2002; Fraser, 2006). 
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Figure  1.13  Stability  of  (a)  wild-type  and  (b)  a  thermostable  mutant  of  the  turkey  β1 
adrenoceptor in various detergents 
In contrast to that observed for the wild-type receptor, the thermostable mutant was able to bind 
radioligand even when it had been solubilised using the harsh detergents octyl-glucoside (OG), 
nonyl-glucoside (NG) and LDAO. Diffracting crystals of the thermostable mutant were obtained 
using  the  short-chain  detergent  octyl-thioglucoside.  (Figure  taken  from  (Serrano-Vega  et  al., 
2008)). 
 
1.9 Membrane protein purification 
Following solubilisation, the protein of interest must be purified to homogeneity 
prior  to  structural  experiments.  Two  of  the  most  common  approaches  to 
purifying soluble proteins are ion-exchange and gel-filtration chromatography. In 
ion-exchange chromatography, proteins are firstly bound to a charged resin and 
then selectively eluted by gradually increasing the ionic strength of the buffer 
(Seddon et al., 2004). With gel-filtration, proteins are separated according to  
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their  molecular  weight  by  passage  through  a  size  exclusion  chromatography 
column  where  large  proteins  pass  through  the  column  quickly  and  smaller 
proteins  travel  more  slowly  through  the  bead  resin.  These  purification 
techniques  can  also  be  used  with  membrane  proteins  but  the  presence  of 
detergent limits their effectiveness.  
More recently, recombinant membrane proteins have been made as fusions with 
affinity tags located at either their N- or C- termini. All affinity tags bind to 
specific chromatographic resin, allowing the protein to be purified rapidly and 
efficiently (Lundstrom, 2005). For example, a deca-histidine tag (His10) binds to 
immobilized metal (usually Ni
2+ but also Co
2+ or Zn
2+) affinity chromatography 
(IMAC) resin. Non-specific proteins can be removed from the column by washing 
it with a buffer of high ionic strength containing a small (30 mM) concentration 
of  imidazole.  The  recombinant  protein  can  be  eluted  using  a  high  (300  mM) 
concentration of imidazole (which competes with the His tag for binding to the 
metal ion). Affinity chromatography is the best approach for purifying membrane 
proteins as long as the detergent micelle does not interfere with binding of the 
tag to the resin.  
 
1.10 Membrane protein crystallisation  
1.10.1  Aggregation 
For  crystallisation  to  occur,  the  protein  must  be  monodisperse  in  solution 
(Krueger-Koplin  et  al.,  2004).  However,  due  to  their  hydrophobic  nature 
membrane  proteins  have  a  propensity  to  aggregate  in  detergent  solution 
rendering efforts to crystallise them meaningless (Sanders and Oxenoid, 2000; 
Gutmann  et  al.,  2007).  Factors  that  affect  membrane  protein  aggregation 
include the protein to detergent ratio, glycerol and salt content of the buffer as 
well as the type of detergent used. However, caution must be exercised when 
changing  any  of  these  parameters  as  they  have  to  be  compatible  with 
crystallisation trials.   
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1.10.2  Crystal growth by vapour-diffusion 
Protein crystallisation typically requires a highly concentrated (>10 mg/ml) pure 
protein  sample  which  on  the  addition  of  a  precipitant  (and  possibly  small 
amphiphile  molecules)  starts  to  form  crystals  (Garavito  et  al.,  1996).  The 
precipitant  drives  the  formation  of  nucleation  sites  which,  as  the  protein 
concentration  within  the  drop  increases  due  to  water  loss,  forms  the  site  of 
crystal growth (Caffrey, 2003). The formation of well-ordered crystals requires 
slow,  regulated  crystal  growth  which  is  highly  influenced  by  the  protein’s 
concentration and solubility. As the range of possible precipitants is large, the 
process of identifying which will be best for crystal growth can be particularly 
time consuming. However, the development and use of sparse matrix screens for 
initial  crystallisation  trials  has  greatly  helped  to  overcome  this  rate-limiting 
step. Crystal hits are then optimised through a series of small variations to the 
original crystallisation condition with a view to facilitating slow, ordered crystal 
growth resulting in good quality diffracting crystals (Caffrey, 2003; Kobilka and 
Schertler, 2008). Depending on the orientation of the individual proteins and the 
position of their lattice contacts, crystals of varied shape and symmetry can be 
formed (Nollert, 2005). However, in the case of membrane proteins the process 
of obtaining crystals is complicated by the presence of detergent(s) (Arora and 
Tamm, 2001), which often mask the extra-membrane/hydrophilic regions of the 
protein, preventing the formation of crystal contacts (Mohanty et al., 2003). 
 
1.10.3  Lipidic Cubic Phase 
As well as trying to grow crystals of membrane proteins in detergent solution, 
the protein of interest can also be crystallised in a lipid environment called a 
lipidic  cubic  phase  (Nollert,  2005).  A  lipidic  cubic  phase  is  a  structured  3-
dimensional matrix of lipid bilayers linked through a network of interconnected 
aqueous  pores  (Landau  and  Rosenbusch,  1996;  Cherezov  et  al.,  2006).  This 
matrix has been used successfully in conjunction with standard crystallization 
techniques  to  solve  the  structure  of  a  range  of  proteins  including  a  purple  
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bacterial photosynthetic RC (Katona et al., 2003) as well as the β2-adrenergic 
(Cherezov et al., 2007) and adenosine 2a receptors (Jaakola et al., 2008). The 
principle advantage of the cubic phase is that it allows the formation of protein 
crystals in a native-like membrane environment (Landau and Rosenbusch, 1996) 
that tend to be of a superior quality than those grown from detergent solution 
(Wadsten et al., 2006). This is due to the increase in stability of the membrane 
protein when it is reconstituted into a bilayer environment (Johansson et al., 
2009).  However,  cubic  phase  can  only  be  used  for  crystallising  membrane 
proteins with small extra-membrane domains as the aqueous channels are not 
big enough to accommodate proteins with large hydrophilic regions (Cherezov et 
al., 2006; Wohri et al., 2008). 
 
1.10.4  Lipidic Sponge Phase 
Recently, it has been shown that the cubic phase can be swollen by treatment 
with solvents such as PEGs (Bender et al., 2008). This ‘swollen’ lipidic phase is 
known as the sponge phase and has aqueous channels ca. 3x larger than the 
cubic phase. This means that the sponge phase has the potential for crystallising 
membrane proteins with large extra-membrane domains (Cherezov et al., 2006; 
Wadsten et al., 2006). Several proteins have already had their structures solved 
in the sponge phase (Wohri et al., 2009), and it is an emerging technique which 
should prove useful for obtaining diffracting crystals of (mammalian) membrane 
proteins. 
 
1.11 Project context 
Currently, the field of mammalian membrane protein structural biology is in its 
infancy. Existing technologies and experiences have shown that it is possible to 
obtain the structures of mammalian membrane proteins if sufficient work and 
thought has been invested. However, there is still an urgent need to develop 
new  methodologies  and  approaches  to  improve  all  aspects  (expression,  
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purification  and  crystallisation)  of  mammalian  membrane  protein  structural 
biology. 
 
1.12 Aim 
The  main  aim  of  my  Ph.D.  was  to  develop  new  technologies  for  the 
overproduction,  purification  and  crystallisation  of  human  membrane  proteins, 
and  then  test  them  with  a  representative  member  from  each  of  the  GPCR 
(adenosine 2a receptor) and membrane enzyme (sterol isomerase) superfamilies.  
 
1.13 Objectives 
i)  to  create  a  series  of  P.  pastoris  expression  vectors  that  give  high 
production  levels  of  recombinant  protein  which  can  be  readily  purified  to 
homogeneity by affinity chromatography  
ii)  to develop an optimised methodology that gives maximal production of 
recombinant membrane proteins in fermenter cultures of P. pastoris  
iii)  to  develop  a  protocol  for  monitoring  the  aggregation  status  of 
recombinant membrane proteins immediately following detergent solubilisation 
and over the course of the purification process 
iv)  to develop a method for determining the stability of purified membrane 
proteins in a range of buffers and salts  
v)  to  create  a  lipidic-sponge  phase  screen  and  compare  its  usefulness  in 
obtaining  mammalian  membrane  protein  crystals  compared  to  conventional 
crystallisation experiments in detergent solution 
 
  
2   G-protein coupled receptors and 
cholesterol biosynthesis 
 
2.1 Human membrane proteins 
In Chapter 1, the problems associated with solving the structures of mammalian 
(including  human)  membrane  proteins  were  detailed  at  length.  However,  as 
there are many different families of human membrane protein it is pertinent to 
ask  whether  or  not  they  are  all  equally  difficult  to  work  with  or  are  some 
proteins more amenable to study than others. All membrane proteins can be 
classified into two main groups ― those that have conformational flexibility (e.g. 
receptors, transporters) and those that are essentially rigid (e.g. enzymes, ion 
channels). This chapter focuses on the human adenosine 2a receptor (a GPCR) 
and  sterol  isomerase  (an  enzyme  involved  in  the  late  stages  of  cholesterol 
biosynthesis)  as  representative  members  of  the  conformationally-dynamic  and 
rigid-body membrane protein superfamilies, respectively. 
 
2.2 Membrane proteins with conformational flexibility 
Receptors,  which  function  in  information  transfer,  and  transporters,  that 
translocate  specific  substances  across  lipid  bilayers,  have  considerable 
conformational flexibility consistent with their function. However, the inherent 
flexibility that allows these proteins to exist in multiple conformational states is 
not readily compatible with growing protein crystals. It is not surprising then 
that  there  are  so  few  structures  of  mammalian  receptors  and  transporters 
compared  to,  for  example,  ion  channels  (which  have  rigid  structures). 
Furthermore, the ligand-activated GPCRs that have had their structures solved 
had  all  been  locked  into  particular  conformations  using  either  ligands 
(Palczewski et al., 2000; Jaakola et al., 2008) or by site-directed mutagenesis 
(Warne et al., 2008). The available structures of mammalian membrane proteins  
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in the PDB suggests that those proteins with high mobility are harder to work 
with  than  those  that  are  rigid.  I  chose  to  work  on  the  human  adenosine  2a 
receptor,  a  GPCR,  as  a  model  human  membrane  protein  with  high 
conformational flexibility.  
 
2.3 G-protein coupled receptors 
G-protein  coupled  receptors  (GPCRs)  are  a  large  protein  super-family  that 
function in the plasma membrane of mammalian cells (Kobilka, 2007). They are 
highly  conserved  throughout  evolution  with  approximately  1%  of  the  human 
genome encoding them (Sarramegna et al., 2003). GPCRs can be classified into 5 
distinct groups (Type 1 to 5) by sequence homology (Deupi and Kobilka, 2007) of 
which type-1 GPCRs (also known as rhodopsin-like receptors) are the largest and 
best studied group (Cherezov et al., 2007; Deupi and Kobilka, 2007; Fredholm et 
al., 2007a). Although GPCRs show poor homology between families (Klabunde 
and  Hessler,  2002),  they  all  have  a  common  7-transmembrane  alpha-helical 
structure  with  an  extracellular  amino  terminus  and  an  intracellular  carboxyl 
terminus (Figure 2.1) The hydrophobic transmembrane domains are connected 
by 3 intra- (IL1-3) and 3 extra-cellular (EL1-3) loops. The size of the loops and 
terminal tails can vary dramatically between receptors (Klabunde and Hessler, 
2002).  GPCRs  perceive  specific  chemical  messages  in  the  extracellular 
environment  and  then  convert  this  information  to  a  signal  within  the  cell 
(Lefkowitz, 1998; Bockaert and Pin, 1999; Kobilka, 2007).  GPCRs are so-called 
because they activate specific heterotrimeric GTP-binding proteins (G-proteins) 
via their intracellular loops and C-terminal tail following agonist-binding (Ladds 
et al., 2003).  
GPCRs can be activated by a wide-range of ligands including single photons of 
light, ions, nucleosides, hormones and large polypeptides (Kobilka, 2007). This 
enables GPCRs to control a wide range of physiological activities within the body 
including  the  perception  of  light  and  smell,  heart  rate  as  well  as  mood 
regulation. The ligand binding site can be located anywhere on the extracellular  
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side  of  the  GPCR  including  the  N-terminal  region,  extracellular  loops  and/or 
within the transmembrane segments. This said, the type and size of ligand does 
not necessarily determine where it binds to the receptor (Deupi and Kobilka, 
2007; Kobilka, 2007). 
 
Figure 2.1 Schematic representation of a G-protein coupled receptor 
(A) The basic topology of a GPCR consists of 7-transmembrane regions connected by 3 intra- (IL1-
3) and 3 extra-cellular (EL1-3) loops. Ligands bind either at the extracellular surface or within the 
protein’s TM domain whereas receptors couple to heterotrimeric G-proteins mainly via their third 
intracellular loop and C-terminal tail. (B) All GPCRs interact with a G-protein Gα subunit which in 
the inactive (GDP) state is tightly associated with the Gβγ complex. 
Receptors were originally classified according to the endogenous ligand found to 
act  upon  it  (Figure  2.2)  (Cherezov  et  al.,  2007).  However,  it  was  quickly 
discovered  that  certain  endogenous  ligands  caused  a  range  of  physiological 
effects in different tissues by binding to more than one receptor (Palmer et al., 
1995). Upon further investigation, it was found that receptors that bound the 
same  ligand  had  quite  distinct  protein  sequences.  For  example,  the  three  β-
adrenergic  receptors  have  only  50%  amino  acid  sequence  identity  in  their 
transmembrane regions (Warne et al., 2008). Therefore, there was a need to 
sub-classify  close  family  relatives.  Receptor  sub-types  usually  have  different 
tissue distributions as well as distinct pharmacological properties (both ligand 
binding and efficacy of G-protein activation), and in many cases bind different 
G-proteins (Bockaert and Pin, 1999).   
G-protein coupled receptors and cholesterol biosynthesis  37 
Due to their abundance and cellular location, GPCRs are the major site of action 
for  therapeutic  drugs  (Kobilka,  2007).  However,  other  than  their  basic  7-
transmembrane topology little is known about the intricacies of their structure 
or mechanism of action.  
 
Figure 2.2 Schematic diagram illustrating GPCR sub-classification 
Many endogenous ligands bind to several highly-related receptors in the body. Receptor sub-types 
mainly differ from each other in the length of their N- and C-termini as well as their extra- and intra-
cellular loop regions.  
2.3.1 GPCRs - signalling mechanisms 
Following  ligand-binding  GPCRs  selectively  activate  signalling  cascades  within 
the  cell  via  the  activation  of  specific  G-proteins  (Bockaert  and  Pin,  1999; 
Kobilka,  2007).  When  a  ligand  binds  to  the  receptor  (Lundström,  2005)  a 
conformational change occurs within the intracellular region of the protein that 
allows  specific  G-proteins  to  bind  and  become  activated  (Bockaert  and  Pin, 
1999; Kobilka, 2007). In their inactive state, G-proteins exist as heterotrimers 
consisting of alpha (α), beta (β) and gamma (γ) subunits that form a high affinity 
complex (Lambright et al., 1996). Activated GPCRs can initiate the exchange of 
the Gα subunits bound GDP for GTP, by acting as guanine-nucleotide exchange 
factors (GEFs) (Ritter and Hall, 2009). This then leads to the dissociation of Gα- 
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GTP from the Gβγ subunits (Ladds et al., 2003), which can alter the activity of 
downstream effecter proteins (such as adenylyl cyclase). By either inhibiting or 
stimulating  the  production  of  second  messengers  (such  as  cyclic  AMP)  an 
intracellular signal is generated (Flower, 1999). 
The DRY motif is found at the boundary between the second transmembrane 
helix and the second intracellular loop of type I GPCRs (Rovati et al., 2007). This 
motif is essential for G-protein coupling to the ligand-bound receptor and plays 
an important role in GPCR activation. Other than forming stabilizing interactions 
within the receptor constraining the inactive form, the role of the DRY motif in 
effecting G-protein coupling is not yet understood (Yao et al. 2006).  
2.3.1.1  G-proteins 
When G-proteins were originally discovered there was thought to be just one of 
each kind of sub-unit. Since then, however, 20 α, 6 β and 11 or 12 γ subunits 
have been identified in humans (Hamm, 1998; Neves et al., 2002) which give rise 
to a large number of distinct G-protein hetero-trimers each of which generate a 
specific range of intracellular signals (Figure 2.3) (Ladds et al., 2003). The α 
subunits can be classified into 4 distinct groups by sequence homology – Gs, Gi, 
Gq/11, G12/13 (Neves et al., 2002). The first group, Gs, is the best studied and 
upon GDP-GTP exchange activates adenylyl cyclase increasing the intracellular 
levels of cyclic AMP (cAMP). Gi acts in direct opposition to Gs inhibiting adenylyl 
cyclase thereby decreasing cAMP levels (Hamm, 1998). Members of the Gq/11 sub-
family  activate  phospolipase  C  which  hydrolyses  phosphatidylinositol 
biphosphate  to  give  the  second  messengers  inositol  triphosphate  (IP3)  and 
diacylglycerol  (DAG)  (Neves  et  al.,  2002).  G12  acts  on  guanine  nucleotide 
exchange factors (GEFs) to activate GTPase-activating proteins.  
In addition, the Gβγ subunits regulate the activity of other proteins/signalling 
events in the cell. For example, Gβγ can activate inward rectifying K
+ channels 
(Logothetis  et  al.,  1987;  Dascal,  1997)  as  well  as  modulate  the  voltage-
dependence of specific calcium channels (Herlitze et al., 1996; Ikeda, 1996; De 
Waard et al., 1997). Furthermore, Gβγ can regulate Ras which, in turn, controls  
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the activity of certain mitogen-activated protein kinases (MAPK) (Schmitt and 
Stork, 2002) (including the extracellular signal-regulated kinases (ERKs) (Koch et 
al., 1994; Obara et al., 2008)), as well as the c-Jun NH2-terminal kinases (JNKs) 
(Coso et al., 1997).  
 
Figure  2.3  Overview  of  intracellular  signals  generated  by  G-proteins  following  GPCR 
activation 
Agonist  binding  at  the  GPCR  leads  to  the  selective  activation  of  associated  G-proteins  by 
catalysing the exchange of GDP for GTP at the Gα sub-unit. This causes the Gα and Gβγ sub-units 
to  dissociate.  Gα-GTP  alters  the  activity  of  downstream  signalling  enzymes  such  as  adenylyl 
cyclase  and  phospholipase  C  which,  in  turn,  alters  the  levels  of  second  messenger  molecules 
cAMP  and  IP3/DAG,  respectively.  The  Gβγ  subunits  modulate  other  signalling  pathways.  For 
example, Gβγ has been found to activate mitogen activated protein kinases (MAPKs) via Ras.  
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The duration of signals propogated by the Gα and Gβγ sub-units is determined by 
the  GTPase  activity  of  the  Gα  subunit  (Cabrera-Vera  et  al.,  2003).  Following 
hydrolysis  of  the  bound  GTP  to  GDP,  the  Gα  and  Gβγ  sub-units  re-associate, 
returning the G-protein to its resting state (Lambright et al., 1996). 
Although  the  third  intracellular  loop  of  GPCRs  is  known  to  be  a  critical 
determinant of which G-protein complex is activated by each receptor (Kobilka 
and Schertler, 2008) certain GPCRs have been shown to couple to more than one 
type of G-protein depending on the particular ligand bound to the receptor as 
well as the pool of G-proteins available within each cell (Ladds et al., 2003).  
2.3.1.2  GPCR desensitisation 
To  prevent  chronic  over-stimulation  of  cells  GPCR  signalling  needs  to  be 
switched  off  (Figure  2.4)  (Ferguson,  2001;  Ma  and  Pei,  2007).  This  is 
accomplished by phosphorylation of specific residues in the cytoplasmic regions 
of agonist-bound GPCRs by G-protein coupled receptor kinases (GRKs) (Tobin et 
al.,  2008).  In  certain  cases,  phosphorylation  is  enough  to  prevent  G-protein 
binding (Maudsley et al., 2005). However, in most cases, GPCR phosphorylation 
is followed by recruitment of an arrestin protein to the receptor’s C-terminal 
tail that physically blocks G-protein activation (Gurevich and Gurevich, 2006; Ma 
and Pei, 2007). There are four arrestin proteins (Ferguson, 2001; Rajagopal et 
al., 2010) that associate with phosphorylated GPCRs (Brzostowski and Kimmel, 
2001; Gurevich and Gurevich, 2006; Ma and Pei, 2007). By blocking G-protein 
activation, arrestins “switch off” the intracellular signalling cascade (Bockaert 
et al., 2004). The arrestins also target the GPCR for internalisation where they 
are either dephosphorylated and recycled to the plasma membrane or targeted 
to  the  lysosome  for  degradation  (Hall  and  Lefkowitz,  2002;  Bockaert  et  al., 
2004; Gurevich and Gurevich, 2006; Kelly et al., 2008). Receptor desensitisation 
is  an  important  aspect  of  GPCR  biology  not  just  in  switching  off  the  current 
signalling  event  but  also  priming  the  receptor  for  receiving  a  new  signal 
(Lefkowitz, 1998).  
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Figure  2.4  GPCR  desensitisation  via  the  combined  action  of  G-protein  receptor  kinases 
(GRKs) and arrestins 
Following agonist binding, GPCRs are able to selectively activate specific G-proteins starting a 
signalling  cascade  within  the  cell.  To  switch  off  signalling  by  the  receptor,  G-protein  receptor 
kinases  (GRKs)  phosphorylate  specific  residues  in  the  cytoplasmic  tail  of  the  agonist-bound 
receptor. This drives the recruitment of arrestin proteins to the receptor and ultimately results in 
receptor  internalization  where  it  is  either  dephosphorylated  and  recycled  to  the  cell  surface  or 
targeted to the lysosome for degradation. Prior to internalisation, arrestins can stimulate G-protein 
independent signalling. In certain cases, phosphorylation of the agonist-bound GPCR by the GRK 
is sufficient to prevent G-protein binding, switching off the signal. This figure is adapted from ((Ma 
and Pei, 2007)).  
2.3.1.3  G-protein independent signalling 
Recently,  it  has  been  shown  that  GPCRs  can  also  signal  in  a  G-protein 
independent  fashion  (Bockaert  and  Pin,  1999;  Kobilka,  2007)  by  binding 
regulatory  proteins  called  GPCR  interacting  proteins  (GIPs)  (Bockaert  et  al., 
2004; Gsandtner et al., 2005; Ritter and Hall, 2009). Due to the large number of  
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proteins that act as GIPs their modes of action can vary considerably. Known 
effects include altering the pharmacological properties, function and trafficking 
of GPCRs (Brzostowski and Kimmel 2001; Ritter and Hall 2009).  
Two  of  the  best  characterised  GIPs  are  β-arrestin  1  and  2  which,  following 
recruitment to a GPCR, act as multi-functional adaptor proteins, scaffolding a 
diverse  group  of  signaling  proteins  at  the  receptor,  thereby  modulating  the 
downstream activity of a number of signaling networks (reviewed in (DeWire et 
al., 2007)). For example, β-arrestin 1 recruits an activated non-receptor tyrosine 
kinase  (SRC),  to  selected  receptors  causing  the  downstream  activation  of 
extracellular-signal  related  kinase  (ERK)  (Luttrell  and  Gesty-Palmer,  1999; 
Luttrell et al., 2001). β-arrestins are also known to cause transactivation of the 
epidermal growth factor receptor (EGFR) in a SRC-dependent manner, as well as 
being involved in the regulation of receptor trafficking and the activity of small 
GTPases (Rajagopal et al., 2010).   
Other GIPs include (i), the Janus family of kinases (JAKs) and members of the 
signal transducers and activators of transcription (STATs) (Marrero et al., 1998), 
(ii)  PDZ  domain  containing  proteins  such  as  the  Na
+  H
+  exchange  regulatory 
factor (which controls the activity of the Na
+-H
+ exchanger type 3 (NHE3)) (Hall 
et  al.,  1998  a,b),  and  (iii)  phosphoinositide-3-kinase  (PI3K)  sub-unit  p85  that 
influences  the  activity  of  the  Akt  signaling  pathway  (Bousquet  et  al.,  2006). 
These examples give just a flavour of the ways that GIPs extend the capacity of 
GPCRs to regulate cellular processes. In summary, by binding GIPs, GPCRs are 
able to generate an enormous diversity of intracellular signals in distinct cellular 
compartments in response to a relatively small number of endogenous ligands. 
2.3.1.4  GPCR oligomerisation 
Another important aspect of GPCR signalling is that of receptor oligomerisation. 
In recent years, considerable evidence has been obtained showing that many 
proteins exist as dimers, and sometimes even as higher order oligomers in both 
homo-  and  hetero-oligomeric  complexes  (Javitch,  2004).  It  has  even  been 
suggested that all GPCRs exist in some form of multimeric complex (Breitwieser,  
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2004; Fredholm et al., 2007a). Dimerisation was first established for members of 
the  type  III  class  of  GPCRs  (including  the  metabotropic  glutamate  receptor  5 
(Romano  et  al.,  1996;  Romano  et  al.,  2001)  and  γ-aminobutyric  acid  (GABA) 
receptors (Jones et al., 1998; Kaupmann et al., 1998; White et al., 1998; Kuner 
et al., 1999; Ng et al., 1999)). Since then, it has become increasing apparent 
that  GPCRs  from  all  families  interact  with  different  partner  GPCRs  on  the 
surface of cells in a variety of complexes. There is considerable evidence that 
GPCR dimerisation occurs at the level of protein synthesis in the endoplasmic 
reticulum or during maturation in the Golgi and it is thought that many, if not 
most  GPCRs,  are  trafficked  to  the  plasma  membrane  as  part  of  a  dimeric 
complex (Bulenger et al., 2005; Milligan, 2007). 
The  biological  significance  of  heterodimerisation  is  not  well  understood,  or 
exploited,  but  is  predicted  to  have  a  major  impact  on  drug  discovery  in  the 
coming years (George et al., 2002). This said, certain ligands have been shown 
to  have  direct  and  selective  effects  on  the  conformation  of  the  individual 
receptors that make up hetero-dimers. For example, in the case of the GABA(B) 
receptor,  binding  of  the  neurotransmitter  in  the  N-terminal  region  of  the 
GABA(B)R1  sub-unit  results  in  activation  of  a  G-protein  by  the  GABA(B)R2 
protomer (Jones et al., 1998; Breitwieser, 2004; Milligan, 2009). This implies 
communication between two receptor units with distinct conformational changes 
in both proteins following ligand binding.  
Although  there  are  now  numerous  reports  of  GPCR  oligomerisation  in  the 
literature, not all of the suggested dimers are likely to occur in native tissues. 
There  are  two  main  reasons  for  this:  i)  in  transient  transfection  experiments 
possible GPCR dimers/oligomers that are detected may just be an artifact of 
receptor overexpression in a non-native background, and ii) even when a number 
of clear differences in the function and pharmacology of co-expressed pairs of 
GPCRs have been observed care has to be taken to discriminate between those 
effects that are due to direct protein-protein interactions and those that are 
produced  indirectly  via  downstream  signaling  and  feedback  control  (Milligan, 
2007).  A  physiologically-relevant  and  therapeutically  interesting  example  of 
receptor  hetero-oligomerisation  is  that  between  the  adenosine  2a  receptor  
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(A2aR) and the dopamine D2 receptor (D2R). These GPCRs have been shown to 
exist as heteromeric complexes in both transfected and striatal tissue (Ferre et 
al.,  2001;  Fuxe  et  al.,  2007).  Furthermore,  in  brain  A2aR  antagonists  have  a 
strong inhibitory effect on the activity of the D2R reducing tremor and rigidity in 
patients with Parkinson’s disease (Ferre et al., 2001; Fuxe et al., 2007).  
2.3.2 GPCRs: conformational complexity 
In the past, GPCRs have been described as “bimodal switches” in which they 
exist  in  either  an  active  or  inactive  conformation  (Kobilka  and  Deupi,  2007) 
(Figure 2.5 (A)). However, this “lock and key” model did not account for the 
association of G-protein with the receptor and so the simple ternary complex 
model as a description of GPCR biology was devised (Figure 2.5 (B)). This model 
was later modified to take account of the high and low affinity states of both 
receptor  and  receptor-G  protein  complexes  for  ligand  (Figure  2.5  (C)).  Many 
receptors have been shown to have constitutive activity (Klinger et al., 2002) 
allowing them to signal in the absence of an agonist (Vauquelin and Van Liefde, 
2005). This finding gave rise to the extended ternary complex model (Figure 2.5 
(D)). Common to all of these models is the assumption that the receptor has a 
unique conformation depending on which partner(s) (eg agonist, G-protein) are 
associated with it. Although these models may appear complicated the reality is 
considerably  more  convoluted  with  the  fact  that  most  GPCRs  bind  partial 
(inverse)  agonists  that  stabilise  the  receptor  in  a  series  of  conformational 
intermediates  each  with  their  own  signalling  properties  (Ladds  et  al.,  2003; 
Kobilka and Deupi, 2007). Although both ligands and G-proteins are known to 
preferentially  interact  with  discrete  GPCR  states,  fluctuations  between 
conformations can occur spontaneously (Vauquelin and Van Liefde, 2005). 
The vast range of conformations that GPCRs are known to exist in has proven to 
be  a  substantial  barrier  in  efforts  to  crystallise  GPCRs.  Well-ordered  crystals 
(required  for  structure  determination)  can  only  be  formed  from  a 
conformationally  homogeneous  sample.  Therefore,  strategies  for  stabilising 
specific receptor conformations have to be used with all GPCRs before crystals 
that diffract to high resolution can be obtained.  
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Figure 2.5 Various models describing the possible conformational states of GPCRs 
(A) The two-state model in which ligand (L) binding to the receptor (R) results in the formation of a 
LR complex generating an active receptor conformation (R*) that signals to downstream effectors. 
(B) The simple ternary complex model (where G is for G-protein). (C) The full ternary complex 
model which accounts for the high and low affinity states of both R and RG for L. (D) The discovery 
of constitutively active GPCR mutants resulted in the development of an extended ternary complex 
model  in  which  the  receptor  can  adopt  an  active  conformation  (Ra)  in  the  absence  of  L  or  G 
binding. Ri denotes the inactive conformation of the receptor. (Red indicates a fully active complex, 
orange is constitutive activity, yellow is inactive receptor.) This figure was modified from (Rajagopal 
et al., 2010).  
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2.3.3 Current structural knowledge of GPCRs  
To date, only four G-protein coupled receptors have had their structures solved 
to atomic resolution (figure 2.6) (Palczewski et al., 2000; Cherezov et al., 2007; 
Rasmussen  et  al.,  2007;  Jaakola  et  al.,  2008;  Warne  et  al.,  2008)  which, 
considering their biological importance, gives some indication of how difficult it 
is to obtain a GPCR structure.  
 
Figure 2.6 GPCR structures in the PDB 
Available structures include (A) rhodopsin (1F88), (B) turkey β1-adrenergic receptor (2VT4), (C) 
human  β2-  adrenergic  receptor  with  IL3  replaced  with  T4  lysozyme  (2RH1),  (D)  human  β2-
adrenergic receptor in complex with a Fab (2R4R), and (E) the human adenosine 2a receptor with 
T4 lysozyme (3EML), (Palczewski et al., 2000; Cherezov et al., 2007; Rasmussen et al., 2007; 
Jaakola et al., 2008; Warne et al., 2008).  
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The first mammalian GPCR to have its structure solved to high resolution was 
bovine rhodopsin (Palczewski et al., 2000). This is not surprising as rhodopsin has 
several properties that make it easier to work with compared to other GPCRs. 
Firstly,  as  rhodopsin  has  a  high  natural  abundance  it  did  not  have  to  be 
overexpressed  in  a  heterologous  host  before  structural  studies  could  begin. 
Secondly,  rhodopsin  covalently  binds  11-cis-retinal  (which  acts  as  an  inverse 
agonist) stabilising the receptor in its inactive conformation (Palczewski et al., 
2000). Finally, the bound retinal chromphore gives rhodopsin a red colour which 
makes  it  easy  to  identify  those  fractions  containing  receptor  throughout  the 
purification process (Teller et al., 2001). 
Rhodopsin functions in the perception of light (Palczewski et al., 2000; Teller et 
al., 2001). On absorbing a photon of light energy the bound retinal changes from 
an all-cis to an all-trans conformation that activates rhodopsin which, in turn, 
activates the G-protein transducin (Sheikh et al., 1996). Thus far, 15 discrete 
rhodopsin structures have been solved and deposited in the PDB, each giving 
different insights into rhodopsin’s mechanism of activation.  
The first rhodopsin structure confirmed the 7TM alpha helical topology that had 
been predicted for all GPCRs. However, an additional irregular α-helix (helix 8) 
that  is  situated  along  the  surface  of  the  cytoplasmic  membrane  was  also 
observed (Figure 2.6 (A)) (Palczewski et al., 2000). The 7 TM helices vary in 
length according to the angle that they cross the membrane. Proline residues in 
TM I, IV, VI and VII creates kinks in the α-helices. The receptor is held together 
by hydrogen bonds between helices, a disulphide bond (between extracellular 
loop 2 and TM3) as well as a salt bridge (between the E/DRY motif (Glu134, 
Arg135 and Tyr136) in TM3 and Glu247 & Thr251 (both TM5)).  
Further  structural  studies  have  identified  several  water  molecules  that  occur 
within  the  transmembrane  region  of  rhodopsin  which  are  essential  for  the 
formation of the hydrogen-bond network between helices (Okada et al., 2002; Li 
et  al.,  2004).  To  understand  the  changes  in  protein  conformation  that 
accompany  rhodopsin’s  photochemical  reactions  structures  of  various 
intermediate photostates (including inactive (or “dark” state) rhodopsin through  
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bathorhodopsin,  lumirhodopsin,  metarhodopsin  I  and  deprotonated 
metarhodopsin II (the active “light” state) have been determined (Choi et al., 
2002; Nakamichi and Okada, 2006 a,b; Salom et al., 2006). 
Although  heterologous  expression  of  rhodopsin  has  proved  difficult,  by 
introducing a stabilising disulphide bond and removing its only glycosylation site 
it  has  been  possible  to  obtain  milligram  quantities  of  recombinant  rhodopsin 
from  which  diffracting  crystals  and  a  high-resolution  structure  have  been 
obtained (Standfuss et al., 2007). This was a landmark achievement as it was the 
first time that any GPCR had been produced in a heterologous host and then 
crystallised. 
More recently, a crystal structure has been obtained for ligand-free opsin that 
shows the structural changes that occur within the E/DRY motif and TM5-7 when 
the receptor is in its active conformation (Park et al., 2008). Furthermore opsin 
has recently been crystallised in complex with a peptide from the alpha subunit 
of the G-protein transducin (Scheerer et al., 2008). This structure has given the 
first insights into the conformational changes that occur on G-protein binding 
and activation by a GPCR.  
As rhodopsin is an atypical GPCR, it was not clear how relevant the structures of 
rhodopsin  would  be  to  the  wider  GPCR  family.  Within  the  past  few  years, 
however, structures of the human β2 adrenergic receptor (Figure 2.6 (C, D)), the 
turkey  β1  adrenergic  receptor  (Figure  2.6  (B))  and  the  human  adenosine  2a 
receptor (Figure 2.6 (E)) have all been deposited in the PDB. For all of these 
proteins,  diffracting  crystals  were  only  obtained  using  modified  receptor 
constructs  in  which  the  highly  mobile  third  intracellular  loop  (known  to  be 
involved in G-protein coupling) had been replaced with T4 lysozyme (Cherezov 
et al., 2007; Jaakola et al., 2008), shortened (Warne et al., 2008) or bound by a 
Fab fragment   (Rasmussen et al., 2007). Furthermore, diffracting crystals were 
only obtained using purified receptor that was deglycosylated, had a truncated 
C-terminal  tail  and  had  either  an  antagonist  or  inverse  agonist  bound  (which 
locked the receptor into an “inactive” state).   
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The  β2-adrenoreceptor  (β2AR)  is  probably  the  best  characterised  ligand-
activated GPCR primarily as it was the first non-rhodopsin GPCR to be cloned 
(Dixon et al., 1986) but also because it is an important therapeutic drug target 
in the treatment of cardiovascular and pulmonary disease (Kolb et al., 2009; 
Overington  et  al.,  2006;  Takeda  et  al.,  2002).  Structures  of  carazolol-bound 
β2AR have been solved in two different ways (Cherezov et al., 2007; Rasmussen 
et al., 2007). In the first method, the β2AR was co-crystallised with a specific 
antibody fragment (Fab) bound to the flexible third intracellular loop. Using this 
approach a structure at a resolution of 3.7 Å was obtained though the electron 
density around the ligand binding site was poorly resolved (Rasmussen et al., 
2007). In the second method IL3 was replaced with T4 lysozyme. Crystals of this 
receptor  construct  were  grown  in  a  lipidic-cubic  phase  that  diffracted  to  a 
resolution of 2.4 Å (Cherezov et al., 2007). Reassuringly, the two methods gave 
structures where the arrangement of the TM helices and the specific interactions 
between carazolol and the receptor were essentially the same (Cherezov et al., 
2007;  Rasmussen  et  al.,  2007;  Rosenbaum  et  al.,  2007).  Furthermore,  the 
arrangement  of  transmembrane  helices  in  the  β2AR  was  found  to  be  largely 
similar to that in rhodopsin. However, an additional short helix in EL2 occurs in 
the β2AR which differs from that in rhodopsin where there is a flexible loop. The 
helix in EL2 is thought to prevent the movement (and closing) of the ligand-
binding  pocket  in  the  β2AR  (which  is  permanently  capped  in  rhodopsin) 
(Standfuss et al., 2007).  
Although carazolol and retinal occupy similar spaces in the β2AR and rhodopsin, 
the β-ionone ring of retinal extends deeper into the ligand binding pocket than 
carazolol  contacting  the  highly  conserved  Trp265  in  helix  VI  of  rhodopsin 
(Cherezov et al., 2007). Changes in the side-chain of Trp 265 are thought to 
occur  upon  activation  of  rhodopsin  (as  well  as  other  type  I  GPCRs).  The 
interactions between retinal (a full inverse agonist) and Trp 265 are thought to 
contribute to rhodopsin’s lack of basal activity. In contrast, the β2AR structure 
shows  that  carazolol  does  not  interact  with  this  “toggle  switch”,  likely 
explaining why it is a partial and not a full inverse agonist (Cherezov et al., 
2007).   
G-protein coupled receptors and cholesterol biosynthesis  50 
A high resolution structure of the turkey β1-adrenergic receptor was obtained 
from diffraction quality crystals of a detergent-resistant thermostable mutant 
(that had been created following extensive mutagenesis of the receptor) (Warne 
et  al.,  2008;  Warne  et  al.,  2009).  By  identifying  mutations  that  conferred 
thermostability on the receptor, as well as locking the protein in an inactive 
conformation,  it  was  possible  to  obtain  pure,  monodisperse  protein  in  short 
chain detergents (Serrano-Vega et al., 2008) which gave crystals that diffracted 
to 2.7 Å (Warne et al., 2008). 
When  the  structures  of  the  β1-  and  β2-ARs  are  compared,  there  are  no 
significant differences in the positions of the TM helices. Furthermore, the short 
α-helix in EL2 identified in the β2AR structures is present in β1AR also. This 
structural  feature  may  allow  GPCRs  to  bind  diffusable  ligands  rapidly  and 
reversibly  (Warne  et  al.,  2008).  The  β1-  structure  varies  from  the  β2-AR, 
however, in that it has an additional helix located within IL2. A hydrogen bond 
between Tyr149 in the IL2 helix and Asp138 in TM3 may potentially play a role in 
receptor  G-protein  specificity  but  further  studies  are  required  to  clarify  this 
suggestion (Warne et al., 2008). 
The  most  recent  GPCR  to  have  its  structure  determined  was  the  human 
adenosine  2a  receptor  which  was  solved  using  the  T4-lysozyme  insertion 
approach  (Jaakola  et  al.,  2008).  The  receptor  was  co-crystallised  with  the 
antagonist ZM241385 and a structure to 2.6 Å resolution obtained. Although the 
hA2aR  has  the  same  helical  scaffold  as  both  the  β1-  and  β2-ARs,  the  way  in 
which the antagonist ZM241385 binds to the receptor (perpendicular to the lipid 
membrane interacting with EL2 and EL3) is completely different (Jaakola et al., 
2008). This suggests that further GPCR structures may reveal a diverse range of 
ligand binding pockets (Jaakola and Ijzerman, 2010). In contrast to the helix that 
occurs in the EL2 of the β-ARs, the hA2aR has three disulphide bridges (which 
are essential for high-affinity antagonist binding) instead (Jaakola and Ijzerman, 
2010).   
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While these structures have greatly enhanced our knowledge of GPCR biology at 
the molecular level, only through obtaining further structures of different GPCRs 
in a range of conformational states will it be possible to fully understand the 
molecular details of GPCR activation. 
2.3.4 Structure-based drug design against GPCRs  
Given that GPCRs are one of the largest protein superfamilies, function at the 
cell  surface  and  regulate  a  vast  array  of  physiological  processes,  it  is  not 
surprising  that  a  large  number  of  existing  therapeutic  molecules  act  against 
them.  However,  many  drugs  have  side-effects  arising  from  non-specific 
interactions of the therapeutic with other cellular proteins. It is hoped that by 
solving the structures of ligand-activated GPCRs to atomic resolution it will be 
possible  to  design  drugs  that  act  specifically  against  particular  receptors, 
reducing the problem of unwanted side-effects. 
2.3.5 Human adenosine receptors 
Adenosine is an important chemical involved in the inflammatory response with 
its  extracellular  accumulation  being  the  first  major  signal  in  response  to 
ischaemia and inflammation (Ohta and Sitkovsky, 2001; Murphree et al., 2002; 
Sands  and  Palmer,  2005).  The  levels  of  adenosine  that  accumulate  can  vary 
dramatically dependent on the level of stress and the tissue affected (Jacobson 
and  Gao,  2006).  Adenosine  is  formed  from  AMP  by  the  action  of  the  AMP 
selective 5’ nucleotidase, and its rate of formation is directly proportional to the 
amount of available AMP (Fredholm et al., 2007b). 
In humans, there are four adenosine receptor subtypes - A1, A2a, A2b and A3. 
Although  all  of  them  are  activated  by  adenosine  (Gsandtner  and  Freissmuth, 
2006),  there  is  only  ~50%  sequence  homology  between  the  receptor  subtypes 
(Figure 2.7) (Moreau and Huber, 1999). Upon adenosine binding, these receptors 
activate different G-proteins and signalling pathways within the cell (Palmer et 
al., 1995; Gsandtner et al., 2005).  For example,  the A2a receptor activates Gαs  
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Figure 2.7 Sequence alignment of the four human adenosine receptor subtypes 
When the amino acid sequences of the adenosine receptor subtypes were compared it was found 
that  they  had  ca.  37%  sequence  identity.  The  alignment  also  shows  that  the  adenosine  2a 
receptor subtype is unique in that it has an extremely long C-terminal tail - over 90 residues longer 
than  any  of  the  other  adenosine  receptor  subtypes.  Residues  highlighted  in  red  have  100% 
consensus while those boxed in blue have amino acid substitutions maintaining type. The green 
arrows indicate potential transmembrane domains.  
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whereas A1 activates Gαi. This means that according to the type of adenosine 
receptor possessed by a cell, the presence of extracellular adenosine may either 
increase or decrease its cAMP level stimulating different intracellular signalling 
pathways (Olah, 1997). As well as their distinct signalling properties, the tissue 
distribution  of  the  different  adenosine  receptor  subtypes  varies  (Moreau  and 
Huber, 1999) - A1 and A2a are present in both the cardiovascular and central 
nervous systems, A2b is ubiquitously expressed throughout the body while A3 
receptors are highly enriched in the brain. 
2.3.6 The human adenosine 2a receptor 
The human adenosine 2a receptor (hA2aR) is expressed in high levels in lymphoid 
tissues such as spleen, leukocytes and blood platelets (Sands et al., 2004) as 
well as vascular endothelial cells and striatal neuronal cells (Ferre et al., 2001; 
Gsandtner and Freissmuth, 2006). hA2aR signaling has been extensively studied 
(Gomez and Sitkovsky, 2003; Sands et al., 2004; Sands and Palmer, 2005) and it 
has  been  shown  to  be  a  key  therapeutic  target  in  the  treatment  of  many 
inflammatory diseases (Jacobson and Gao 2006). Agonist molecules that interact 
with  the  A2aR  down-regulate  inflammation  by  inhibiting  pro-inflammatory 
responses within the cell (Sands and Palmer, 2005), and are useful for treating 
diseases such as atherosclerosis, sepsis and tumour progression. More recently, 
hA2aR  antagonists  have  become  of  interest  to  researchers  developing  new 
treatments  for  Parkinson’s  disease  as  the  hA2aR  dimerises  with  dopamine  D2 
receptors (Ciruela et al., 2004) increasing the affinity of the D2 receptor for 
agonists in the presence of an A2aR antagonist (Ferre et al., 2001).  
The hA2aR has a unique C-terminal tail 122 amino acids in length (Figure 2.8). 
This is considerably longer than what is typical for a family I GPCR whose C-tails 
are usually in the region of 10-40 amino acids long. The hA2aR C-tail shows no 
sequence  similarity  with  any  other  GPCR  yet  it  is  highly  conserved  between 
species,  and  is  thought  to  play  an  important  role  in  either  trafficking  or  G-
protein independent signaling but is not involved in G-protein coupling (Olah,  
1997; Moreau and Huber, 1999). This region is predicted to be highly disordered, 
and likely explains why it is able to interact with a diverse range of adaptor  
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proteins (Fredholm et al., 2007b). For example, the C-tail of the hA2aR has been 
shown  to  interact  with  α-actinin  (which  mediates  receptor  internalization) 
(Burgueno  et  al.,  2003),  Usp4  (which  is  important  for  maintaining  the  cell 
surface position of the hA2aR) (Milojevic et al., 2006) and ARNO (which activates 
MAP kinase) (Gsandtner et al., 2005). 
 
Figure 2.8 Schematic diagram of the human adenosine 2a receptor 
Of note are the regions of the hA2aR predicted to be transmembrane as well as the receptor’s 
large intracellular C-terminal tail. Colours are dependent on individual amino acid. 
 
2.4 Rigid-bodied membrane proteins 
In  contrast  to  those  membrane  proteins  with  high  conformational  flexibility, 
rigid bodied membrane proteins are considered relatively easy to work as they 
have  defined  structures  with  very  little,  if  any,  regions  that  are  natively 
disordered.  Furthermore,  these  MPs  tend  to  exist  in  a  limited  number  of 
conformational states only. For example, ion channels tend to exist in either an 
open or closed state. For these reasons a relatively large number of mammalian 
rigid-bodied MPs have had their 3-dimensional structures solved including water  
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channels  (Murata  et  al.,  2000;  Horsefield  et  al.,  2008;  Ho  et  al.,  2009),  ion 
channels (Long et al., 2005; Tao et al., 2009), transporters (Aller et al., 2009) 
and enzymes (Binda et al., 2002; Hernandez-Guzman et al., 2003; Ago et al., 
2007; Martinez Molina et al., 2007). 
As  yet,  only  three  mammalian  integral  membrane  enzymes  have  had  their 
structures solved (Binda et al., 2002; Hernandez-Guzman et al., 2003; Ago et 
al.,  2007;  Martinez  Molina  et  al.,  2007).  This  is  rather  surprising  considering 
enzymes have highly-ordered structures with fixed active sites where specific 
substrates  bind  in  a  particular  orientation  in  proximity  to  those  amino  acid 
residues  that  participate  in  the  catalytic  reaction  (Nelsetuen,  1995;  Welch, 
1995; Binda et al., 2002). In my Ph.D., I worked on the cholesterol biosynthetic 
enzyme sterol isomerase as an example of a human rigid-bodied MP.  
 
2.5 Cholesterol 
Cholesterol  is  the  principal  mammalian  sterol.  It  is  an  amphipathic  molecule 
consisting  of  a  hydrophilic  hydroxyl  group,  a  rigid  four-ring  structure  and  a 
hydrocarbon  tail  (Figure  2.9).  Cholesterol  is  an  essential  component  of 
mammalian  cell  membranes  where  it  regulates  the  membrane’s  structure, 
permeability and fluidity. The hydroxyl group of cholesterol interacts with the 
polar head groups of both phospho- and sphingo-lipids while the hydrocarbon 
part  restricts  the  movement  of  the  fatty  acid  chains  of  neighbouring  lipid 
molecules (Rietveld and Simons, 1998). Cholesterol rich regions of membranes 
are  known  as  lipid  rafts.  These  have  been  shown  to  play  important  roles  in 
regulating a diverse range of cellular processes including polarised trafficking 
events, endo- and exo-cytosis as well as signal transduction (Lucero and Robbins, 
2004; Ramstedt and Slotte, 2006). Cholesterol is essential for the full activity of 
many different mammalian membrane proteins including GPCRs (Gimpl et al., 
1995; Klein et al., 1995; Albert et al., 1996; Gimpl et al., 1997; Pang et al., 
1999; Lagane et al., 2000; Gimpl and Fahrenholz, 2002), transporters (Shouffani 
and  Kanner,  1990;  Rothnie  et  al.,  2001;  Tate,  2001;  Magnani  et  al.,  2004),  
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pumps (Ding et al., 1994; Cornelius, 2001) and ion channels (Fernandez-Ballester 
et al., 1994). Cholesterol can modulate the activity of membrane proteins in two 
different ways: firstly, cholesterol contributes to the stability and functionality 
of  membrane  proteins  by  exerting  lateral  pressure  on  their  transmembrane 
domains  (Gimpl  et  al.,  1997);  secondly,  specific  interactions  between  the 
protein and cholesterol can be essential for the protein’s activity (Gimpl et al., 
1997; Tate, 2001; Hanson et al., 2008). In addition to its role in the membrane, 
cholesterol  is  also  the  biosynthetic  precursor  of  a  wide-range  of  biologically 
active molecules including bile acids (Song et al., 2007; Ferdinandusse et al., 
2009), steroid hormones (eg cortisol, aldosterone, progesterone, estrogen and 
testosterone) (He et al., 2010) as well as several fat-soluble vitamins (eg Vitamin 
D) (Holick, 1995). In short, cholesterol is a pivotal molecule at the centre of 
mammalian cell biology. 
 
Figure 2.9 Chemical structure of cholesterol  
Cholesterol has three distinct regions comprising of (A) a hydroxyl head group, (B) a rigid ring 
structure and (C) a hydrocarbon tail. 
2.5.1 Cholesterol homeostasis 
The amount of cholesterol in our bodies is more or less the same from day to 
day, and in a typical male adult is ca. 35g. However, cholesterol is made and 
turned  over  on  a  daily  basis.  Although  each  day  we  make  ca.  1000  mg  of  
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cholesterol  and  take-in  an  additional  200-500  mg  from  our  diet,  we  lose  an 
equivalent amount of cholesterol via excretion in bodily fluids (Charlton-Menys 
and  Durrington,  2008).  Cholesterol  is  continuously  moved  between  different 
parts of the body and, due to its hydrophobic nature, is transported in the blood 
within lipoproteins (Moebius et al., 2000; Ikonen, 2006; Daniels et al., 2009). For 
example, very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL) 
transport cholesterol from the liver to peripheral tissues (Simons and Ikonen, 
2000). In contrast, high-density lipoproteins (HDL) carry cholesterol back from 
the  extremities  of  the  body  to  the  liver  where  it  is  either  broken  down  or 
converted into bile salts (Schmitz and Grandl, 2009). The cholesterol content of 
cells is dynamic, and the steady-state levels of cholesterol in individual cells are 
determined  by  the  relative  rates  of  cholesterol  synthesis,  uptake  and  export 
(Daniels et al., 2009). Moreover, within each cell a cholesterol gradient exists 
with  the  highest  and  lowest  levels  occurring  in  the  plasma  membrane  and 
endoplasmic reticulum, respectively (Schmitz and Grandl, 2009). When excess 
amounts  of  cholesterol  accumulate  in  the  body,  disease  always  results.  For 
example,  elevated  blood  LDL-cholesterol  levels  are  a  major  risk  factor  for 
atherosclerosis (and from this other cardiovascular diseases such as heart attacks 
and stroke) (Ikonen, 2006; Daniels et al., 2009).  
2.5.2 Cholesterol biosynthesis 
In humans, cholesterol is primarily made in the liver and cells of the central 
nervous  system  (Charlton-Menys  and  Durrington,  2008).  An  overview  of 
cholesterol  synthesis  is  presented  in  Figure  2.10.  Cholesterol  synthesis  starts 
with  the  reaction  of  acetyl  CoA  with  acetoacetyl-CoA  to  form  3-hydroxy-3-
methylglutaryl CoA (HMG-CoA). Reduction of this molecule to mevalonate is the 
committed  step  in  cholesterol  biosynthesis.  This  reaction  is  catalysed  by  the 
enzyme  HMG-CoA  reductase  which  is  inhibited  by  the  statin  family  of  drugs 
(which are commonly used to lower blood cholesterol levels) (Charlton-Menys 
and Durrington, 2008). Following this, a series of molecular reactions occurs that 
results in the formation of squalene which is then cyclicised to form lanosterol 
(Do et al., 2009). Lanosterol is converted to zymosterol through another series  
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of chemical modifications. Finally, cholesterol is made from zymosterol via three 
intermediates  -  cholesta-7,24-dienol,  cholesta-5,7,24-trienol  and  7-
dehydrocholesterol  –  requiring  the  activity  of  a  C8-C7  sterol  isomerase,  a  C5 
desaturase,  a  C24-  and  a  C7-sterol  reductase,  respectively  (Figure  2.10)  
(Moebius et al., 2000).  
2.5.3 C8-C7 sterol isomerase 
Sterol isomerase (SI) catalyses the movement of the double bond in the second 
sterol ring from the C8 to the C7 position (Figure 2.10) (Moebius et al., 1998). SI 
does not require any redox co-factors or metal ions to perform the isomerisation 
reaction, and it is unique amongst the cholesterol biosynthetic enzymes in that 
it is able to catalyse the reverse reaction also (Bae et al., 2001). SI is located in 
the membrane of the endoplasmic reticulum (Simons and Ikonen, 2000), and is 
predicted to have four transmembrane domains (Figure 2.11). SI was originally 
identified as an emopamil-binding protein (EBP) (Silve et al., 1996), and was 
thought to have an effect on ischemia, immunosuppression and neuroprotection 
(Moebius et al., 2000). Since then, it has been shown that emopamil does not 
exert its effects through sterol isomerase activity as originally thought. 
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Figure 2.10 Overview of cholesterol biosynthesis 
Cholesterol  is  formed  from  acetyl  CoA  and  acetoacetyl  CoA  through  a  series  of  molecular 
reactions. Of note, C8-C7 sterol isomerase catalyses the conversion of zymosterol to cholesta-
7,24-dienol.   
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Figure 2.11 Schematic representation of sterol isomerase 
Sterol  isomerase  is  predicted  to  have  four  transmembrane  domains  (amino  acids  coloured 
individually). 
2.5.3.1  Monogenic disease of sterol isomerase 
At  present,  seven  inherited  disruptions  of  cholesterol  biosynthesis  have  been 
described,  five  of  which  are  post-squalene  (Moebius  et  al.,  2000).  Conradi-
Hünermann-Happle  (CHH)  syndrome  is  caused  by  stable  loss-of-function 
mutations within the gene encoding sterol isomerase (Has et al., 2000). Due to 
its X-linked dominant inheritance pattern (Moebius et al., 2000), CHH is also 
called  chondrodysplasia  punctata  type  II  (CPDX2)  (Becker  et  al.,  2001).  The 
disease occurs almost exclusively in females but there has been a recent report 
of CDPX2 in a male patient (Aughton et al., 2003). The key clinical features of 
CDPX2  are  due  to  the  skeletal  dysplasia  causing  assymeteric  limb  shortening, 
short stature and scoliosis however it also affects the skin (linear ichthyosis),  
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eyes  (cataracts)  and  hair  (alopecia)  (Figure  2.12).  This  severe  phenotype  is 
discernable from birth, and is caused by an inability to make cholesterol during 
fetal  development.  Several  loss-of-function  mutations  (E80K,  R110Q,  R147G, 
R147H) in SI have been identified in CDPX2 patients (Braverman et al., 1999; 
Derry et al., 1999; Has et al., 2000; Becker et al., 2001). Currently, there is no 
treatment for this debilitating disease.  
 
Figure 2.12 The physical abnormalities of a person with CDPX2 
(a) Asymmetric facial appearance, showing coarse, sparse hair, undirected growth of eyebrows 
with sparse lateral growth, a flat nasal bridge, bilateral epicanthus, and strabismus. (b) Cicatricial 
alopecia and sparse irregular hair growth and premature graying. Figure courtesy of (Whittock et 
al., 2003). 
2.6 Conclusion 
By working with the adenosine 2a receptor (a flexible membrane protein) and 
sterol  isomerase  (a  rigid-bodied  membrane  protein)  together,  I  wanted  to 
determine  whether  or  not  it  is  equally  easy  (or  difficult)  to  produce  highly- 
dynamic  and  rigid  human  membrane  proteins  in  milligram  quantities,  purify 
them  to  homogeneity  without  aggregation  and  grow  diffracting  crystals. 
Moreover,  over  the  course  of  my  Ph.D.,  I  wanted  to  develop  new 
technologies/methodologies  that  would  make  it  easier  to  work  with  my  two 
target  proteins  (and  could  be  readily  adapted  for  use  with  other  mammalian 
membrane proteins).  
3  Materials and Methods 
 
3.1 Strains 
Escherichia coli strain DH5α (Invitrogen) was routinely used for transforming and 
propagating  both  the  cloning  and  recombinant  expression  plasmids. 
Occasionally,  the  Dam-  E.  coli  strain  SCS110  (Stratagene)  was  used  when 
unmethylated  plasmid  DNA  was  required  for  digestion  with  a  methylation-
sensitive restriction enzyme (such as XbaI). All protein production in E. coli used 
the BL21 (DE3) strain (Novagen). Recombinant MP expression was performed in 
the Pichia pastoris strain X33 (Invitrogen).  
3.2 Media 
E. coli was grown either on LB (1% tryptone, 0.5% yeast extract and 1% NaCl) or 
LS-LB (1% tryptone, 0.5% yeast extract and 0.5% NaCl) media according to the 
antibiotic  being  used  for  selection.  Bacteria  containing  ampicillin-resistant 
plasmids were grown on LB, zeocin resistant ones on LS-LB.  
P.  pastoris  strains  were  routinely  cultured  using  YPD  (1%  yeast  extract,  2% 
peptone and 2% glucose) medium. For small-scale expression experiments, the 
yeast transformants were grown on BMGY (1% yeast extract, 2% peptone, 100 mM 
potassium phosphate pH 6, 1.34% yeast nitrogen base, 4 x 10
-5% biotin and 1% 
glycerol) and then induced using BMMY (same as BMGY except that it contains 
0.5% methanol instead of 1% glycerol). 
3.3 Expression plasmid construction 
The original human adenosine 2a receptor cDNA was obtained from Dr. Timothy 
Palmer  (University  of  Glasgow).  Previously,  the  N-linked  glycosylation  site  at 
Asn154 had been removed by mutating this residue to Gln (Fraser, 2006). This  
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deglycosylated version of the receptor cDNA was denoted dG hA2aR. cDNA of 
thermostabilized  mutants  of  hA2aR  which  were  conformationally-fixed  to 
preferentially bind either antagonist or agonist, (known as Rant21 and Rag23, 
respectively) were provided by Dr. Chris Tate (MRC-LMB, Cambridge). 
Human sterol isomerase cDNA was purchased from OriGene (US). 
hSI and the hA2aR were expressed using modified versions of the basic Pichia 
pastoris expression vectors pPICZA and pPICZαA (both Invitrogen), respectively.  
3.3.1 PCR amplification and sub-cloning strategies 
Oligonucleotide  primers  used  in  all  PCR  reactions  had  at  least  21  bases 
complimentary to the template DNA, and had a GC content of ca. 40%. Primers 
were  synthesised  by  either  Sigma-Genosys  (UK)  or  Eurofins  MWG  Operon 
(Germany). Primers were resuspended in H2O to a concentration of 50 pmol/µl, 
and stored at -20°C.  
All PCR reactions were performed using KOD HotStart DNA Polymerase (Merck 
Biosciences) using the appropriate template and primer combinations. Typically, 
PCR reactions consisted of an initial 2 min Polymerase activation step at 98°C. 
This  was  followed  by  between  25-35  cycles  each  consisting  of  a  DNA 
denaturation  step  (98°C  for  20s),  primer  annealing  (55°C  for  10s)  and  DNA 
extension (70°C for 20s per kb of DNA being amplified). After the last cycling 
step, the PCR reaction was concluded with a further 10 min at 70°C to ensure all 
de novo DNA synthesis had occurred. 
PCR products were run on 1% (w/v) agarose gels alongside a 1kb DNA ladder 
(Promega). DNA was visualised using SYBR Safe DNA gel stain (Invitrogen). DNA 
fragments were extracted from the agarose gel using QIAquick Gel Extraction kit 
(QIAGEN).  A-tails  were  added  to  all  extracted  PCR  products  using  Taq 
polymerase (New England Biolabs) with dATP as substrate prior to ligation into 
the  cloning  vector  pGEM-T  Easy  (Promega).  The  ligation  mixture  was 
transformed into DH5α cells by heat shock (42°C for 1 min; 2 min on ice; 1h  
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shaking  at  37°C  in  LB),  plated-out  on  LB  agar  plates  containing  100  µg/ml 
ampicillin  (Invitrogen)  and  100  µg/ml  5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) (Roche Applied Science), and incubated overnight at 
37°C. Colonies containing recombinant vector where white whereas those that 
contained vector only were blue. 
Several putative white colonies for each pGEM construct were grown up in 5 ml 
of  LB  containing  100  µg/ml  ampicillin  overnight  at  37°C.  Plasmid  DNA  was 
isolated from cell cultures using the QIAprep spin miniprep kit (QIAGEN). The 
identity of recombinants was confirmed first by restriction digestion and then by 
sequencing (which was carried out at the DNA Sequencing and Services facility, 
University of Dundee). 
At a later stage, DNA fragments were sub-cloned from the pGEM-T Easy vectors 
into  the  P.  pastoris  expression  plasmids.  Ligation  reactions  were  performed 
using T4 DNA ligase (New England Biolabs). Following transformation into DH5α, 
the cells were plated-out onto low-salt LB plates containing the antibiotic zeocin 
(25 µg/ml). pPICZ(α)A plasmid DNA was isolated and charaterised as described 
for  pGEM-T  Easy  except  that  the  colonies  were  grown  up  in  LS-LB/Zeocin. 
Glycerol  stocks  were  prepared  for  all  E.  coli  transformants  containing  the 
desired plasmids (both cloning and expression), which were stored at -80°C. 
3.3.2 Making a truncated version of dG hA2aR 
Truncated dG hA2aR was amplified using the primers GCGCCTGAATTCATGCCCAT 
CATGGGCTCCTCG  and  ATCTTAGCGGCCGCACTGGTGCCAGCTGCCTTGAAAGG  that 
contained the restriction sites EcoRI and NotI, respectively (restriction sites are 
coloured red). The reverse primer truncated the C-terminal tail of the hA2aR at 
Ser 320. The PCR was carried out as described in Section 3.3.1 using a full-length 
dG hA2aR cDNA as template (Fraser, 2006). The PCR fragment was sub-cloned 
into pGEM-T Easy as described in Section 3.3.1.   
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3.3.3 Construction of the AαHT – TB expression plasmid 
A His10-tag followed by a TEV protease recognition site was incorporated into a 
pPICZαA vector that already contained dG hA2aR  immediately upstream of the 
EcoRI  cloning  site  using  the  forward  primer  GAGGCTGAAGCTCATCATCATC 
ATCATCATCATCATCATCATGAAAATCTGTATTTCCAGAGTGAATTCATGCCCATCATGG
GC and reverse primer GCCCATGATGGGCATGAATTCACTCTGGAAATACAGATTTTC 
ATGATGATGATGATGATGATGATGATGATGAGCTTCAGCCTC  (where  the  hA2aR 
sequence is in green, the EcoRI site is in red, the TEV site is in purple, the His10 
tag is in blue and the pPICZaA sequence is in black). 
Furthermore, the biotin acceptor domain from P. shermanii was amplified by 
PCR using the PinpointTM Xa-1 vector (Promega) as template using the primers 
GCGGCCGCTGAAAATCTGTATTTCCAGAGTGCCGGTAAGGCCGGAGAGGGCGAG  and 
TCTAGATCACCCGATCTTGATGGACCCTGACCGCCCTGCACGGC  which  contained 
NotI and XbaI restriction sites, respectively. [Restriction sites are in red, the TEV 
site is in purple and the biotin acceptor site is in aqua]. The PCR fragment was 
sub-cloned into pGEM-T Easy (Section 3.3.1) before it was transferred to the 
AαHT- dG hA2aR expression vector introducing the TEV-biotin acceptor domain 
between the NotI and XbaI restriction sites.  
3.3.4 Creating HT – trunc dG hA2aR – TB  
The truncated dG hA2aR cDNA described in 3.3.2 was sub-cloned into the AαHT – 
TB expression vector detailed in 3.3.3 between the EcoRI and NotI restriction 
sites.  
3.3.5 Creating HT – trunc dG hA2aR – TLB 
The HT – trunc dG hA2aR – TB vector was modified by Dr. Niall Fraser introducing 
SpeI and NdeI restrictions immediately downstream of the TEV protease site and 
upstream of the biotin acceptor site, respectively.  
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The iLOV domain was amplified by PCR with the primers GCTTAGACTAGTATAGA 
GAAGAATTTCGTCATCACTG (forward) and ACGATCCATATGTACATGATCACTTCCAT 
CGAGCTG (reverse) using a cDNA template gifted to me by Dr. John Christie 
(University of Glasgow). [Restriction sites are coloured red and ilOV sequence is 
in pink]. The forward and reverse primers contained SpeI and NdeI restriction 
sites, respectively.  The iLOV PCR product was first sub-cloned into pGEM-T Easy 
(Section 3.3.1) and then transferred to the modified HT- trunc dG hA2aR – TB 
expression vector by restriction digestion with SpeI and NdeI.   
3.3.6 Creation of GU hA2aR, Rant21 and Rag23 cDNAs 
The trunc dG hA2aR cDNA was modified to i) remove a part of IL3 predicted to 
be disordered, and ii) shorten the truncation so that it was the same as the 
Rant21/Rag23 constructs. This was accomplished by PCR in several stages using 
the  HT-  trunc  dG  hA2aR  -TLB  construct  as  template.  PCR  reaction  1  was 
performed  using  the  5AOX1  primer  that  binds  to  the  pPICZαA  vector, 
GACTGGTTCCAATTGACAAGC  (forward)  with  the  reverse  IL3  deletion  primer, 
AGCATGGACCTCCTTCAGCTGTCGTCGCGCCGCCAG).  [C-terminal  to  the  IL3 
deletion is in orange; N-terminal is blue]. PCR reaction 2 was performed using 
the forward IL3 deletion primer CGACAGCTGAAGGAGGTCCATGCTGCCAAGTCACT 
G  and  reverse  reduced  C-terminal  truncation  primer  ACGATTTTCAGCGGCCGC 
TGCCTTGAAAGGTTCTTGCTGCCT). These two PCR products were combined in a 
third PCR reaction using the forward 5AOX1 and reverse truncation primers to 
create the Glasgow University (GU) version of the hA2aR.  
A Rant21 PCR product was generated in exactly the same way as for the GU 
construct. Rag23, however, required an additional modification to remove its 
glycosylation site so it was made by combining three PCR products (instead of 
two for GU & Rant21). Firstly, the glycosylation site was removed by performing 
a  PCR  reaction  using  the  5AOX  forward  primer  with  a  reverse  primer  that 
overlapped  the  glycosylation  site  GGAGTGCGCCTTGCCCTCCTTTGGCTGACCGCA 
[underline denotes the Asn154Gln change]. PCR reaction 2 was performed using 
the glycosylation site forward primer GGCAAGGCGCACTCCCAGGGCTGCGGGGAG 
GGC with the reverse IL3 deletion primer AGCATGGACCTCCTTCGCCTGTCGTCGC  
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GCCGCCAG. [C-terminal to the IL3 deletion is in orange; N-terminal is blue]. PCR 
reaction  3  was  performed  using  the  forward  IL3  deletion  primer 
CGACAGGCGAAGGAGGTCCATGCTGCCAAGTCACTG  and  the  reverse  reduced  C-
terminal truncation primer. These three PCR products were combined in a fourth 
PCR reaction using the forward 5AOX1 and reverse truncation primers to create 
the deglycosylated IL3 deleted version of Rag23. 
The GU, Rant21 and Rag23 PCR products were first sub-cloned into pGEM-T Easy 
(Section 3.3.1) and then transferred into the modified HT- TLB expression vector 
by restriction digestion with EcoRI and NotI.   
 
3.3.7 Creating the -CLBH expression plasmids  
The CLBH tag was generated by PCR with the primers GCGGCCGCTGTCCTATTCC 
AGGGCCCAACTAGTATAGAGAAGAAT (forward) and TTCTAGATCAGTGATGGTGATG 
GTGATGGTGATGGTGATGCCCGATCTTGATGAGACCCTGACC (reverse). [Key: the C3 
protease  site  is  denoted  by  purple,  the  His10  tag  in  blue].    The  -CLBH  PCR 
product  was  first  sub-cloned  into  pGEM-T  Easy  (Section  3.3.1)  and  then 
transferred into the basic pPICZA and pPICZαA vectors by restriction digestion 
with NotI and XbaI.   
GU-,  Rant21-  and  Rag23-CLBH  were  created  by  sub-cloning  the  three  hA2aR 
cDNAs from the HT-TLB vectors into the Aα-CLBH vector by restriction digestion 
with EcoRI and NotI. 
Sterol isomerase was amplified from the cDNA obtained from Origene using the 
primers GAATTCATGACTACCAACGCGGGCCCCTTG (forward) and GCGGCCGCAGTT 
CTTCTTGCTCTTGGCTTTTG (reverse). The hSI PCR product was first sub-cloned 
into pGEM-T Easy (Section 3.2.1) and then transferred into the A-CLBH vector by 
restriction digestion with EcoRI and NotI. 
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3.4 Transformation of recombinant expression plasmids 
into P. pastoris 
E.  coli  that  had  been  previously  transformed  with  the  P.  pastoris  expression 
vectors were grown up overnight from glycerol stocks in 100 ml of LS-LB/Zeocin 
at 37°C with constant shaking. The cells were pelleted by centrifugation and 
plasmid  DNA  isolated  using  the  QIAGEN  plasmid  Maxi  kit.  The  DNA  was  then 
concentrated by precipitating it using ethanol. 10-50 µg of plasmid DNA in a final 
volume of 20 µl was linearised overnight by digesting with PmeI (New England 
Biolabs). Linearised plasmid was mixed with 80 µl of competent X33 cells (that 
had been made as described in the Pichia Easy Select manual (Invitrogen)). After 
incubating on ice for 5 min, the yeast were transformed by electroporation (2kV, 
5 ms). The yeast were allowed to recover for 2h at 30°C in 1 M sorbitol before 
they  were  plated  out  on  YPDS  plates  containing  different  concentrations  of 
Zeocin (from 0.2 to 2.0 mg/ml). Following a 72 h incubation at 30°C, numerous 
colonies appeared on the plates. These were re-streaked on fresh YPD plates 
containing 0.5 mg/ml Zeocin. 
3.5 Recombinant MP production in P. pastoris 
3.5.1 1 ml cultures in 48-well plates 
Clonal  selection  of  yeast  that  had  been  transformed  with  iLOV-containing 
expression plasmids was performed by measuring whole cell fluorescence from 
yeast cells that had been grown and induced on a 1 ml scale in a 48-well sterile 
plate (Section 5.3). Per clonal selection, the expression level was determined for 
12 different colonies. For each of the transformants, two 1 ml cultures were 
established in BMGY. The plate was then shaken for 24 h at 30°C. The cells were 
pelleted by centrifugation (1500 g, 5 min), and then resuspended in BMMY. The 
plate was returned to the shaking incubator for a further 24 h at 22°C. After 
this,  cells  were  harvested  by  centrifugation  and  washed  twice  with  distilled 
water before being resuspended in 1 ml of distilled water. 20 µl of the cells from 
every culture were transferred to a 96-well black plastic plate (Corning) and  
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made upto to a final volume of 200 µl with distilled water for determining whole 
cell  fluorescence  levels.  Glycerol  stocks  were  prepared  for  the  transformant 
found to have the highest expression level of the target protein by mixing equal 
volumes of an overnight culture grown in YPD with sterile 50 % (v/v) glycerol in a 
sterile cryovial. The cultures were snap-frozen using liquid nitrogen and stored 
at –80°C.  
3.5.2 Small-scale (10 ml) expression cultures 
Clonal selection of yeast transformed with αHT – trunc dG hA2aR – TB and αHT – 
full-length  dG  hA2aR  –TB  was  performed  by  single-point  radioligand  binding 
analysis on membranes isolated from cells grown and induced on a 10 ml scale 
(Section 4.3.2). Individual transformants were grown up in 10 ml of BMGY in 
sterile 50 ml falcon tubes at 30°C for 24h. The cells were spun down (1500 g, 5 
min) and re-suspended in 10 ml of BMMY, and grown for a further 24 h at 22°C. 
Cells were harvested by centrifugation (4000g, 5min, 4°C), and membranes made 
as described in Section 3.6.2. 
3.5.3 Medium-scale (100 ml) expression cultures 
Yeast transformed with αHT- dG hA2aR – TB and αHT- trunc dG hA2aR – TB were 
grown  at  30°C  in  500  ml  shake-flasks  containing  100  ml  of  BMGY  until  the 
cultures had an OD600 of between 2-6. At this point, receptor production was 
induced by adding 0.5% methanol, reducing the temperature to 22°C and adding 
10 mM theophylline. 0.5% methanol was also added 12 and 24 h post-induction. 
Cells  were  harvested  by  centrifugation  (5000g,  20  min,  4°C)  after  36  h. 
Membranes were made as described in Section 3.6.2 which were later used in 
radioligand binding assays for assessing the pharmacological properties of the 
expressed receptors (Section 4.4). 
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3.5.4 Recombinant MP production in fermenter culture 
All fermentations were carried out using an Applikon® 7L fermentor vessel and 
ADI 1025 bioreactor system. Dissolved oxygen (dO2) was maintained above 25% 
through feedback of agitation (minimum 1000 r.p.m.) and compressed air (0.8 
litre min
-1). Oxygen (1 bar pressure) was automatically drawn in as necessary to 
help maintain the dO2 setpoint during growth at high-cell densities. The pH was 
maintained at around 5 through addition of 23% NH4OH. Antifoam A (Fluka) was 
added drop-wise as required to reduce foaming during culture growth.  
4 litres of basal salts media containing 4% glycerol (Table 3.1) was autoclaved 
within  the  glass  fermentation  vessel.  To  this,  15  ml  of  PTM1  trace  salts  was 
added (Table 3.1). The media was inoculated with 200 ml of yeast that had been 
grown up overnight in YPD so that the initial fermenter culture had an OD600 of 
0.5-1.0. Cultures were grown on basal salts media for 18 h at 30°C until all of 
the original glycerol had been consumed. Following this, the culture was feed 
50% glycerol (v/v) for 11 h at a rate of 1.09 ml/min. The yeast were then starved 
for  1  h  to  ensure  that  any  residual  glycerol  had  been  consumed  before  the 
culture was adapted for growth on methanol (4 h at 0.07 ml/min followed 12 h 
at 0.09 ml/min methanol). Target MP production was induced by reducing the 
culture  temperature  to  22°C.  [When  hA2aR  was  being  made  in  fermenter 
culture, 50 mM theophylline powder was added at this stage].  Methanol feeding 
continued for a further 12 h at 0.13 ml/min followed by 36 h at 0.33 ml/min. 
Samples were taken at regular timepoint intervals to assess culture growth by 
measuring OD600 and/or wet cell weight. Recombinant MP production levels were 
determined either by single-point radioligand binding analysis or measuring iLOV 
fluorescence. After 80 – 96 h cultivation, the fermentations were stopped and 
the  cells  harvested  by  centrifugation  (5000g,  20min,  4°C).  The  pellets  were 
stored at -20°C, and used as they were required.  
  
Materials and Methods     71 
  Components  Amount per litre 
Basal salts medium  Phosphoric Acid (85%) 
Calcium Sulphate 
Potassium Sulphate 
Magnesium Sulphate – 7H20 
Potassium Hydroxide 
Glycerol 
Water 
(26.7 ml) 
0.93 g 
18.2 g 
14.9 g 
4.13g 
40.0 g 
to 1 litre 
Sterilised by autoclaving 
 
PTM1 trace salts  Cupric Sulphate – 5H2O 
Sodium Iodide 
Magnesium Sulphate – H2O 
Sodium Molybdate – 2H2O 
Boric Acid 
Cobalt Chloride 
Zinc Chloride 
Ferrous Sulphate – 7H2O 
Biotin 
Sulphuric Acid 
Water 
6.0 g 
0.08 g 
3.0 g 
0.2 g 
0.02 g 
0.5 g 
20.0 g 
65.0 g 
0.2 g 
5.0 ml 
to a final volume of 1 
litre 
Sterilised by filtration 
 
Table 3.1 Recipes for fermentation media and trace feed solution  
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4 litres of basal salts media was prepared and autoclaved immediately prior to commencing a 
fermentation. PTM1 trace salts were made and stored in 50 ml aliquots at 4°C, and used as it was 
required.  
 
3.6 Cell lysis and membrane preparation 
3.6.1 Chemical cell lysis 
After  the  iLOV  fluorescence  intensity  had  been  measured  in  intact  cells,  the 
cells  from  the  1  ml  yeast  cultures  in  the  48  well  plates  were  re-pelleted  by 
centrifugation (1500g, 5 min) and the water discarded.  The cells were lysed 
using  100  µl  of  Yeast  Buster™  Protein  Extraction  Reagent  (Merck)  and  10  µl 
Benzonase nuclease (Merck). To ensure complete rupturing the cells were placed 
in a shaking incubator at 30
oC for 30 min. Following this, 1 ml of distilled water 
was  added  to  each  well  before  the  plate  was  centrifuged  (1500g,  5  min)  to 
pellet cell debris. The supernatants containing the cell contents were removed 
and their protein concentration determined by BCA assay (Pierce) using BSA as 
standard.  
3.6.2 Small-scale membrane preparation 
10 ml cell pellets (Section 3.5.2) were resuspended in Breaking Buffer (4 mg/ml 
BSA, 5 mM EDTA, 150 mM NaCl in 50 mM Tris HCl pH 7.4). An equal volume of 
glass beads was added and the cells were broken by vortexing (5 x 1 min). The 
beads were separated by filtration through a chromatography column and the 
flow-through  containing  membranes  was  subjected  to  centrifugation.  A  low 
speed spin (10,000g, 10 min) was used to pellet cell debris and unbroken cells. 
The supernatant was retained and centrifuged at high speed (150,000g, 30 min) 
to pellet membranes. Membrane pellets were resuspended in 1 ml of 150 mM 
NaCl in 50 mM Tris HCl pH 7.4, and the protein concentration determined by BCA 
assay (Pierce) using bovine serum albumin (BSA) as standard.   
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3.6.3 Large-scale membrane preparation 
Cell  pellets  from  fermentation  cultures  were  thawed  overnight  at  4°C  and 
resuspended in Breaking Buffer (5 mM EDTA, 150 mM NaCl in 50 mM Tris HCl pH 
7.4). Homogenised cells were passed through a Constant Systems cell disrupter 
three  times  at  a  pressure  of  30  kPsi.  Following  this,  10%  glycerol  (v/v)  and 
protease  inhibitors  (phenylmethanesulfonylfluoride  (PMSF)  and  benzamidine) 
were  added  to  the  ruptured  cells.  Membranes  were  then  isolated  by 
centrifugation  as  described  in  Section  3.5.2.  Membrane  pellets  were 
resuspended in a Membrane Resuspension Buffer consisting of 10% glycerol and 
150 mM NaCl in either 50 mM Tris HCl, HEPES or sodium phosphate buffer at a pH 
of 7.4). The protein concentration of the membranes was determined by BCA 
assay  (Pierce)  using  BSA  as  standard.  Membranes  were  diluted  with  the 
appropriate  Membrane  Resuspension  Buffer  so  that  they  had  a  final 
concentration of 20 mg/ml. These were stored at -20°C in 50 ml aliquots. 
 
3.7 Measuring iLOV fluorescence 
3.7.1 iLOV excitation and emission spectra 
Excitation  and  emission  spectra  for  pure  iLOV  (a  gift  from  Dr.  John  Christie, 
University of Glasgow) were recorded and compared against those obtained for 
flavin  mononucleotide  (FMN)  and  P.  pastoris  X33  membranes.  Measurements 
were  made  in  quartz  cuvettes  (pathlength  1  cm)  using  a  Perkin-Elmer  L550B 
spectrophotometer. Fluorescence was measured at right angles to the excitation 
beam.  Excitation  spectra  were  recorded  from  300  –  460  nm  measuring 
fluorescence emission at 485 nm. Emission spectra were recorded between 470 
and 600 nm, exciting the samples at 450 nm.   
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3.7.2 Measuring iLOV fluorescence in 96 well plates 
The iLOV fluorescence of individual samples (e.g. whole cells or FSEC elution 
fractions) was determined using a FLUOstar OPTIMA plate-reader. 200 µl of each 
sample was added to a single well in a black Corning 96-well plate. Samples 
were excited at 450 nm and iLOV fluorescence emission measured at 520 nm. 
Results  were  analysed  using  the  OPTIMA  data  analysis  software.  Fluorescence 
readings  from  intact  yeast  cells  were  used  in  combination  with  protein 
concentration measurements to determine expression levels in clonal selection 
experiments. 
 
3.8 Radioligand binding analysis 
All radioligand binding assays on ‘wild-type’ hA2aR were carried out using the 
potent,  selective  A2a  antagonist  [
3H]  ZM241385  (American  Radiolabelled 
Chemicals).  Assays  on  Rag23  were  performed  using  the  agonist  [
3H]  NECA 
(Amersham Biosciences). The same Binding Buffer (5 mM EDTA in 50 mM Tris HCl 
pH  7.4)  was  used  with  both  radioligands.  All  measurements  were  made  in 
quadruplicate.  
3.8.1 [
3H] ZM241385 binding 
Saturation and single-point binding assays on membrane-bound hA2aR contained 
between  1-10  µg  protein  in  a  final  volume  of  500µl.  0.1U  of  adenosine 
deaminase (Roche Applied Science) was also added to each cocktail in order to 
degrade any adenosine released from the membranes. Saturation binding was 
performed by incubating [
3H] ZM241385 (final concentration 0.02 – 12 nM) with 
receptor for 1 h at 30°C. Non-specific binding was determined in the presence of 
10  mM  theophylline.  Following  incubation,  bound  and  free  radioligand  were 
separated  by  sucking  the  suspension  onto  glass  fibre  filters  (Whatman)  pre-
soaked in 0.3% polyethyleneimine under vacuum using a Brandel Harvester. The 
filters were washed three times with 50 mM Tris HCl pH 7.4 before they were  
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counted using Ultim Gold™ XR scintillation fluid (Perkin Elmer). The counts in 
dpm were converted to fmol of [
3H] ZM241385 bound using the specific activity 
of the radioligand. Specific binding was determined by subtracting the binding 
measured  in  the  presence  of  theophylline  (non-specific)  away  from  those 
measured in buffer only (total). Binding data was analysed using the computer 
package  GraphPad  Prism.  Curves  of  total,  non-specific  and  specific  binding 
against [radioligand] (nM) were plotted and fitted using a non-linear regression. 
The curve fit gave values for the maximum number of binding sites occupied by 
the ligand (Bmax) as well as the receptor’s equilibration dissociation constant (Kd) 
for [
3H] ZM241385. The Kd is the concentration of radioligand required to occupy 
half of the available binding sites and, therefore, is a measure of the affinity of 
the ligand for the receptor. The Bmax is a reliable estimate of the receptor’s 
expression level.  
Single-point binding assays on membrane bound hA2aR had a final volume of 200 
µl, contained between 1-10 µg of protein and ca. 10 nM [
3H] ZM241385. Non-
specific binding was determined in the presence of 10 mM theophylline. 
3.8.2 [
3H] NECA binding 
Saturation  binding  using  [
3H]  NECA  was  performed  on  membranes  containing 
Rag23 in the same way as that described for [
3H] ZM241385 with the following 
differences: i) the assay cocktail had a volume of 100 (instead of 500) µl, ii) [
3H] 
NECA  was  used  at  considerably  higher  concentrations  (20  –  500  nM),  and  iii) 
adenosine  deaminase  was  omitted  as  it  metabolises  NECA  rendering  the 
radioligand unable to bind to the receptor.  
3.9 SDS-PAGE 
20 µl of each protein sample to be analysed by SDS-PAGE was mixed with 5 µl of 
NuPAGE®  LDS  Sample  Buffer  (Invitrogen)  and  heated  for  10  min  at  60°C. 
Denatured samples were loaded onto a 12-well 10% NuPAGE® Bis–Tris pre-cast 
gel (Invitrogen) along with an aliquot of SeeBlue Plus2 pre-stained marker. The  
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gel was run in MES buffer according to the manufacturer’s instructions (200V for 
40-50 min). Protein bands were visualised by staining with SimplyBlue™ SafeStain 
(Invitrogen). 
 
3.10 Detergent screening and fluorescence size-
exclusion chromatography (FSEC)  
2 ml of yeast membranes (at a concentration of 20 mg/ml) containing either HT-
Rag23-TLB or SI-CLBH were solubilised using the detergents DDM, DM, NM and 
βOG as well as the detergent-lipid mixture DDM/CHS. 0.6 ml of 10% detergent 
stock solutions were added to the membranes and the mixtures stirred for 1 h at 
4°C. Samples were then centrifuged at high speed (50,000g, 10 min) to pellet 
any unsolubilised material. The supernatant containing the iLOV-tagged MP was 
filtered before 500 µl of it was injected onto a Superose™ 6 FLPC gel filtration 
column equilibrated in buffer (either Tris, HEPES or sodium phosphate – all pH 
7.4) containing 5% glycerol and an appropriate concentration of the detergent 
being studied (0.05% DDM, 0.15% DM, 0.3% NM and 0.8% βOG). The column was 
run at a rate of 0.3 ml/min, and 0.6ml fractions were collected. 200 µl of each 
fraction was transfered to a black Corning 96-well plate and the intensity of 
iLOV fluorescence measured using a platereader. Following this, FSEC profiles 
were plotted. 
 
3.11 Expression and purification of accessory enzymes 
3.11.1  Tobacco Etch Virus (TEV) protease 
BL21(DE3) cells that had been previously transformed with pET15b-TEV protease 
(a  gift  from  Dr.  Alan  Riboldi-Tunnicliffe,  University  of  Glasgow)  were  grown 
overnight from a glycerol stock in 5 ml of LB media at 37°C. The next morning, 
the cells were added to 500 ml of fresh media and grown to an OD600 of 0.7. TEV 
protease expression was induced by adding 1 mM IPTG. The temperature was  
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reduced to 22°C, and the cells shaken for a further 16 h. Cells were harvested by 
centrifugation  (4000g,  20  min)  and  then  resuspended  in  lysis  buffer  (150  mM 
NaCl,  25  mM  imidazole  in  50mM  Tris  HCl  pH  8.0).  Cells  were  broken  using  a 
Constant Systems cell disruptor (3 passages at 20 kPsi). The broken cells were 
centrifuged at 10,000g and the supernatant containing TEV protease passed over 
a 5 ml Nickel column that had been equilibrated in lysis buffer. The column was 
washed extensively with lysis buffer to remove any contaminant proteins before 
the TEV protease was released from the column using an imidazole (0 – 800 mM) 
gradient in 150 mM NaCl, 50 mM Tris HCl pH 8.0. DTT and EDTA were added to 
the elution fractions (both to a final concentration of 1 mM) to prevent the TEV 
protease precipitating out of solution. Fractions containing TEV protease were 
pooled and desalted into 150 mM NaCl in 50 mM Tris HCl pH 7.4 using a PD10 
column. TEV protease was aliquoted (1 ml samples with a protein concentration 
of 5 mg/ml) before being snap-frozen with liquid nitrogen and stored at -20°C.  
3.11.2  Human Rhinovirus C3 protease 
BL21(DE3) cells that had been previously transformed with pET15b-C3 protease 
(a  gift  from  Dr.  Alan  Riboldi-Tunnicliffe,  University  of  Glasgow)  were  grown 
overnight from a glycerol stock in 5 ml of LB media at 37°C. Expression and Ni
2+-
affinity purification of C3 protease was performed as described for TEV protease 
(Section  3.11.1).  An  additional  gel  filtration  step  (Sepharose  C6  column 
equilibrated in 150 mM NaCl, 50 mM Tris HCl pH 7.4) was then performed to 
improve enzyme purity. 
3.11.3  Biotin ligase 
The biotin ligase (BirA) gene was amplified from E. coli strain 0157 genomic DNA 
using  the  primers  TGACCACATATGATGAAGGATAACACCGTGCCACTG  and 
CGTAGAGGATCCTTATTTTTCTGCACTACGCAGGGA.  The  PCR  product  was 
introduced into pGem T-Easy as described in Section 3.3.1 before it was sub-
cloned into NdeI/BamHI-digested pET15b vector. Correct recombinant plasmids 
were  identified  by  restriction  analysis  and  sequencing.  The  BirA  expression 
plasmid was transformed into BL21 (DE3) cells and expressed and purified as  
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described in Section 3.11.1. The only exception being that no DTT and EDTA 
were added to the elution fractions. 
 
3.12 Purification of HT – trunc dG hA2aR – T(L)B  
The basic buffer (HT-TLB buffer) used to purify HT – trunc dG hA2aR – T(L)B was 
150 mM NaCl, 10% glycerol in 50 mM Tris HCl pH 8, 0.05% DDM, 0.01% CHS.  
3.12.1  Membrane solubilisation 
Membranes containing either HT – trunc dG hA2aR – TB or HT – trunc dG hA2aR – 
TLB at a concentration of 20 mg/ml were solubilised by adding a 10:2 DDM:CHS 
stock solution to the membranes so that the final DDM concentration was 2.5%. 
The  mixture  was  stirred  for  2  h  at  4°C.  Following  this,  the  sample  was 
centrifuged at 150,000g for 30 min. The supernatant containing the detergent-
solubilised receptor was added to an equal volume of HT-TLB buffer prior to the 
Ni
2+-affinity chromatography step. 
3.12.2  Ni
2+-affinity purification of HT– trunc dG hA2aR –T(L)B 
A  5ml  Ni
2+  column  was  equilibrated  in  HT-TLB  buffer  containing  75  mM 
imidazole.  The  supernatant  containing  receptor  was  then  passed  over  the 
column three times. The Ni
2+ column was washed with HT-TLB buffer containing 
500 mM (instead of 150) NaCl and 75 mM imidazole. Receptor was eluted from 
the  column  using  500  mM  imidazole  in  HT-TLB  buffer.  Elution  fractions  were 
analysed by SDS-PAGE (Section 3.9)  
3.12.3  Biotinylation and purification using streptavidin  
In  vitro  biotinylation  of  Ni
2+-affinity  purified  HT-trunc  dG  hA2aR  –  TLB  was 
performed by adding 1 mg of pure BirA to the receptor along with 50 µM biotin, 
20  µM  ATP  and  10  mM  Mg-o-acetate.  The  mixture  was  stirred  continuously  
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overnight at 4°C. The next morning the receptor protein was doubly desalted 
into HT-TLB buffer using PD-10 columns (GE Healthcare) to remove free biotin. 
Streptavidin  resin  (Pierce)  was  equilibrated  with  HT-TLB  buffer.  Biotinylated 
receptor was added to the streptavidin slurry and mixed by rotating on a wheel 
at 22°C for 4 h. The sample was centrifuged (4500 g, 10 min) to pellet the resin. 
The supernatant containing contaminant proteins was discarded. The beads were 
washed  extensively  with  HT-TLB  buffer  to  ensure  that  any  proteins  that  had 
weakly bound to the beads were removed.   
3.12.4  Tag removal using TEV protease 
Tag removal from biotinylated HT – trunc dG hA2aR – TLB bound to streptavidin 
beads was performed by adding 5 mg of TEV protease to the resin in HT-TLB 
buffer containing 0.5 mM EDTA, 3 mM reduced glutathione and 0.3 mM oxidised 
glutathione. The slurry was stirred slowly overnight at 4°C. The next morning, 
the  sample  was  centrifuged  (4500g,  10  min),  and  the  supernatant  reverse-
purified with Ni
2+ beads to remove the HT tag and TEV protease. The cleaned-up 
sample was retained for SDS-PAGE analysis.  
3.12.5  Gel filtration of enriched HT – trunc dG hA2aR – TB 
Ni
2+-affinity purified HT – trunc dG hA2aR – TB was concentrated to a volume of 
ca.  500  µl  and  injected  onto  a  Superose™  6  FLPC  gel  filtration  column 
equilibrated  in  HT-TLB  buffer.  The  column  was  run  at  0.3  ml/min  and  1  ml 
fractions  collected.  The  elution  profile  (A280  v  time)  was  recorded.  Peak 
fractions were retained for analysis by SDS-PAGE.  
3.13 Purification of Rag23 in DDM 
Membranes  containing  Rag23-CLBH  were  resuspended  in  100  mM  NaCl,  10% 
glycerol in 10 mM HEPES pH 7.4 (Rag buffer) at a concentration of 20 mg/ml. 
Membranes were stirred with 100 µM NECA for 30 min at 4°C before DDM was 
added from a 10% (w/v) stock solution so that the final detergent concentration  
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was 2.5%. The solubilisation mixture was stirred for a further 2 h before it was 
centrifuged at 150,000g for 30 min. The supernatant containing Rag23-CLBH was 
diluted with an equal volume of Rag buffer containing 0.05% DDM. A 5 ml Ni
2+ 
charged  His-trap  column  was  equilibrated  in  Rag  buffer  containing  75  mM 
imidazole and 0.05% DDM. The detergent-solubilised material was batch-loaded 
onto  the  column.  This  process  was  repeated  three  times.  The  column  was 
washed with Rag buffer containing 75 mM imidazole and 0.05% DDM. Rag23-CLBH 
was eluted from the column using Rag buffer containing 500 mM imidazole and 
0.05%  DDM.  Aliquots  of  those  fractions  that  were  fluorescent  (i.e  contained 
iLOV-tagged receptor) were retained for analysis by SDS-PAGE. The remainder of 
the  material  was  pooled  and  desalted  into  Rag  buffer  containing  0.05%  DDM 
using PD-10 columns. 20 µl of C3 protease was added per ml of partially-purified 
Rag23-CLBH along with 1 mM DTT and 1 mM EDTA. The cleavage cocktail was 
mixed overnight using a rotating wheel at 4°C. The next morning, Ni
2+ beads 
equilibrated  in  Rag  buffer  containing  0.05%  DDM  was  added  to  the  cleavage 
mixture. The sample was placed back on the wheel for 30 min before it was 
centrifuged at 3000g for 5 min. This process was repeated until the supernatant 
was non-fluorescent. At this point, Rag23 was expected to be largely pure. The 
supernatant  was  concentrated  to  a  volume  of  ca.  500  µl  and  applied  to  a 
Superose 6 column on an AKTA prime plus system (GE Healthcare) that had been 
equilibrated in Rag buffer containing 0.05% DDM. The column was run with a 
flow rate of 0.3 ml/min and 1 ml fractions were collected (which were later 
analysed by SDS-PAGE).  
3.14 Purification of SI in DDM 
SI was purified in DDM as described for Rag23 with the following exceptions. The 
basic purification buffer contained 150 and not 100 mM NaCl. The membranes 
were not pre-incubated with NECA prior to detergent solubilisation. The wash 
buffer for the Ni
2+ column contained 500 and not 100 mM NaCl. Following SDS-
PAGE analysis of pure SI, the major band on the gel was excised for protein 
identification by tandem mass spectroscopy (MS-MS). This work was performed 
at  the  Proteomics  Facility  at  the  University  of  Dundee.  The  protein  
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concentration of pure SI was determined by measuring the A280 of the sample 
and dividing this number by 2.8 (which is the theoretical extinction coeffiecient 
at  280  nm  for  SI  as  determined  by  its  amino  acid  content).  This  value  was 
obtained  using  the  ProtParam  tool  on  the  ExPASy  Proteomics  Server 
(http://www.expasy.ch/tools/protparam.html). 
3.15 Purification of SI in DM 
The purification of SI in DM was the same as that described in Section 3.14 with 
the following exceptions. The basic purification buffer was 150 mM NaCl, 10% 
glycerol in 50 mM sodium phosphate pH 7.4. The membranes were solubilised in 
DM and not DDM. All of the purification buffers contained 0.15% DM instead of 
0.05% DDM. The gel-filtration column was equilibrated with and run in 150 mM 
NaCl, 10% glycerol in 50 mM sodium phosphate pH 6, 0.15% DM. 
3.16 Circular dichroism 
All  CD  measurements  were  made  at  the  Biophysical  Characterisation  Unit, 
University of Glasgow by Dr. Sharon Kelly. 
3.16.1  CD characterisation of SI 
Far- (region 190 - 260 nm) and near-UV (250 – 320 nm) circular dichroism spectra 
of  pure  SI  were  recorded  on  a  Jasco  J-810  spectropolarimeter  using  quartz 
cuvettes with 0.02 and 0.5 cm pathlengths, respectively. The SI sample had a 
protein concentration of 0.6 mg/ml. The far-UV CD data was fitted using the 
CDSSTR  alogorithm  (Johnson,  1999)  to  give  an  estimate  of  the  secondary 
structure content of SI. 
3.16.2  Thermostability analysis of SI by CD 
A series of far-UV CD spectra of pure SI were recorded between 5 and 80°C at 
5°C intervals. Measurements were made in a cuvette with a pathlength of 0.2 cm  
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using  protein  with  a  concentration  of  0.2  mg/ml  protein.  The  extent  of  SI 
unfolding with temperature was determined by plotting the the size of the CD 
signal at wavelengths 209 and 222 nm as a % of the original values prior to heat 
denaturation.  
3.17 CPM assay 
A  stock  solution  of  CPM  reagent  (7-Diethylamino-3-(4-maleimidophenyl)-4-
methylcoumarin)  (Sigma-Aldrich)  was  made  by  first  dissolving  it  in  dimethyl 
sulfoxide (DMSO) to a concentration of 25 mg/ml and then further diluting it 
with  H2O  to  a  final  concentration  of  4  mg/ml.  Care  was  taken  to  prevent 
photobleaching  of  the  CPM  dye  by  storing  it  in  the  dark.  The  CPM  thermal 
denaturation assays were performed in black Corning 96-well plates. For each 
condition investigated, protein and buffer control measurements were made in 
triplicate. Each protein well contained 10 µl of pure SI (0.5 mg/ml), 20 µl of a 
10x buffer solution and 20 µl of either a 10x additive (such as a salt) or H2O. 
Plates were incubated at room temperature for 5 min before 140 µl of 10% SDS 
was added to each well followed by 10 µl of the stock CPM reagent. Control 
samples were set-up in a similar fashion except that the protein aliquot was 
replaced  with  10  µl  of  buffer.  The  plate  was  immediately  transferred  to  a 
fluorescence platereader set at a temperature of 45°C. Fluorescence intensity 
readings  were  taken  at  regular  intervals  over  a  period  of  3  h.  Baseline 
fluorescence recorded in the buffer controls were subtracted from the values 
recorded  in  the  protein  wells,  before  the  three  difference  values  for  each 
condition  were  averaged.  Curves  showing  SI  denaturation  were  plotted  as  an 
increase  in  fluorescence  over  time.  To  allow  comparison  of  the  extent  of  SI 
unfolding in different conditions, the maximum amount of unfolding was defined 
as the fluorescence intensity at t = 8000 s.   
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3.18 Crystallisation trials with SI 
3.18.1  Crystallisation of SI from detergent solution 
Pure SI (in both DDM and DM) was concentrated to ca. 10 mg/ml. SI purified in 
HEPES buffer containing DDM was used with the MemStart, MemSys and PegIon 
crystallisation  screens  (Table  3.2).  SI  purified  in  sodium  phosphate  buffer 
containing  DM  was  used  with  the  MemGold  screen  (Table  3.2).  A  Cartesian 
HoneyBee nanoliter dispensing system (Genomic Solutions Ltd) was used to add 
500 nl of the protein solution to 500 nl of the reservoir in each of the wells in 
the 96 well plate. The plates were stored in a Rhombix Crystal Plate Imager 
(Thermo Scientific) at 20°C and trays monitored automatically over a 3 month 
period. Possible crystal hits were followed-up manually by microscope. Crystals 
obtained in the initial screens were tested for X-ray diffraction using the in-
house X-ray facility at Glasgow (consisting of a Rigaku MicroMax 007 rotating 
anode generator coupled with MarResearch 345 image plate detector). 
Screen  Manufacturer 
MemGold  Molecular Dimensions  
 
MemStart  Molecular Dimensions 
 
MemSys  Molecular Dimensions  
 
Peg/Ion 1 & 2  Hampton Research 
 
Table 3.2 Commercially-available screens used for crystallising SI in detergent solution 
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3.18.2  Lipidic-sponge phase preparation 
Cholesterol doped sponge phases were prepared by dissolving either 0.5 or 5% 
(w/w)  of  cholesterol  directly  into  melted  mono-olein  (MO)  (1-mono-oleyl-rac-
glycerol) (Nu-Chek Prep). The molten MO/cholesterol mixture was weighed into 
small  glass  vials  along  with  the  appropriate  amounts  of  either  PEG400  or 
PEG1500 with 100 mM of a buffer solution (with or without 100 mM of a salt). 
The compositions of all the sponges are listed in Table 6.1. The vials were sealed 
tight and incubated on a roller for one day at 37°C. In cases where the sample 
was not homogenous after this treatment, it was heated to 50°C for 2-3 h and 
then  re-incubated  at  37°C.  Afterwards,  the  samples  were  centrifuged  (20°C, 
5500g, 30 min) and left until a transparent phase was observed. 
3.18.3  Crystallisation of SI in the lipidic-sponge phase 
Pure SI in DM was concentrated to ca. 10 mg/ml and then dialysed for 2h against 
sodium  phosphate  buffer  containing  0.15%  DM  using  mini-dialysis  cassettes 
(Pierce). Trays were set-up as a series of hanging drops using EasyXtal Tool 24-
well crystal trays (QIAGEN). 1 µl of each sponge was pipetted onto the screw-in 
crystallisation support before 1 µl of the protein solution was added on top. The 
crystallization  supports  were  screwed  into  the  reservoir  chambers  which  all 
contained 500 µl of reservoir solution (0.1 g l
-1 Na3PO4, 0.55 M sodium acetate 
and 0.75 M HEPES pH 6.3). Trays were stored in a 20°C incubator and checked 
regularly for crystals.  
4   Creating a generic system for the over-
expression and purification of human 
membrane proteins 
 
4.1 Introduction 
Although  there  are  a  few  exceptions  (e.g.  rhodopsin),  most  mammalian 
membrane  proteins  have  a  low  natural  abundance.  Therefore,  the  first  step 
towards  solving  the  structure  of  any  mammalian  membrane  protein  usually 
involves devising a robust methodology for making milligram quantities of the 
target  protein  in  a  heterologous  system.  The  functional  over-expression  of 
membrane proteins is a non-trivial issue, and is one of the key “bottlenecks” in 
determining the structure of a membrane protein.    
The methylotrophic yeast Pichia pastoris is commonly used for producing soluble 
proteins of mammalian origin. There are several reasons for this including the 
yeast’s  capacity  to  perform  a  range  of  higher-eukaryotic  post-translational 
modifications  as  well  as  its  ability  to  grow  to  high  cell  densities  (ca.  10
9 
cells/ml) on cheap media in fermenter culture. Recombinant protein production 
is driven from the strong, methanol-inducible AOX1 promoter (Macauley-Patrick 
et al. 2005; Hartner and Glieder 2006), and can result in the production of tens 
or even hundreds of milligrams of target protein per litre of culture (Cregg et al. 
2000; Cereghino et al. 2002). It has also been recently shown that a diverse 
range of mammalian membrane proteins, including G-protein coupled receptors, 
transporters and ion channels, can be successfully made in P. pastoris (Weiss et 
al.  1998;  Weiss  et  al.  1998;  Newton-Vinson  et  al.  2000;  Andre  et  al.  2006; 
Horsefield et al. 2008; Aller et al. 2009; Ho et al. 2009; Tao et al. 2009; Alisio 
and  Mueckler).  However,  a  potential  limitation  of  P.  pastoris  as  a  host  for 
making mammalian MPs is its inability to make cholesterol. Instead P. pastoris  
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synthesises another type of sterol called ergosterol which, despite being highly 
similar to cholesterol, is unable to stabilise mammalian MPs in the ways that 
cholesterol does (Opekarova and Tanner 2003). 
Even when a heterologous host as powerful as P. pastoris is used, the expression 
conditions  for  each  target  membrane  protein  must  be  optimised  so  that  the 
maximal yield of protein possible is obtained (Singh et al. 2008). The amount of 
functional  GPCR  obtained  in  P.  pastoris  can  be  increased  by  reducing  the 
induction temperature from 30 to 22°C (Andre et al. 2006; Fraser 2006) as well 
as  adding  either  DMSO  (which  stimulates  membrane  synthesis)  (Andre  et  al. 
2006) or a ligand (e.g. an antagonist) that stabilises the target protein (Weiss et 
al. 1998; Andre et al. 2006; Fraser 2006). With P. pastoris, a dramatic increase 
in protein production level occurs when expression is performed in a fermenter 
as compared to shake flask-culture. Careful optimisation of the methanol feed 
rate  is  essential  to  ensure  that  there  is  sufficient  methanol  present  in  the 
fermenter  to  drive  maximal  protein  production  without  accumulating  excess 
levels  of  methanol  (which  is  toxic  to  the  yeast  at  high  (>4%)  concentrations) 
(Cereghino et al. 2002). 
Once the target MP has been successfully expressed in milligram quantities, it 
must be purified to homogeneity before crystallisation trials can be started. MPs 
can  be  readily  purified  by  affinity  chromatography  using  tags  such  as  His10 
(which  binds  to  Ni
2+  resin)  and  biotin  (which  binds  to  (strept)avidin)  (Terpe 
2003). Tags can be added to a recombinant protein at either its N- or C-terminus 
by manipulating the DNA sequence of the expression vector using PCR. When 
working with MPs, however, it is imperative to determine the expression level of 
the recombinant protein with and without tags to ensure that addition of the tag 
has not affected the amount or functionality of the protein produced by the host 
cell.  
Previous work in our laboratory focused on producing the human adenosine 2a 
receptor  (hA2aR)  in  shake-flask  cultures  of  P.  pastoris  (Fraser  2006).  A  full-
length  cDNA  encoding  the  human  adenosine  2a  receptor  was  cloned  into  a 
modified version of the P. pastoris vector pPICZαA. The basic expression plasmid  
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obtained from Invitrogen had been altered by inserting a His10 tag between the 
Kex2 protease cleavage site and the EcoRI cloning site (Fraser 2006) (Figure 4.1). 
hA2aR  was  made  as  a  fusion  with  the  α-factor  leader  sequence  from  S. 
cerevisiae (Figure 4.1). When fused to the N-terminus of GPCRs expressed in P. 
pastoris, the α-factor leader sequence has been shown to increase the yield of 
functional receptor made by the yeast (Grunewald et al. 2004). The α-factor 
leader sequence is removed from the receptor following cleavage by the yeast 
protease Kex2 (which resides in the golgi complex) (Julius et al. 1984; Julius et 
al. 1984; Redding et al. 1991). The modified expression plasmid described in 
(Fraser 2006) was the starting point of all the work described in this thesis.  
 
Figure 4.1 Schematic diagram of the initial hA2aR expression construct (αH – dG hA2aR) 
Previously, a deglycosylated version (dG) of a full-length hA2aR cDNA had been cloned into a 
modified version of the P. pastoris expression vector pPICZαA (Fraser, 2006). The hA2aR is made 
as a fusion protein with the α-factor leader sequence from S. cerevisiae. The leader sequence is 
later cleaved off endogenously by the protease Kex2 resulting in the yeast making dG hA2aR with 
a His10 tag at its N-terminus.  
4.2 Identifying and removing the disordered C-terminal 
tail of the hA2aR 
Signalling proteins, including receptors, are involved in molecular information 
transfer. For these proteins to be able to function, they must be able to adopt 
multiple distinct conformations (Kobilka and Deupi 2007). This is accomplished 
through the proteins having great inherent flexibility and it is not uncommon for 
signalling  proteins  to  contain  natively-disordered  regions  (Gsponer  and  Babu 
2009). To identify those regions of the hA2aR that are highly flexible its amino 
acid  sequence  was  analysed  using  the  disorder  prediction  program  RONN 
(www.strubi.ox.ac.uk/RONN).  The  results  suggest  that  the  C-terminal  region  
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(αα 347 – 412) of the receptor is largely disordered as well as part of the third 
intracellular loop (αα 206 – 228) (Figure 4.2).  
The disordered regions that were identified are likely to hinder the formation of 
lattice contacts necessary for crystal formation (Lundstrom 2005; Warne et al. 
2009).  As  the  receptor’s  third  intracellular  loop  is  involved  in  G-protein 
activation (and necessary for function), it was decided at this stage to retain this 
part of the protein. In contrast, others have shown that the last 100 ααs of the 
hA2aR can be removed without substantially altering the ability of the receptor 
to activate Gs (Piersen et al. 1994; Olah 1997; Klinger et al. 2002). Therefore, a 
truncated hA2aR mutant (αα 1 – 320) in which the C-terminal region had been 
largely removed was created by PCR amplification and sub-cloned into pGEM T-
Easy  (Figure  4.3).  The  truncated  version  of  the  hA2aR  (with  the  C-terminal 
disordered region removed) was thought more likely to crystallise than the wild-
type receptor. 
 
Figure 4.2 RONN disorder prediction plot for the human adenosine 2a receptor 
The prediction software analyses the primary sequence of the target protein to try to identify those 
regions with high flexibility. Residues with a “probability of disorder” value >0.5 (indicated by the 
solid  black  line)  are  predicted  to  be  natively  disordered.  The  plot  suggests  that  the  C-terminal 
region (αα 347 – 412) of the receptor is largely disordered as well as part of the third intracellular 
loop (αα 206 – 228).  
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Figure 4.3 Restriction analysis of pGEM T-Easy containing either full-length or truncated 
deglycosylated hA2aR  
Digestion of recombinant plasmid with EcoRI gave a vector band of 3.0 Kb and another band of 
either 1.2 or 0.9 Kb corresponding to full-length and truncated receptor, respectively.  
4.3 Fusion of a biotin acceptor domain to the C-terminus 
of the hA2aR increases its expression in P. pastoris 
4.3.1 Vector construction 
Previously, it has been shown that fusion of the biotin acceptor domain from 
Proprionibacterium  shermanii  to  the  C-terminus  of  selected  GPCRs  improves 
both  the  yield  and  stability  of  the  protein  when  it  is  made  in  P.  pastoris 
(Grunewald et al. 2004; Lundstrom et al. 2006). Here, we wanted to determine 
whether or not attachment of this domain to the C-terminus of the hA2aR would 
similarly increase its expression level in P. pastoris. Another reason for wanting 
to fuse this domain to our protein of interest was to create a second affinity tag 
for purification purposes. This domain can be specifically biotinylated in vitro 
using the enzyme biotin ligase. Following this, the target protein can be isolated  
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by  affinity  chromatography  using  (strept)avidin  beads  (Chapman-Smith  and 
Cronan 1999). This approach has a high purification factor as the abundance of 
biotinylated proteins in nature is very rare (Cronan 1990). 
The 75αα biotinylation domain from P. shermanii was cloned into αH – trunc dG 
hA2aR  (Figure  4.1)  downstream  of  the  NotI  site  according  to  Materials  and 
Methods Section 3.3.3 (Figure 4.4). At the same time, two Tobacco Etch Virus 
(TEV) protease recognition sites were incorporated into the vector. The first one 
was introduced between the N-terminal His10 tag and the EcoRI site used for 
cloning the target proteins (Figure 4.4). The second is situated between the C-
terminal tail of the receptor and the biotin acceptor domain (Figure 4.4). The 
purpose of adding the TEV sites was 2-fold. Firstly, cleaving off the His tag with 
TEV opens up the possibility of performing a reverse purification step using Ni
2+ 
resin allowing cleaved tag, His-tagged TEV protease as well as contaminant His-
rich proteins to be removed (Ford et al. 1991; Walker et al. 1994). Secondly, 
cleavage at both TEV sites will generate “tag-free” target protein that can be 
used  in  crystallisation  experiments  (Ford  et  al.  1991).  Constructs  were  made 
that contained both full-length and truncated versions of the hA2aR (Sections 
3.3.3-4) (Figure 4.5). 
 
Figure 4.4 Schematic diagram showing the αHT-TB vectors containing either (A) full-length 
or (B) truncated hA2aR 
The original GU P. pastoris expression vector (Figure 4.1) was modified by the introduction of a 
biotin acceptor domain at the receptor’s C-terminus.  Following  biotinylation,  this  tag  allows  the 
protein  to  be  purified  by  affinity  chromatography  using  (strept)avidin  beads.  TEV  protease 
recognition sites were inserted immediately up- and down-stream of the receptor coding sequence. 
Cleavage with TEV allows untagged hA2aR to be isolated.  
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Figure 4.5 Restriction analysis of αHT-TB recombinant plasmids containing either (A) full 
length or (B) C-terminal truncated hA2aR 
Digestion of the vectors with EcoRI/NotI resulted in release of the hA2aR cDNA (1.2 Kb full-length; 
0.9 Kb truncated) from the HT-TB vector (3.9 Kb). 
4.4 Yeast transformation and clonal selection 
There  are  several  possible  P.  pastoris  strains  that  can  be  used  for  making 
recombinant proteins. Two of the most common are the wild-type strain X33 and 
the  protease-deficient  strain  SMD1163  (his4  pep4  prb1).  Following  synthesis, 
recombinant  proteins  are  susceptible  to  attack  by  site-specific  proteases 
(Milojevic  et  al.  2006).  Heterologously  expressed  MPs  can  be  cleaved  by 
proteases  located  in  the  culture  medium  as  well  as  those  within  the  cell 
(Macauley-Patrick  et  al.  2005).  Proteins  with  extensive  natively  disordered 
regions  tend  to  show  high  protease-sensitivity.  Proteolysis  can  be  overcome 
either by removing the susceptible protease site(s) by mutagenesis or by making 
the  protein  in  a  host  cell  where  several  of  the  key  proteaseσs  have  been 
genetically  knocked-out.  Previously,  the  Fraser  group  used  the  P.  pastoris 
protease-deficient strain SMD1163 for making full-length hA2aR (Fraser 2006).  
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Here, however, the αHT - (trunc) dG hA2aR – TB constructs were introduced into 
X33  as  this  strain  gives  significantly  higher  biomass  in  fermenter  culture 
compared to SMD1163 (Niall Fraser, personal communication).  
Both constructs were transformed into X33 according to Section 3.3 where the 
linearised  DNA  integrated  into  the  yeast  genome.  Multi-copy  integrants  were 
isolated following selection with the antibiotic zeocin. Previously, it has been 
shown  that  the  production  level  of  recombinant  proteins  in  P.  pastoris  is 
influenced by the number of expression cassettes that are incorporated into the 
genome following transformation (Grunewald et al. 2004; Macauley-Patrick et 
al.  2005).  As  different  transformants  make  different  amounts  of  the  target 
protein it is essential to screen a range of colonies to identify the clone making 
the highest levels of recombinant protein. Small-scale (10 ml) expression trials 
were  performed  with  eight  transformants  for  both  constructs  according  to 
Section 3.5.2. Membranes were isolated for each colony and receptor expression 
levels were determined by single-point radioligand binding assay as described in 
Section  3.8  using  a  tritiated  version  of  the  high-affinity  hA2aR-specific 
antagonist ZM241385 (Palmer et al. 1995; Poucher et al. 1995) (Figure 4.6). For 
both constructs, an approximate 3-fold difference in receptor expression level 
was observed between clones that had been transformed with the same plasmid 
(Figure  4.6).  The  average  expression  levels  for  the  full-length  and  truncated 
receptors across all the tested transformants were 18.0 +/- 2.5 and 16.4 +/- 2.5 
pmol/mg  protein,  respectively,  showing  that  the  yeast  made  the  full-length 
receptor  and  truncated  mutants  to  essentially  the  same  level.  The  highest 
expressing colony for both constructs was retained for subsequent experiments.   
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Figure 4.6 Clonal analysis of Pichia pastoris X33 transformants making either full-length or 
truncated hA2aR  
Small-scale expression trials were performed with eight transformants for both αHT-TB expression 
constructs (Figure 4.4). Membranes were isolated for each colony and receptor expression levels 
determined by single-point radioligand binding assay using a saturating (ca. 12 nM) concentration 
of [
3H] ZM241385. The highest expressing colony for both constructs was retained for subsequent 
experiments. 
4.5 Saturation binding analysis of full-length and 
truncated hA2aR made in shake flask cultures  
The  highest  expressing  colonies  isolated  from  section  4.4  were  grown  on  a 
medium scale (500 ml) in shake flasks. Following induction, cells were harvested 
and  membranes  made  according  to  Section  3.6.3.  The  pharmacological 
properties of the expressed receptors were determined by saturation radioligand 
binding. In this approach, the amount of radioactivity that specifically binds to 
membrane-bound  hA2aR  was  measured  at  a  series  of  concentrations  of  [
3H] 
ZM241385. For both αHT-TB tagged full-length and truncated receptor constructs 
specific radioligand binding against radioligand concentration was plotted and 
the dissociation constant (Kd) as well as the total number of binding sites (Bmax)  
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determined. Representative saturation binding curves are shown in Figure 1.7 
with the Bmax and Kd values for each construct shown in Table 4.1.  
Construct  Bmax (pmol)  Kd (nM) 
αH – full length dG hA2aR 
 
 
 
8.2 +/- 0.9 
8.5 +/- 0.1 
9.6 +/- 2.2 
1.8 +/- 0.4 
0.4 +/- 0.1 
1.2 +/- 0.6 
αHT- full length dG hA2aR – TB 
 
 
 
15.8 +/- 6.8 
18.8 +/- 0.3 
24.3 +/- 3.9 
1.5 +/- 0.3 
0.7 +/- 0.1 
4.2 +/- 1.6 
αHT- truncated dG hA2aR – TB 
 
 
20.9 +/- 2.0 
30.1 +/- 1.2 
31.8 +/- 1.5 
2.9 +/- 0.7 
4.4 +/- 0.4 
3.8 +/- 0.8 
Table 4.1 Pharamcological data for three different hA2aR constructs grown in shake flask 
culture 
Each construct was subjected to three separate radioligand binding experiments as indicated by 
the three Bmax and Kd values.  
Comparison of the Bmax values for the different hA2aR constructs suggests that 
the fusion of the biotin acceptor domain to the C-terminus of hA2aR increases 
the receptor expression level by approximately 2-fold. However, the truncation 
of the receptor’s C-terminal tail does not significantly affect its expression level. 
In native tissues the hA2aR has a Kd for ZM241385 of ca. 1.0 nM. In shake flask 
cultures of P. pastoris, Kd values in the range 1-4 nM were observed, indicative 
of weaker drug-receptor binding than in the physiological background. The most 
likely explanation for this observation is that oxygen starvation during receptor 
production  prevented  complete  formation  of  its  disulphide  bonds  (which  are 
known to be essential for high-affinity ligand binding (Jaakola et al. 2008)). It  
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was  hoped  that  this  problem  could  be  overcome  by  making  receptor  in 
fermenter  culture  where  the  dissolved  oxygen  (DO)  levels  can  be  readily 
regulated (Cereghino et al. 2002; Jahic et al. 2006). 
 
Figure 4.7 Representative saturation binding curves for three different hA2aR constructs 
made in X33 shake flask cultures: (A) αH– dG hA2aR, (B) αHT– dG hA2aR –TB, and (C) αHT– 
trunc dG hA2aR –TB  
Saturation binding analysis was performed according to Section 3.8.1. The data was fitted using 
GraphPad Prism software.   
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4.6 hA2aR production in fermenter culture 
One  of  the  main  advantages  of  using  P.  pastoris  for  recombinant  protein 
production  is  its  ability  to  grow  to  high  cell  densities  (ca.  10
9  cells/ml)  in 
fermenter culture (Jahic et al. 2006). This can be achieved by maintaining the 
DO  content  of  the  culture  greater  than  20%  as  well  as  tightly  regulating  the 
methanol feed rate (Cregg et al. 2000). The transition from recombinant protein 
production in low cell-density shake flask cultures to that in high cell-density 
fermentations requires considerable optimisation to obtain maximal yields of the 
target protein (Cereghino et al. 2002; Singh et al. 2008). This is particularly true 
when the methanol induction (protein expression) phase is performed at low (22 
instead of 30°C) temperatures where care has to be taken not to overfeed the 
culture with methanol. In fermentations of P. pastoris the yeast are first grown 
on glycerol to increase the culture biomass before switching the carbon source 
to methanol for recombinant protein production.  
A  series  of  fermentations  were  performed  on  a  5  litre  scale  using  the  X33 
transformant found to make the highest levels of αHT – trunc dG hA2aR – TB, in 
which a series of parameters including length of the glycerol feed phase as well 
as the methanol feed rates were optimised. Maximal cell biomass was obtained 
by growing the yeast for 18h on basal medium followed by feeding the culture 
with glycerol for a further 11 h (Figure 4.8). This resulted in a culture OD600 of 
over 300 which is equivalent to ca. 200g wet weight of cells per litre of culture. 
This phase was followed by a 1h starvation period during which time the culture 
was not fed any carbon source. This step was included to ensure that all of the 
added glycerol had been completely consumed by the yeast as glycerol represses 
protein  expression  from  the  AOX1  locus  even  in  the  presence  of  methanol 
(Cereghino et al. 2002).  
At the start of the methanol-feed phase, the hA2aR antagonist theophylline was 
added to the culture to enhance the levels of functional receptor made by the 
yeast (Fraser 2006). In addition, receptor production was carried out at 22°C as 
previously  it  has  been  shown  that  twice  as  much  functional  hA2aR  can  be  
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obtained  in  shake-flask  cultures  of  P.  pastoris  by  performing  induction  at  22 
instead  of  30°C  (Fraser  2006).  The  induction  phase  was  started  on  a  low 
methanol feed rate (4 h at 0.09 ml min-1) to allow time for the cells to adapt to 
growth on methanol as its sole carbon source preventing unnecessary cell death 
(Cereghino and Cregg 2000; Cereghino et al. 2002). 
 
Figure 4.8 A typical fermentation showing how yeast biomass and hA2aR production level 
varies with time 
The yeast were grown on basal media for 18h (A) followed by a glycerol-feed phase lasting a 
further 11h (B). A starvation period (C) ensured that all of the added glycerol had been completely 
consumed. A short methanol adaptation phase (D) allowed the cells to accommodate the change 
of carbon source reducing the possibility of cell death. Finally, receptor production occurred during 
the methanol-feed phase (E) with maximum expression levels obtained after ca. 30 h.  
The methanol feed-rate was increased in a step-wise fashion in order to identify 
the rate that gave the maximum hA2aR expression level without causing cell-
toxicity arising from the accumulation of excess methanol. The yeast were fed 
at a particular rate for 12 h and then sample removed from the culture to allow 
the  receptor  expression  level  to  be  determined  by  single-point  radioligand 
binding  analysis  (results  not  shown).  This  allowed  the  development  of  an 
optimised  feeding  protocol  which  after  the  cells  had  acclimatised  to  the 
methanol carbon source consisted of 12 h at 0.13 ml/min followed by 36 h at 
0.33 ml/min. Under optimal conditions, the human adenosine 2a receptor could  
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be routinely made with expression levels greater than 100 pmol receptor per mg 
protein (eg Figure 4.9). 
The αHT-trunc dG hA2aR-TB made in fermenter culture had Kd values for [
3H] 
ZM241385  of  0.7  +/-  0.1,  0.8  +/-  0.1  and  0.9  +/-  0.2  nM.  These  values  are 
essentially the same as that observed for the hA2aR in native tissues (Uustare et 
al., 2005), and reflected tighter binding of the radioligand to the receptor when 
it was made in fermenter as compared to shake-flask culture (Section 4.5). The 
improvement in the quality of receptor made by the yeast in fermenter culture 
is most likely due to the consistently high levels of dissolved oxygen that will 
ensure all of the disulphide bonds in the recombinant protein are fully formed.  
 
Figure 4.9 A representative saturation binding curve of αHT- trunc dG hA2aR-TB produced 
in fermenter culture 
Saturation binding analysis was performed as described in Section 3.8.1. The data was fitted using 
Graph Pad Prism. Receptor production levels greater than 100 pmol/mg protein were routinely 
obtained. The Kd values obtained for hA2aR made in fermenter culture were essentially the same 
as that observed in native tissue (Uustare et al., 2005), suggesting that the receptor made was of 
high quality. 
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4.7 Purification of HT- trunc dG hA2aR - TB 
To solve the 3-dimensional structure of any mammalian membrane protein it is 
first necessary to obtain milligram quantities of pure, monodisperse and stable 
protein. Mild non-ionic detergents (e.g. DDM) are often used to remove proteins 
from biological membranes as they are not sufficiently harsh to strip away all of 
the  native-lipids  (some  of  which  are  often  essential  for  protein  function) 
(Johansson et al. 2009). Previously, it has been shown that the hA2aR can be 
released from yeast membranes in an active state using a combination of DDM 
with  the  cholesterol  derivative  cholesterol  hemisuccinate  (CHS)  (Weiss  and 
Grisshammer  2002;  Fraser  2006).  Here,  αHT  –  trunc  dG  hA2aR  –  TB  in  X33 
membranes  was  similarly  treated  with  DDM/CHS.  Insoluble  material  was 
removed by centrifugation and the supernatant containing receptor passed over 
Ni
2+  resin.  After  the  receptor  had  bound  to  the  column,  it  was  washed  with 
buffer  containing  75  mM  imidazole  (to  remove  contaminant  His-rich  proteins) 
and 500 mM NaCl (to remove those proteins that had bound to the column by 
ionic  interactions).  Receptor  was  released  from  the  column  using  a  0-1  M 
imidazole gradient and the elution fractions analysed by SDS-PAGE (Figure 4.10).  
 
Figure 4.10 SDS-PAGE analysis of partially purified HT – trunc dG hA2aR – TB 
Receptor containing membranes were solubilised using DDM/CHS. The recombinant protein was 
purified by Ni
2+ affinity chromatography. 20 µl aliquots from each elution fraction were analysed by 
SDS-PAGE. Following treatment with Simply Blue Safe Stain (Invitrogen), a major band at ca. 49 
kDa corresponding to the tagged receptor was observed.   
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As  the  receptor  was  relatively  pure  following  the  Ni
2+  column,  the  hA2aR 
fractions  were  pooled,  concentrated  and  loaded  onto  a  Sepharose  C6  gel 
filtration column (which allows proteins to be separated according to their size). 
In addition to its purification capacity, size-exclusion chromatography (SEC) is 
also a good indicator of protein quality as the size and shape of the elution peak 
gives  insights  into  the  heterogeneity  and  aggregation  status  of  the  applied 
protein(s) (Gutmann et al. 2007). The ideal result denoting pure, monodisperse 
protein is a single large symmetrical elution peak while several peaks arising 
from  the  one  protein  suggests  that  it  may  be  aggregated  and  as  such  is 
unsuitable for structural studies (Kawate and Gouaux 2006). When the highly-
enriched hA2aR sample was applied to the column several major peaks were 
observed in the SEC elution profile (Figure 4.11), suggesting that the receptor 
population contained aggregate complexes. However, it was not obvious at what 
stage receptor aggregation had occurred – whether it was during the detergent-
solubilisation  step,  Ni
2+  purification  and/or  application  to  the  gel  filtration 
column. This result made it clear that substantially more work was going to be 
required  to  develop  an  optimal  purification  protocol  for  the  hA2aR. 
Furthermore, it highlighted the need for an experimental tool that would allow 
the  receptor’s  dispersity/aggregation  status  to  be  followed  throughout  the 
purification procedure.  
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(A) 
 
(B) 
 
Figure 4.11 Analysis of a highly-enriched hA2aR sample 
(A) Elution profile following application to a Sepharose C6 gel filtration column. If the partially-
purified receptor was monodisperse, the elution profile would have contained essentially a single, 
large symmetric peak. However, several heterogeneous peaks were observed, demonstrating that 
the receptor was aggregated. However, it was not obvious at what stage during the purification 
process  receptor  aggregation  had  occurred.  (B)  SDS-PAGE  analysis  showing  multiple  bands 
therefore substantiating aggregation had formed. 
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4.8 Conclusion 
Pichia pastoris is an excellent host cell for the overproduction of recombinant 
proteins  including  membrane  proteins  of  mammalian  origin.  However,  as 
illustrated  by  the  work  described  in  this  chapter,  the  commercially  available 
vector is far from what is required to maximise the production levels as well as 
simplify  the  detergent  extraction  and  subsequent  purification  procedures  for 
human membrane proteins. 
The addition of the biotinylation domain from P. shermanii had previously been 
shown to increase protein expression (Grunewald et al. 2004; Lundstrom et al. 
2006)  and  through  its  addition  to  the  C-termini  of  the  hA2aR  expression 
construct a minimum of a 2-fold expression level increase was seen. However, 
while the truncation of the hA2aR C-termini did not have signification effects on 
its expression it was retained to help improve its crystallizability. 
An optimised protocol was developed that gave maximal production of our target 
proteins in fermenter culture at an induction temperature of 22°C. Care was 
taken  to  find  a  methanol  feed  rate  that  gave  the  highest  levels  of  protein 
production without causing the accumulation of excess methanol in the culture 
(which is known to be toxic to the yeast). The hA2aR produced in fermenter 
culture  had  more  native-like  pharmacology  than  when  the  yeast  cells  were 
grown  in  shake  flasks.  This  is  likely  due  to  the  incomplete  formation  of 
disulphide  bonds  (which  are  known  to  be  necessary  for  high-affinity  ligand 
binding) in the hA2aR when it is made in shake-flask cultures of yeast. This is not 
surprising as the DO levels in fermenter culture can be maintained >20% whereas 
the  DO  levels  in  shake  flasks  are  essentially  zero.  This  observation  will  be 
applicable  to  other  proteins  made  in  P.  pastoris  and  suggests  that  following 
clonal selection the highest-expressing transformant should be put straight into 
fermenter culture to assess whether or not the yeast is going to be a suitable 
host for making milligram quantities of the target protein for structural studies.  
Over-expression and purification of human MPs    103 
     
In  short,  by  investing  time  optimising  both  the  expression  construct  and 
expression method it is possible to obtain yields of active protein suitable for 
structural studies.   
5   iLOV: a novel fluorescent reporter for 
membrane protein applications  
 
5.1 Introduction 
The  over-expression  and  purification  of  membrane  proteins  can  be  a  labour-
intensive process. One of the many challenges of working with MPs concerns the 
detection of recombinant MPs in both expression and purification experiments. 
As  most,  though  not  all,  MPs  are  colourless,  target  protein  identification  is 
usually  performed  by  methods  such  as  radioligand  binding  and/or  Western 
blotting. However, these techniques can be time-consuming, use a lot of protein 
and  do  not  give  any  information  on  the  aggregation  state  of  the  protein  in 
detergent solution.  
The  process  of  identifying  target  membrane  proteins  can  be  accelerated  by 
fusing a fluorescent reporter to the protein of interest (Sarramegna et al., 2002; 
Drew et al., 2006). This allows recombinant MPs to be monitored indirectly by 
measuring  fluorescence  from  the  tag  (Drew  et  al.,  2006).  To  be  successfully 
employed as a reporter protein, the fusion partner must be stable in the host 
cell used for recombinant expression, easily quantifiable and give fluorescence 
levels that accurately correlate with the amount of recombinant protein present 
(Drew et al., 2008). 
Green fluorescent protein (GFP) from the jellyfish Aequorea victoria was the 
first, and remains the most commonly used, fluorescent reporter (Chalfie et al., 
1994).  GFP  is  so-called  due  to  its  strong  green  fluorescence  emission  upon 
illumination  with  visible  light.  GFP  consists  of  238  amino  acids,  and  has  a 
molecular weight of ca. 25 kDa (Prasher et al., 1992). The GFP chromophore is 
situated in a central α-helix located within an 11-stranded β-barrel (Figure 5.1) 
(Ormo  et  al.,  1996),  and  is  formed  by  the  autocatalytic  cyclisation  of  the  
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tripeptide Ser65 – Tyr66 - Gly67 (Remington, 2006; Huang et al., 2007; Malo et 
al., 2007). Chromophore maturation consists of four distinct phases: folding of 
the  β-barrel,  peptide  cyclisation,  oxidation  and  dehydration  (Huang  et  al., 
2007).  The  oxidation  reaction  is  the  rate-limiting  step  in  chromophore 
formation,  and  requires  molecular  oxygen.  Despite  its  usefulness  as  a 
fluorescence reporter, GFP has a couple of drawbacks: i) it has a tendency to 
oligomerise, and ii) it cannot be used in conditions that are anaerobic/have low 
oxygen content (Drepper et al., 2007).  
(A) 
 
(B) 
 
Figure 5.1 The three-dimensional structures of (A) GFP and (B) LOV2  
The structure of GFP (accession code 1EMA) was described in (Ormo et al., 1996) and that for 
LOV2 (accession code 1G28) in (Crosson and Moffat, 2001). 
Although GFP has been traditionally used to monitor biological events in vivo, it 
has  recently  been  used  as  a  tool  to  monitor  protein  folding  in  vitro.  For 
example,  it  has  been  shown  that  the  folding  state  of  soluble  recombinant 
proteins made in E. coli can be rapidly determined by fusing GFP to their C-
termini as the level of GFP fluorescence observed was found to correspond with  
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the amount of correctly folded target protein (Waldo et al., 1999). In contrast, 
fusion protein that had been misfolded ended up in inclusion bodies and was 
non-fluorescent  (as  the  GFP  chromophore  did  not  form).  Since  this  first 
observation,  this  methodology  has  been  successfully  adapted  for  use  with 
membrane  proteins  where  C-terminal  GFP  fusions  have  been  used  to  identify 
those membrane proteins that express well in both E. coli (Drew et al., 2002; 
Hamman et al., 2002; Drew et al., 2005; Drew et al., 2006; Link et al., 2008) 
and S. cerevisiae (Newstead et al., 2007; Drew et al., 2008) and those that do 
not.  The  GFP  tag  has  also  been  shown  to  be  useful  for  identifying  those 
detergents that give monodisperse protein immediately following solubilisation 
of  the  membrane  via  fluorescence  size-exclusion  chromatography  (FSEC) 
(Kawate and Gouaux, 2006; Newstead et al., 2007; Drew et al., 2008). 
Although highly useful for organisms such as E. coli and S. cerevisiae, GFP is not 
ideal for use with P. pastoris as this yeast grows to high cell densities in culture 
largely consuming the dissolved oxygen in the media. This is particularly true in 
shake-flask cultures of P. pastoris. The strict requirement for molecular oxygen 
in the formation of the GFP chromophore suggested to us that a LOV-type of 
fluorescence reporter (derived from plant phototropins) may be better suited for 
use  in  P.  pastoris  than  GFP  as  LOV  fluorescence  is  not  affected  by  oxygen 
availability (Drepper et al., 2007).  
Phototropins are blue-light (region 320-500 nm) receptors that regulate several 
different physiological processes in plants that serve to maximise the efficiency 
of photosynthesis. These include phototropism, light-induced stomatal opening, 
as  well  as  chloroplast  movements  in  response  to  changes  in  light  intensity 
(Christie,  2007).  Phototropins  consist  of  two  distinct  regions:  a  N-terminal 
photosensory domain with a serine/threonine kinase domain at its C-terminus. 
Within  the  photosensory  domain  are  two  highly  conserved  regions  that  have 
sequence homology with a family of proteins that are activated by light, oxygen 
or voltage (LOV) called LOV1 and LOV2 (Christie et al., 1999; Jones and Christie, 
2008). Light-induced phototropin kinase activity requires LOV2 (but not LOV1) 
photoreactivity  though  the  mechanism  by  which  LOV2  regulates  the  kinase  
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domain  is  poorly  understood  (Christie  et  al.,  2002;  Matsuoka  and  Tokutomi, 
2005).  
Purification  of  milligram  amounts  of  individual  LOV  domains  expressed  in 
bacteria has allowed their structure and photochemistry to be investigated in 
fine-detail. Individual, purified LOV domains are bright yellow and emit a strong 
green  fluorescence  when  irradiated  with  UV/blue  light.  LOV  domains  non-
covalently  bind  flavin  mononucleotide  (FMN)  in  a  central  cavity  through  a 
combination  of  hydrogen  bonds  and  van  der  Waals  interactions  (Figure  5.1) 
(Christie  et  al.,  1998;  Crosson  and  Moffat,  2001;  Christie,  2007).  Upon 
irradiation,  a  covalent  adduct  forms  between  the  flavin  chromophore  and  a 
conserved cysteine within the LOV domain (Salomon et al., 2000). This reaction 
is fully reversible, and in darkness the LOV domains return to their initial ground 
state (Salomon et al., 2000).  
Recently, Christie and co-workers have created a novel LOV-based fluorescence 
reporter called iLOV that can be used for both in vivo and in vitro applications 
(Chapman  et  al.,  2008).  iLOV  was  derived  from  the  LOV2  domain  of  the 
Arabidopsis  thaliana  phototropin  2  by  performing  several  rounds  of  DNA 
shuffling.  The  iLOV  protein  has  increased  fluorescence  quantum  yield  and 
reduced photobleaching compared to wild-type (Chapman et al., 2008). iLOV has 
certain intrinsic properties that suggested that it may make a useful reporter of 
recombinant membrane protein production in all systems but particularly in P. 
pastoris. These include: i) iLOV is relatively small (10 as compared to 25 kDa for 
GFP),  ii)  fluorescence  from  the  flavin  co-factor  occurs  immediately  from  the 
time that the iLOV domain is assembled (in contrast to GFP where formation of 
the fluorophore takes ca. 4 h (Heim et al., 1994)) making it useful for accurate 
time-course  studies,  and  iii)  iLOV  fluorescence  is  unaffected  by  oxygen 
availability  (unlike  GFP  where  chromophore  maturation  has  an  absolute 
requirement for molecular oxygen) (Drepper et al., 2007). This last property of 
iLOV  is  of  particular  relevance  for  studying  recombinant  (membrane)  protein 
production  in  shake  flask  cultures  of  P.  pastoris  as  their  oxygen  content  is 
essentially zero.  
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Over the course of my Ph.D., I made several different P. pastoris expression 
constructs containing the iLOV fluorescent reporter which are describes in this 
chapter. In all of the vectors, an iLOV cDNA was inserted into the plasmid C-
terminal to the cloning sites for the recombinant protein, and was introduced to 
simplify  the  expression  and  purification  of  my  target  MPs.  In  addition  this 
chapter describes the photochemical properties of iLOV, as well as how this tag 
can be used to monitor protein expression (clonal selection; time course of MP 
production  in  fermenter  culture),  perform  detergent  screening  and  facilitate 
protein purification.  
5.2 Fusion of a fluorescent reporter protein to the 
receptor’s C-terminus  
As  the  vast  majority  of  mammalian  membrane  proteins  are  colourless  they 
cannot  be  followed  visually  during  the  purification  process.  Rather  those 
fractions containing the target protein have to be found either by visualisation 
techniques  (e.g.  Western  blotting)  or  by  performing  a  functional  assay  (e.g. 
radioligand binding). While these approaches are highly successful in identifying 
the desired fractions they have many drawbacks not least in the amount of time 
and protein required to do the assay. However, by fusing the protein of interest 
to a fluorescent marker it is possible to track the expression and purification of 
the  recombinant  protein  by  eye  following  excitation  of  the  reporter  at  an 
appropriate wavelength (Drew et al., 2006). Although green fluorescent protein 
(GFP) from Aequorea victoria has been successfully used for tracking membrane 
protein production in E. coli and S. cerevisiae (Chalfie et al., 1994; Drew et al., 
2008), we decided to use a fluorescent protein derived from a plant phototropin 
Light-Oxygen-Voltage  (LOV)  domain  (Briggs,  2007  a,b).  This  reporter  protein 
fluoresces  from  the  time  it  is  synthesised  (upon  binding  its  co-factor  flavin 
mononucleotide),  and  has  oxygen-independent  fluorescence  intensity  (both 
unlike  GFP)  (Christie,  2007).  The  native  LOV  domain  has  been  modified  by 
Christie and co-workers to give the iLOV reporter which has improved stability 
and fluorescence intensity compared to the WT protein (Chapman et al., 2008).   
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iLOV cDNA was incorporated into the HT-TB expression plasmid between the C-
terminal TEV recognition site and the biotinylation domain (Figure 5.2). This was 
accomplished by introducing two new restriction sites (SpeI and NdeI) between 
the TEV site and the biotinylation domain, and then sub-cloning the iLOV DNA 
between the new restriction sites (Figure 5.3). By positioning the iLOV domain 
downstream  of  the  target  protein,  it  was  possible  to  measure  recombinant 
protein expression level via iLOV fluorescence (Section 5.6).  Furthermore, the 
tag was useful for determining the dispersity of the receptor following detergent 
solubilisation as well as during the purification process by fluorescence SEC.  
 
Figure 5.2 Schematic diagram showing the αHT-TLB expression plasmid 
The fluorescent reporter protein iLOV was incorporated between the downstream TEV protease 
recognition  site  and  the  biotin  acceptor  domain.  The  iLOV  tag  was  useful  for  determining 
recombinant  membrane  protein  expression  levels  as  well  as  their  aggregation  status  following 
detergent solubilisation. 
 
Figure 5.3 Restriction analysis of HT – trunc dG hA2aR – TLB 
Digestion of the recombinant plasmid with (a) EcoRI/NotI, (b) SpeI/NdeI and (c) EcoRI/NdeI gave 
bands at 1.0, 0.3 and 1.2 kb corresponding to trunc hA2aR, iLOV and trunc hA2aR-iLOV fragments 
of DNA, respectively. (The 0.3kb band is indicated with an arrow due to poor contrast).  
iLOV : a novel fluorescent reporter    110 
     
5.3 Using conformationally-fixed hA2aR mutants to 
improve receptor stability 
Many  signalling  proteins  including  GPCRs  have  intrinsic  flexibility  that  allows 
them  to  adopt  multiple  conformations  (Kobilka  and  Deupi  2007).  While  this 
flexibility  is  essential  for  receptor  activity  it  is  also  an  impediment  to 
crystallisation (Warne et al. 2009). This problem can, however, be overcome by 
trapping GPCRs in particular conformations using appropriate ligands. Indeed, 
the ligand-activated GPCRs that have had their structures solved thus far have 
all been co-crystallised with either a high-affinity antagonist or inverse agonist 
bound  (e.g.  (Palczewski  et  al.  2000;  Cherezov  et  al.  2007;  Rasmussen  et  al. 
2007; Rosenbaum et al. 2007; Hanson et al. 2008; Jaakola et al. 2008; Warne et 
al. 2008). In these examples, the ligands were not just used to fix the receptor’s 
conformation  but  to  increase  the  thermostability  of  the  protein  in  detergent 
solution also.  
An  alternative  approach  to  solving  the  twin  problem  of  conformational 
heterogeneity  and  poor  stability  of  GPCRs  in  detergent  solution  has  recently 
been  described  by  Tate  and  co-workers  who,  after  performing  an  extensive 
mutational  analysis  of  the  turkey  β1-adrenergic  receptor,  created  a  modified 
version of the receptor called M23 that preferentially binds antagonists and was 
ca. 30°C more thermostable than the WT receptor (Warne et al. 2009). This 
mutant was even stable in C8 detergents including octylthioglucoside in which it 
was crystallised with the antagonist cyanopindolol bound and structure solved to 
atomic resolution (Warne et al. 2009). 
More recently, Tate and co-workers have described two conformationally-fixed 
thermostable  hA2aR  mutants  called  Rant21  (which  preferentially  binds 
antagonists)  and  Rag23  (agonists)  (Magnani  et  al.  2008)  (Figure  5.4).  To 
determine whether or not these mutants aggregated in the same way that had 
been found for the truncated hA2aR construct (Section 4.7), Rant21 and Rag23 
cDNAs (a kind gift from Dr. Chris Tate) were cloned into the αHT-TLB vector. 
The Rant21 and Rag23 cDNAs that had been provided to us had been truncated  
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at αα316. We, therefore, made an equivalent truncation of the WT receptor 
construct denoted GU. The glycosylation site in all three constructs was removed 
by  site-directed  mutagenesis.  Finally,  to  further  improve  their  stability  and 
potential crystallisability the flexible region in intracellular loop 3 (αα 210-227) 
that had been identified previously using RONN (Section 4.2) was removed from 
the GU, Rant21 and Rag23 constructs. The integrity of the desired constructs 
was explored first by restriction analysis (Figure 5.5) and then by sequencing. 
All  three  constructs  were  transformed  into  yeast  strain  X33.  Following 
fermentation, membranes containing iLOV-tagged receptor were isolated and a 
series of trial solubilisation experiments performed. Using FSEC, it was possible 
to determine the extent of receptor aggregation immediately after treatment 
with detergent. These results are presented fully in Section ?. In short, the CHS 
was found to be the cause of receptor aggregation observed in Section 4.6. My 
work focussed on Rag23 which could be purified with monodispersity in DDM in 
the absence of CHS (Section 6.2).  
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Figure 5.4 Sequence alignment of GU, Rant21 and Rag23 DNA sequences against WT hA2aR 
All three modified forms of the hA2aR had their glycosylation sites as well as 18 residues from the 
third intracellular loop and the C-terminal 96 residues removed. The αα changes in the Rag23 and 
Rant21 mutants are highlighted in red boxes.  
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Figure 5.5 Restriction analysis of recombinant αHT-TLB vectors containing either Rag23 or 
GU hA2aR 
Due to the mutations forming the conformationally-fixed Rag23 mutant, the Rag23 cDNA does not 
have a PvuII restriction site while the GU sequence does. On digestion of the Rag23 construct with 
PvuII a single band was observed due to linearization of the vector. In contrast, two bands were 
seen for the GU plasmid due to a single cut each within the insert and vector.  
5.4 Optimised tag removal by digestion with C3 protease 
The expression construct containing iLOV was re-engineered to simplify the tag 
removal  process.  With  the  HT-TLB  vector,  complete  tag  removal  required 
successful  cleavage  at  both  TEV  sites.  Even  allowing  for  the  problems 
encountered with TEV solubility (section 5.10), it was thought that requiring two 
cleavage events for tag removal was unnecessarily complicated. To simplify the 
proteolytic procedure, the His10 tag was moved from upstream of the receptor 
coding  sequence  to  downstream  of  the  biotin-acceptor  domain  (Figure  5.6), 
creating a iLOV-biotin-His10 (LBH) tag. The remaining TEV site was replaced with 
one for human rhinovirus C3 protease (C), creating an αCLBH vector. A version 
without  the  α-factor  leader  sequence  was  also  made  -CLBH  (Figure  5.6).  C3 
protease has considerably higher cleavage activity than TEV which means that it 
gives  efficient  removal  of  tags  from  recombinant  proteins  even  at  low  (4°C) 
temperatures  (Knott  et  al.  1989;  Terpe  2003).  Moreover,  unlike  TEV  where  
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milligram  amounts  of  protease  are  required  for  tag  removal  (Mohanty  et  al. 
2003), only microgram quantities of C3 need to be added to the recombinant 
protein. It was envisaged that the superior enzymatic properties of C3 would 
overcome the solubility problems that had been encountered with TEV.  
 
 
Figure 5.6 Schematic diagram of the CLBH expression constructs with and without α-factor 
To simplify the proteolytic processing of the recombinant protein, the His10 tag in the αHT-TLB 
vector  was  re-positioned  downstream  of  the  biotin  acceptor  domain.  Furthermore,  the  TEV 
protease recognition site was replaced with one for human C3 rhinovirus protease. A version of the 
CLBH vector without α-factor leader sequence was made, and a cDNA for human sterol isomerase 
cloned into it.  
Vector modifications were performed as described in Section 3.3.7. GU, Rant21 
and Rag23 versions of hA2aR were cloned into the Aα-CLBH vector and hSI cloned 
into A-CLBH. To ensure that all of the constructs had been made correctly, they 
were  analysed  by  restriction  digestion  (Figure  5.7)  prior  to  sequencing.    The 
CLBH constructs  allowed  for  the  rapid  purification  of both Rag23 and SI on a 
milligram scale. This work is described in Sections 6.2, 6.3 and 6.7. 
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Figure 5.7 Restriction digest analysis of (A) αGU-, (B) αRant21-, (C) αRag23- and (D) SI-
CLBH constructs 
All of the recombinant plasmids could be linearised using either EcoRI or NotI. Treatment with both 
of these enzymes resulted in release of either the hA2aR (0.9 Kb) or SI (0.7 Kb) cDNA from the 
CLBH vector (α factor – 4.2 Kb; no α factor – 3.9 Kb). Treatment with EcoRI and NdeI or SalI 
instead of NotI resulted in the release of larger inserts containing either iLOV (0.3 Kb) or LB (0.6 
Kb), respectively, in addition to the target protein cDNA.  
5.5 The spectral properties of iLOV 
Before  iLOV  could  be  used  as  a  fluorescence  reporter,  it  was  necessary  to 
characterise  its  spectral  properties  so  that  optimal  excitation  and  emission  
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wavelengths could be determined (Figure 5.8). As the flavin co-factor is itself 
fluorescent,  it  was  necessary  to  measure  (and  compare)  the  excitation  and 
emission  profiles  for  the  same  concentration  of  flavin  (with  that  for  iLOV). 
Lastly, excitation and emission spectra were recorded for yeast membranes to 
assess the extent of background fluorescence from endogenous flavoproteins. 
The iLOV emission spectrum has a distinctive peak at 485 nm with a pronounced 
shoulder at 525 nm. This is appreciably different from flavin which has a single 
broad  peak  from  510  -  540  nm  (Figure  5.8  (A)).  The  fluorescence  emission 
spectrum of the iLOV tag was the same when it was fused to the hA2aR (results 
not shown). As the spectral properties of iLOV are unchanged when it is attached 
to  another  protein  iLOV  can  be  used  as  a  fluorescence  reporter.  Negligible 
fluorescence  from  the  yeast  membranes  was  observed  (Figure  5.8  (A)), 
indicating that any fluorescence subsequently observed in membranes containing 
recombinant protein had to come from the iLOV tag. The optimal wavelength for 
measuring emission from iLOV was 485 nm. However, the shape of the emission 
spectrum suggested that iLOV fluorescence could be effectively measured in the 
range 485 – 530 nm. 
iLOV has a strong, broad absorption in the region 320-460 nm which gives rise to 
peaks at 350, 370 and 450 nm in its excitation spectrum (Figure 5.8 (B)). The 
equivalent spectrum for flavin is subtly but significantly different with just peaks 
at 355 and 390 nm. These results show that it is possible to selectively excite 
iLOV over flavin by using light with wavelength around 450 nm. 
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Figure 5.8 The fluorescence properties of equal concentrations of iLOV and flavin compared 
to native yeast membranes 
(A) Emission spectra were recorded from 470 – 600 nm following chromophore excitation at 450 
nm. (B) Excitation spectra were recorded from 300 – 460 nm measuring fluorescence emission at 
485 nm.  The optimal wavelength for exciting iLOV is 450 nm, whereas emission can be effectively 
measured in the range 485 – 530 nm.   
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5.6 Clonal selection using iLOV 
Once a recombinant expression plasmid has been transformed into P. pastoris, it 
is essential to screen a range of colonies to identify the clone making the highest 
levels of recombinant protein (as different transformants make different levels 
of the target protein). Screening is usually done by radioligand binding (where 
one  is  available)  or  by  Western  blotting.  In  Chapter  4,  X33  transformants 
expressing  HT-trunc  dG  hA2aR-TB  were  screened  using  the  radioligand  [
3H] 
ZM241385.  To  accomplish  this,  small-scale  (10  ml)  expression  trials  were 
performed with eight transformants, membranes isolated for each colony and 
receptor expression levels determined by single-point radioligand binding assay. 
Although  this  process  allowed  the  highest  expressing  transformant  to  be 
identified,  this  approach  is  cumbersome  and  consumed  valuable  time  and 
resources. Here, clonal selection was performed on X33 colonies that had been 
transformed with GU-, Rant21- and Rag23-CLBH by measuring iLOV fluorescence 
in whole cells following induction. 
Twelve transformants for each construct were grown up overnight at 30°C in 1 
ml cultures of BMGY in a 48-well plate. To induce receptor production, the BMGY 
was replaced with BMMY and the yeast incubated at 22°C for 24 h. The test 
expression experiments for each colony were performed in duplicate. The cells 
were harvested by centrifugation, washed twice and then resuspended in 1 ml of 
water. The cells were transferred (in duplicate) to a 96 well plate, where iLOV 
fluorescence was measured (λexcitation = 450, λemission = 520 nm). Expression levels 
are always in the form amount of target protein per total amount of protein. To 
convert iLOV fluorescence into an expression level, it was necessary to have an 
accurate  measure  of  the  number  of  cells  that  contributed  to  the  measured 
fluorescence.  Initially,  the  optical  density  (OD600)  of  each  culture  was 
determined  in  a  96-well  plate.  However,  it  proved  difficult  to  obtain 
reproducible data largely caused by cell sinkage as well as high turbidity (results 
not shown). Instead, cell biomass was quantitated by chemically permeabilising 
the cells and then measuring the protein concentration of the lysate. The main 
benefit of this approach was the improved reproducibility of the cell biomass  
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data which allowed the expression levels of different constructs to be compared. 
The clonal selection results for GU-, Rant21- and Rag23-CLBH are presented in 
Figure  5.9.  For  all  three  constructs,  the  vast  majority  of  the  transformants 
differed in their expression level by a factor of 2-3, similar to that which had 
been observed in the clonal analysis of HT- trunc dG hA2aR – TB (where receptor 
amount had been determined by radioligand binding analysis).   
 
Figure 5.9 Clonal selection using iLOV fluorescence  
GU-, Rant21- and Rag23-CLBH transformants were grown up overnight at 30°C in 1 ml cultures of 
BMGY. Receptor production was induced by replacing the media with BMMY and then incubating 
the yeast at 22°C for 24 h. Receptor levels were determined by measuring iLOV fluorescence from 
whole  cells.  Cell  biomass  was  quantitated  by  chemically  permeabilising  the  cells  and  then 
measuring  the  protein  concentration  of  the  lysate.  For  all  five  constructs,  the  majority  of  the 
transformants differed in their expression level by a factor of 2-3. 
To address whether or not higher expressing clones could be isolated on plates 
with high levels of antibiotic, X33 cells that had been transformed with GU-CLBH 
were  grown  on  YPD  plates  containing  different  (0.2,  0.5,  1  and  2  mg/ml) 
concentration of zeocin. Twelve colonies from each plate were grown in 1 ml 
cultures,  and  receptor  production  induced  as  described  in  Section  3.5.1.  The 
expression level was determined by measuring iLOV fluorescence per amount of 
total cell protein (Figure 5.9).   
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Although colonies isolated from the plates with higher zeocin concentrations did 
show the highest expression levels, they did not vary significantly from colonies 
isolated on plates with lower levels of antibiotic (Figure 5.10). As the expression 
level profile was essentially the same for all four plates, it suggested that there 
was  no  significant  benefit  in  performing  clonal  selection  at  high  (2  mg/ml) 
concentrations  of  zeocin.  Rather,  the  results  suggested  that  the  best  way  to 
identify a highly expressing transformant is to screen a large number of colonies.  
Figure 5.10 The expression level of GU-CLBH in different transformants selected on plates 
with increasing concentrations of the antibiotic Zeocin 
The X33 P. pastoris strain was transformed with an expression plasmid containing GU-CLBH. The 
cells were grown on YPD plates containing different (0.2, 0.5, 1 and 2 mg/ml) concentrations of 
zeocin. Twelve colonies from each plate were grown in 1 ml cultures, and receptor production 
induced as described in Section 3.5.1. The expression level was determined by measuring iLOV 
fluorescence per amount of total cell protein. The expression level profile was essentially the same 
for all four plates, suggesting that there was no significant benefit of performing clonal selection at 
high (2 mg/ml) concentrations of zeocin. 
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5.7 Using iLOV to optimise MP production in fermenter 
culture  
The main benefit of using P. pastoris for recombinant MP production is its ability 
to  grow  to  high  cell  densities  in  fermenter  culture  (where  dissolved  oxygen 
content, pH, temperature and feed rates can all be tightly controlled (Cereghino 
et al., 2002; Jahic et al., 2006)). For each different MP, the basic fermentation 
protocol  needs  to  be  optimised  to  ensure  that  maximal  levels  of  the  target 
protein  are  obtained.  If  recombinant  protein  expression  levels  have  to  be 
determined by either radioligand binding or Western Blotting, the optimisation 
process can be unnecessarily long.  
Previously,  HT-  trunc  dG  hA2aR  –  TB  production  in  fermenter  culture  was 
optimised  by  determining  the  levels  of  membrane  bound  receptor  at  various 
time  points  by  radioligand  binding  (Section  4.3.2).  Receptor  levels  were  only 
determined once the fermentation had been completed as it was simplest to 
make  membranes  for  all  of  the  time-points  together  before  performing 
radioligand  binding.  Here,  Rag23-  and  Rant21-CLBH  production  in  fermenter 
culture was followed by measuring iLOV fluorescence from intact cells at regular 
intervals (Figure 5.11). Culture biomass was determined by measuring the wet 
cell  weight  per  ml  of  culture  at  each  of  the  time-points.  From  these  two 
measurements,  the  receptor  expression  level  could  be  quantified  promptly 
(generally  within  30  minutes  of  taking  the  sample).  This  speed  of  analysis  is 
beneficial as it allows time-courses of recombinant MP production to be followed 
in  real-time,  allowing  decisions  about  when  is  the  best  time  to  stop  the 
fermentation  during  each  run.  The  iLOV  marker  is  ideal  for  time-course 
applications as, unlike GFP, there is no delay period between iLOV assembly and 
fluorescence  from  the  chromophore.  For  both  constructs,  growth  on  glycerol 
gave a maximal cell density of ca. 300 g wet weight of cells per litre of culture. 
Maximal receptor expression was achieved by feeding the yeast on methanol for 
ca. 40 h.  
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Figure 5.11 Time-course of (A) Rag- and (B) Rant-CLBH production in fermenter culture 
Samples were taken at regular intervals throughout the fermentation. For each time point, 1 ml of 
cells was centrifuged and the pellet weight measured. The cell pellet was washed twice with (to 
remove free flavin present in the media) and then resuspended in water. iLOV fluorescence was 
measured using a platereader. Rag23- and Rant21-CLBH production levels were expressed as 
amount of iLOV fluorescence per amount of wet weight of cells. For both constructs, growth on 
glycerol gave a maximal cell density of ca. 300 g wet weight of cells per litre of culture. Maximal 
receptor expression was achieved by feeding the yeast on methanol for ca. 40 h.  
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5.8 Monitoring MP aggregation status using iLOV 
Although it is relatively easy to assess a protein’s purity (e.g. by SDS-PAGE) it is 
rather more difficult to determine its aggregation status. Often, it is not realised 
that the target protein has aggregated until it has been purified to homogeneity, 
rendering  it  useless  for  structural  biology  purposes  (Postis  et  al.,  2008). 
Aggregation is a common problem encountered when working with membrane 
proteins, and is usually caused by protein instability in the detergent that has 
been chosen for membrane solubilisation and purification purposes. Recently, 
the  approach  of  fluorescence  size-exclusion  chromatography  (FSEC)  has  been 
developed as a method for monitoring the aggregation status of MPs throughout 
the  purification  process  following  membrane  solubilisation.  When  a  pure 
monodisperse protein is applied to a SEC column, it elutes as a single peak with 
Gaussian symmetry (Gutmann et al., 2007). By attaching a fluorescent tag to the 
MP  of  interest,  it  is  possible  to  assess  whether  or  not  the  target  protein  is 
monodisperse  at  any  stage  of  the  solubilisation/purification  procedure  by 
applying  it  to  a  SEC  column  and  then  measuring  fluorescence  (target-protein 
specific) rather than A280 (all proteins) in the elution fractions. The elegance of 
FSEC is that it allows the aggregation status of recombinant MPs to be monitored 
even in the presence of other proteins (Kawate and Gouaux, 2006). A single, 
symmetric fluorescent SEC peak throughout the purification indicates that the 
target protein is stable. If the SEC elution profile has multiple fluorescent peaks 
with one of them located in the void volume it suggests that the target protein 
has  become  aggregated,  and  is  unsuitable  for  further  purification  and 
crystallisation trials. GFP is the tag most commonly used for FSEC experiments 
(Kawate  and  Gouaux,  2006).  Here,  the  usefulness  of  iLOV  to  monitor  the 
aggregation status of HT – trunc dG hA2aR – TLB as well as Rag23- and SI-CLBH 
following detergent solubilisation is described.  
Previously, it has been shown that functional solubilisation of the hA2aR can be 
accomplished using a combination of DDM and cholesterol hemisuccinate (CHS) 
(Weiss  and  Grisshammer,  2002;  Fraser,  2006).  However,  CHS  is  bulky, 
hydrophobic and has a tendency to drive MP aggregation (Chris Tate, personal  
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communication). Here, I wanted to investigate whether or not i) HT – trunc dG 
hA2aR – TLB was monodisperse in detergent solution following solubilisation with 
DDM/CHS,  and  ii)  the  DDM:CHS  ratio  affected  the  hA2aR  aggregation  status. 
Membranes were solubilised with DDM (final concentration of 2.5%) containing 
different  amounts  of  CHS  (CHS:DDM  ratios  of  1:5,  1:10,  1:25,  1:50,  no  CHS). 
Following  centrifugation,  the  supernatant  was  applied  to  a  Sepharose  C6  gel 
filtration  column  in  buffer  containing  0.05%  DDM  with  CHS  added  in  the 
appropriate  ratio.  iLOV  fluorescence  was  measured  in  all  of  the  elution 
fractions.  The FSEC profiles showed that only a DDM:CHS ratio of 50:1 gave 
monodisperse receptor following solubilisation (Figure 5.12). At both higher and 
lower  DDM:CHS  ratios,  the  receptor  was  found  to  aggregate  (Figure  5.12). 
Receptor that had been solubilised with a 50:1 DDM:CHS ratio was able to bind 
[
3H]  ZM241385  in  solution  (results  not  shown).  These  results  showed  that  if 
enough CHS was included in the solubilisation mixture monodisperse receptor 
that retained its activity in detergent solution could be obtained. If, however, 
too much CHS was added, the additive caused the receptor to aggregate. In all 
of the profiles, a small broad peak with an elution volume around 25 ml was 
observed. On measuring the fluorescence emission spectrum of this peak, it was 
found to be flavin. The other, higher MW peaks all had the characteristic LOV 
emission profile consistent with them being oligomers/aggregates of LOV-tagged 
receptor.  The  free  flavin  comes  from  denaturation  of  the  iLOV  domain  on 
treatment  with  detergent.  As  this  peak  did  not  obscure  monitoring  of  the 
receptor’s aggregation status, it was concluded that iLOV could be used as an 
alternative reporter to GFP for FSEC experiments.  
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Figure 5.12 The effect of different DDM:CHS ratios on the aggregation status of HT – trunc 
dG hA2aR - TLB 
Membranes containing HT – trunc dG hA2aR – TLB were solubilised with DDM (final concentration 
of  2.5%)  containing  different  amounts  of  CHS.  Following  solubilisation,  the  samples  were 
centrifuged and the resulting supernatants analysed by FSEC. iLOV fluorescence in each of the 
elution fractions was measured using a platereader.  
Having  identified  conditions  that  gave  monodisperse  receptor  following 
solubilisation,  a  Ni
2+  purification  step  was  performed.  (This  is  detailed  in 
Section). An aliquot of the partially purified receptor was applied to the gel 
filtration  column,  and  the  fluorescence  content  of  the  elution  fractions 
measured (Figure 5.13). Disappointingly, a single broad peak that eluted at ca. 
12 ml was observed (that was appreciably different from the sharp peak around 
20  ml  that  had  been  seen  in  the  post-solubilisation  sample),  showing  that 
purification with the Ni
2+ column had caused the receptor to aggregate. This 
effect may have of been caused by one of the chemicals contained within the 
purification  buffers  used  with  the  Ni
2+  column.  To  explore  this  possibility,  a 
series  of  test  solubilisation  experiments  were  performed  in  the  presence  of 
either NaCl, imidazole or histidine. The detergent-solubilised material was then 
applied  to  the  gel-filtration  column  equilibrated  in  a  buffer  containing  the  
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chemical under investigation. Fluorescent elution profiles are shown in Figure 
5.14. The results showed that none of the reagents tested, in and of themselves, 
caused the receptor to aggregate. Rather it looked like the receptor became 
aggregated during the time it was bound to the column perhaps through a local 
enrichment  in  the  concentration  of  CHS.  Despite  considerable  effort  to 
overcome this problem of aggregation, none could be found. In all subsequent 
hA2aR  solubilisation  and  purification  experiments  conformationally-fixed 
thermostable mutants were used (Magnani et al., 2008). 
 
Figure 5.13 Analysis of HT - trunc dG hA2aR - TLB before and after Ni
2+-affinity purification 
by FSEC and SEC 
The  hA2aR  was  solubilised  from  yeast  membranes  using  a  combination  of  DDM  (final 
concentration 2.5%) and CHS (ratio 50:1). The receptor was purified by Ni
2+ chromatography as 
described in Section 3.12. Aliquots containing the hA2aR before and after purification were applied 
to a Sepharose C6 gel-filtration column, and the fluorescence elution profile measured for both 
samples (before – green; after blue). A single sharp peak at ca. 20 ml was observed for the post-
solubilisation sample. However, after Ni
2+ purification, the peak was shifted to an earlier elution 
time (12 ml) and was considerably broader suggesting that during the purification step the receptor 
had become aggregated. This was confirmed by the absorbance profile following purification.   
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Figure 5.14 The effects of a range of buffer components on the aggregation status of HT-
trunc dG hA2aR – TLB in detergent solution 
A  series  of  test  solubilisation  experiments  were  performed  using  a  combination  of  DDM  (final 
concentration of 2.5%) and CHS (50:1) in the presence of either NaCl, imidazole or histidine. The 
detergent-solubilised material was then applied to the gel-filtration column equilibrated in a buffer 
containing the chemical under investigation. The elution profiles showed that none of the reagents 
tested, in and of themselves, caused the receptor to aggregate. 
The hA2aR thermostable mutants Rant21 and Rag23 can bind [
3H] ZM241385 and 
[
3H] NECA in short chain detergents, respectively (Magnani et al., 2008). Here, I 
wanted to explore whether or not these mutants were monodisperse in a range 
of different detergents following solubilisation. As the hA2aR has already had its 
structure solved with ZM241385 bound (Jaakola et al., 2008), I focussed on the 
hA2aR  agonist  mutant  Rag23.  Membranes  containing  HT-Rag23-TLB  were 
incubated with a saturating (100 µM) concentration of NECA and then solubilised 
with either DDM (alkyl chain C=12), DM (C=10), NM (C=9) or βOG (C=8). After 
centrifugation, the supernatants were applied to the gel filtration column pre-
equilibrated  in  buffer  containing  NECA  as  well  as  the  appropriate  detergent. 
Rag23 was found to be monodisperse in all of the non-ionic detergents tested 
even in βOG (Figure 5.15). Furthermore, monodisperse peaks were also obtained 
(for  all  of  the  detergents  tested)  when  the  receptor  containing  supernatants  
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were applied to the column 48 h after solubilisation, demonstrating that Rag23 
has prolonged stability in detergent solution (results not shown). Unfortunately, 
due to time constraints, it was not possible to characterise the Rant21 mutant 
by FSEC. 
 
Figure 5.15 FSEC analysis of HT-Rag23-TLB  
Membranes containing HT-Rag23-TLB were incubated with a saturating concentration (100 µM) of 
NECA before they were solubilised using detergents with different alkyl chain lengths – DDM (C = 
12), DM (10), NM (9) and βOG (8). Even with the harshest detergent βOG, monodisperse receptor 
was  obtained.  This  experiment  suggested  that  Rag23  is  an  excellent  candidate  for  structural 
studies as it is remarkably stable even in short chain detergents.  
In  order  to  determine  the  stability  of  SI  in  detergent  solution  membranes 
containing  SI-CLBH  in  sodium  phosphate  buffer  were  solubilised  using  either 
DDM, DM, NM or βOG. After centrifugation, the supernatants were applied to the 
gel filtration column pre-equilibrated in sodium phosphate buffer containing the 
appropriate detergent. SI was found to be monodisperse in both DDM and DM 
(Figure 5.15). In NM, although a single fluorescent peak was observed it was 
appreciably broader than that which had been observed in either DDM or DM 
suggesting that the enzyme was starting to lose its stability in NM (Figure 5.15). 
When  SI  was  solubilised  with  βOG,  the  protein  was  completely  aggregated  
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(Figure 5.15). Remarkably, for a wild-type protein, SI displays good stability in 
the short-chain detergent DM (and to a lesser extent NM) suggesting that this 
protein may be an excellent candidate for structural studies.  
 
Figure 5.16 FSEC analysis of SI-CLBH 
Membranes containing SI-CLBH in sodium phosphate buffer were solubilised with either DDM, DM, 
NM or βOG. Remarkably for a native protein, SI was monodisperse in both DDM and DM. By NM, 
however, the fluorescent peak was starting to broaden suggesting that the enzyme was starting to 
lose its stability in this detergent. When SI was solubilised with βOG, the protein was completely 
aggregated.  
 
5.9 iLOV as a purification aid 
All protein purification steps involve binding of the target protein to a resin, 
washing the column or beads and then selectively eluting the protein of interest.  
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When performing any purification step, it is necessary to know how much of the 
target protein has bound to the column as well as which elution fractions contain 
the protein of interest. Such basic information can be hard to obtain if there is 
not a simple assay to measure the activity/presence of the protein of interest. 
Here, I describe how the iLOV tag can be used to overcome these purification 
difficulties.  
Yeast membranes containing HT – trunc dG hA2aR – TLB were solubilised with 
2.5%:0.05% DDM:CHS according to Section 3.103.12.1. Following centrifugation, 
the soluble fraction containing receptor was passed over a Ni
2+ column. Receptor 
binding was monitored by comparing the fluorescence of the supernatant before 
and after passage over the column. Receptor binding to the Ni
2+ column was 
readily visualised by illuminating it with UV light (Figure 5.17 (A)). The resin was 
washed with buffer containing 500 mM NaCl and 75 mM imidazole according to 
Section  3.13.  This  was  to  remove  any  contaminant  proteins  that  had  non-
specifically-bound to the column. The receptor was released from the column by 
passing  buffer  over  it  containing  300  mM  imidazole,  and  fractions  collected. 
Those containing iLOV-tagged receptor were readily recognised, as they were 
yellow in the light and fluorescent on exposure to UV (Figure 5.17 (B-C)). The 
fractions containing receptor were pooled and analysed by FSEC which showed 
that the hA2aR had become aggregated during the Ni
2+ purification step (Section 
?).  
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(A) 
 
(B) 
 
(C) 
 
 
Figure 5.17 Visualisation of iLOV-tagged hA2aR during Ni
2+-affinity purification 
(A) iLOV-tagged hA2aR bound to a Ni
2+ column has a fluorescent green colour under UV-light. The 
receptor was eluted from the column using 300 mM imidazole. Fractions containing HT-trunc dG 
hA2aR -TLB are (B) yellow in colour and (C) fluorescent green following UV-irradiation. 
5.10 Immobilisation of fluorescently-tagged hA2aR using 
streptavidin beads 
The  biotinylation  domain  was  primarily  included  in  the  in-house  expression 
vector  as  a  second  affinity  tag  for  protein  purification  purposes.  Biotinylated 
proteins are rare in nature with only one known in E. coli (Fall 1979), five in S. 
cerevisiae (Lim et al. 1987) and four in mammalian cells (Robinson et al. 1983; 
Chandler and Ballard 1988). As the levels of endogenous biotinylated proteins in 
P. pastoris are very low, it was envisaged that purification using this tag would 
result in a substantial enrichment of the target protein. Although it has been 
previously  shown  that  the  biotin  acceptor  domain  from  the  P.  shermanii 
transcarboxylase  can  be  biotinylated  endogenously  by  S.  cerevisiae  (Cronan, 
1990) to ensure that all of the fusion domains were biotinylated Ni
2+ enriched 
HT-  GU  hA2aR-TLB  was  incubated  at  4°C  overnight  with  recombinant  E.  coli  
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biotin  ligase  in  vitro  (Figure  5.18  (A)).  After  biotinylation  was  complete,  the 
fluorescently  tagged  receptor  was  desalted  before  application  to  streptavidin 
beads. All of the fluorescently-labelled receptor bound to the beads (Figure 5.18 
(B)), showing that all of the fusion domains had been biotinylated in vitro. As 
the  interaction  between  biotin  and  streptavidin  is  incredibly  tight  it  was  not 
possible to elute bound receptor from the beads using free biotin. Although the 
biotin-streptavidin bond can be broken at low pH (<3) these conditions were far 
too harsh to expose the receptor to. Rather, it was thought that the best way to 
remove the receptor from the beads was through tag cleavage. Initial studies 
using TEV protease were unable to get satisfactory cleavage, at either end of the 
recombinant  protein,  as  the  TEV  that  I  made  in  the  lab  had  poor  solubility 
(results not shown). However, the usefulness of this immobilization technique 
has been confirmed using constructs containing the C3 protease recognition site 
(data not shown). 
(A) 
 
(B) 
 
Figure 5.18 In vitro treatment of HT – GU hA2aR – TLB with biotin ligase allows the receptor 
to be immobilised on streptavidin beads 
(A) SDS-PAGE of purified recombinant E. coli biotin ligase, (B) Following in vitro biotinylation of 
Ni
2+-enriched hA2aR the receptor could be readily immobilised on streptavidin beads. This was 
visualised by looking at fluorescence from the iLOV tag under a UV light source.   
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5.11 Conclusion 
Having made a series of related expression constructs, optimal (CLBH) vectors 
were created that gave high level production of two different human membrane 
proteins  (one  Nin  –  hSI;  one  Nout  –  hA2aR)  that  could  be  rapidly  purified  to 
homogeneity using a generic protocol. The biotin acceptor site could be fully 
biotinylated  in  vitro  using  recombinantly  expressed  BirA.  Due  to  the  high 
expression levels achieved with both the hA2aR and hSI in fermenter culture, 
this tag was not required for their successful purification. However, the ability 
to immobilise any target protein by its C-terminus is an incredibly useful feature 
of  the  expression  vector  and  should  be  compatible  with  drug  discovery 
approaches  such  as  Biacore  and  target-immobilised  NMR  spectroscopy.  The 
inclusion of a fluorescent reporter C-terminal to the protein of interest helped 
greatly  to  assess  the  expression,  detergent-extraction  and  purification 
processes. Finally, C3 protease was found to be a considerably better enzyme for 
removing  the  expression/purification  tags  from  the  recombinant  protein  than 
TEV as the TEV made in our lab had poor solubility. For the sake of simplicity, 
the final optimised expression vector had the iLOV-biotin-His10 (LBH) tags fused 
to the C-terminus of the recombinant protein. This allowed removal of all the 
tags in a single cleavage event with C3. The major disadvantage of having all of 
the purification tags at one end of the recombinant protein as compared to tags 
at both ends is that there is no guarantee of purifying protein that is completely 
intact. When all of the purification tags are at one end of the protein, it is 
possible to purify a proteolytic fragment of the target protein. However, when 
there are tags at either end of the target protein, by performing a two-step 
purification procedure it is possible to isolate protein that has both its N- and C-
termini intact.  
The iLOV fluorescent reporter protein is a useful tool for optimising processes 
such as clonal selection, protein production in fermenter culture, detergent and 
construct screening as well as protein purification. The primary benefits of using 
iLOV are that it saves time, labour and cost as well as giving important insights 
into the stability of the target MP immediately after solubilisation as well as  
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during the purification process. This second advantage is considerable given the 
propensity of MPs to aggregate. An unexpected but incredibly useful property of 
the  iLOV  tag  was  discovered  during  the  FSEC  experiments  where  all  of  the 
elution profiles had a “late” peak consisting of flavin (that had been released on 
breakdown of the iLOV tag). The size of the flavin peak gave a direct measure of 
the amount of target protein denaturation that had occurred on treating the 
membranes  with  detergent.  The  presence  of  a  large  flavin  peak  in  a  FSEC 
experiment (following either detergent-solubilisation or -exchange) suggests that 
the target protein is unstable in the chosen detergent whereas the absence of a 
flavin peak in the elution profile suggests that the iLOV-tagged MP is stable. In 
short,  by  monitoring  the  free-flavin  content  of  iLOV-tagged  MPs  in  detergent 
solution  it  should  be  easy  to  identify  those  detergents  in  which  the  MP  is 
unstable/has become denatured. 
One disadvantage of iLOV compared to GFP is that it is not compatible with in-
gel  fluorescence  experiments.  As  fluorescence  from  the  iLOV  chromophore 
comes from the flavin co-factor, when iLOV tagged receptor is treated with SDS, 
the iLOV domain denatures rendering it non-fluorescent. This means that iLOV-
tagged proteins on a SDS-PAGE cannot be visualised by placing it under a UV 
source. This is different from GFP-tagged proteins which retain their structure 
and fluorescence even after treatment with SDS (Drew et al., 2006). 
This  Chapter  also  highlights  the  usefulness  of  conformationally-fixed 
thermostable mutants of GPCRs for structural biology purposes. Rag23 was stable 
in DDM without any CHS present. This is important as CHS has a tendency to 
drive MP aggregation. Furthermore, as Rag23 was monodisperse in a series of 
short-chain  detergents  it  suggested  that  this  mutant  will  make  an  excellent 
candidate for structural trials. Although time-consuming to make, thermostable 
mutants will likely allow structures of numerous proteins to be solved in the 
future that otherwise would likely to have proved to be intractable.   
6  Structural studies on Rag23 and sterol 
isomerase  
 
6.1 Introduction 
Having  created  an  optimal  expression  vector  for  making  fluorescently-tagged 
mammalian membrane proteins in P. pastoris, I now wanted to use it to obtain 
milligram quantities of pure Rag23 and SI for structural studies. Although I could 
have worked on any of the three hA2aR constructs that I had made (Section 5.4) 
I chose to focus on Rag23 as it is the one that I considered most biologically 
interesting. Currently, the only structures of ligand-activated GPCRs in the PDB 
are in the inactive state. The next major challenge for structural biologists is to 
solve the structure of a receptor in an active conformation. Although Rag23 is a 
thermostable mutant, it is considerably less stable than its antagonist equivalent 
Rant21 (Magnani et al., 2008). I was, therefore, interested to know if Rag23 
could be purified to homogeneity in a mild-detergent (such as DDM) without the 
receptor becoming aggregated. As SI is an integral membrane enzyme, it was 
thought that this protein would be significantly more stable than the hA2aR. To 
test this hypothesis, I wanted to determine whether or not wild-type SI could be 
purified to homogeneity while retaining its monodispersity in short- (e.g. DM) as 
well as long-chain detergents (DDM). This Chapter describes my efforts to purify 
and  biophysically  characterise  both  Rag23  and  SI.  In  addition,  crystallisation 
trials  (detergent  and  lipidic  sponge  phase)  were  performed  with  SI,  and  the 
results presented.   
6.2 Purification of Rag23 in DDM 
Aα-Rag23-CLBH was produced in fermenter cultures of P. pastoris as described in 
Section  3.5.4.  Membranes  were  isolated  according  to  Section  3.6.3,  and 
saturation radioligand binding analysis performed using [
3H] NECA (Figure 6.1). A  
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Bmax value of ca. 26 pmol/mg protein was obtained with a Kd value of ca. 3 µM. 
Accurate Bmax or Kd values for [
3H] NECA binding to my Rag23 construct could not 
be  obtained  as  the  experimental  data  suggested  that  complete  receptor 
saturation would require the addition of between 10-50 µM radioligand – this was 
neither  practical  nor  affordable.  This  result  was  both  disappointing  and 
unexpected. The Kd of the original Rag23 construct for [
3H] NECA is ca. 21 nM 
(Magnani  et  al.,  2008),  displaying  two-orders  of  magnitude  higher-affinity  for 
NECA  than  the  version  I  had  made.  The  most  likely  explanation  for  the 
difference in pharmacological properties between constructs is that my version 
of Rag23 has a substantial part of IL3 removed, trapping the receptor in a low-
affinity  state  for  NECA.  To  test  this  hypothesis,  the  original  Rag23  construct 
(which has its third intracellular loop intact) needs to be cloned into the Aα-
CLBH  expression  vector  and,  following  transformation,  the  receptor’s 
pharmacological properties in yeast membranes determined. Unfortunately, due 
to the lack of time, it was not possible to do this.  
 
Figure 6.1 Saturation binding of [
3H] NECA to Rag23-CLBH in P. pastoris membranes 
Saturation binding analysis was performed according to Section 3.8.2. The data was fitted using 
GraphPad Prism Software. A Bmax value of ca. 26 pmol/mg protein was obtained with a Kd value of 
ca. 3 µM.  
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Even  though  the  Rag23  construct  I  had  made  did  not  have  the  expected 
pharmacology,  I  still  went  onto  to  purify  it.  Prior  to  solubilisation,  yeast 
membranes containing Rag23-CLBH were stirred with 100 µM NECA for 1h at 4°C. 
This was to ensure that all of the receptor binding sites were occupied with 
agonist prior to detergent treatment (as it has been previously shown that NECA 
confers an extra 16°C of thermostability on Rag23 in detergent solution (Magnani 
et al., 2008)). The receptor was released from the membranes by treatment 
with  DDM.  Following  centrifugation,  the  supernatant  containing  receptor  was 
applied to a Ni
2+ column. The material that bound was washed with HEPES buffer 
containing 100 mM NaCl and 75 mM imidazole (to remove His rich proteins). It 
was not possible to wash the column with buffer containing a high (e.g. 500 mM) 
salt concentration as NaCl abrogates NECA binding to Rag23 (results not shown). 
Finally, the protein was eluted using 500 mM imidazole. Those fractions that 
were fluorescent (i.e. those containing iLOV tagged receptor) were analysed by 
SDS-PAGE (Figure 6.2). At this stage, Rag23 was only partially pure and it was 
not readily obvious which band corresponded to Rag23-CLBH. In contrast, after 
HT- trunc dG hA2aR - TB had been Ni
2+-purified the receptor was largely pure 
with a single band clearly visible at ca. 49 kDa (Figure 4.10). The difference in 
purity  of  the  Rag23  and  trunc  dG  hA2aR  constructs  following  Ni
2+-affinity 
purification  reflects  their  relative  abundance  in  yeast  membranes  (compare 
Figure 6.1 with Figure 4.7). HT – trunc dG hA2aR- TB had an expression level 4-8 
times greater than that of Rag23-CLBH explaining why this receptor construct 
was  significantly  purer  than  Rag23  following  a  single  Ni
2+-affinity 
chromatography step. An aliquot of partially-purified Rag23-CLBH was analysed 
by FSEC, and a single sharp symmetric peak observed (Figure 6.3). This showed 
that my version of Rag23 was sufficiently stable in the presence of NECA to be 
purified using DDM as detergent.   
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Figure 6.2 SDS-PAGE of Ni
2+-affinity purified Rag23-CLBH 
Elution fractions from the Ni
2+ column that were fluorescent (i.e. those that contained iLOV-tagged 
Rag23) were analysed by SDS-PAGE. At this stage in the purification process, it was not readily 
obvious which band corresponed to Rag23-CLBH.  
 
Figure 6.3 FSEC elution profile following application of Ni
2+-affinity purified Rag23-CLBH to 
a Sepharose C6 gel filtration column 
A single, symmetric fluorescent peak was observed demonstrating that monodisperse Rag23 could 
be purified in the presence of NECA using DDM as detergent.  
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Pooled Rag23-CLBH was desalted to remove the imidazole before it was cleaved 
overnight  at  4°C  with  C3  protease.  The  following  morning,  a  reverse  Ni
2+ 
purification  step  was  performed.  It  was  envisaged  that  when  the  cleavage 
mixture was applied to the Ni
2+ beads the cleaved CLBH tag, the His-tagged C3 
protease as well as all of the contaminant proteins that bound to the original 
Ni
2+  column  would  bind  to  the  beads,  leaving  largely  Rag23  in  solution.  The 
reverse-purified sample was concentrated and applied to a Sepharose C6 gel-
filtration column. The peak fraction from the gel filtration column was run on a 
gel and a single faint band at ca. 26 kDa was observed (Figure 6.4), consistent 
with the receptor’s MW (32.8 kDa). If time had allowed, the band thought to 
contain Rag23 would have been cut out from the gel and sent for analysis by 
tandem  mass  spectrometry  (MS-MS)  to  unequivocally  identify  the  purified 
protein. 
 
Figure 6.4 SDS-PAGE of pure Rag23 
Following treatment of partially-purified Rag23-CLBH (Figure 6.2) with C3 protease, the sample 
was reverse-purified using Ni
2+ beads. The supernatant containing Rag23 was concentrated and 
applied to a Sepharose C6 gel-filtration column. The peak elution fraction was analysed by SDS-
PAGE and a single faint band at ca. 26 kDa corresponding to Rag23 was observed.  
Here,  it  has  been  shown  that  conformationally-fixed  GPCR  mutants  that 
preferentially  binds  agonists  (such  as  Rag23)  can  be  purified  to  homogeneity 
with  monodispersity  as  long  as  they  are  sufficiently  thermostable  to  prevent  
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aggregation in detergent solution. If time had allowed, I would have liked to 
have  repeated  this  purification  using  the  shorter  chain  detergent  DM.  If 
monodisperse Rag23 could be purified in DM, it would significantly increase the 
exposed polar surface area of the receptor available for making lattice contacts, 
potentially allowing the formation of ordered protein crystals from detergent 
solution. However, the results in this Section also highlight the need to perform 
rigorous functional analysis of any mutants that are made for structural studies.  
6.3 Large-scale production of SI 
The A-SI-CLBH vector (Section ?) was introduced into the P. pastoris expression 
strain X33 by electroporation. Transformants were selected by growing the yeast 
on plates containing zeocin. Twelve colonies were grown up in 1 ml cultures of 
BMGY (basal media) overnight at 30°C. The following morning, the BMGY was 
replaced with 1ml of BMMY (induction media), and the cultures left for 24 h at 
22°C. The production level of SI for each clone was determined by measuring 
the amount of LOV fluorescence (FU) (emitted by whole cells) per milligram of 
protein  (following  chemical  cell  lysis)  (Figure  6.5).  Of  the  twelve  colonies 
tested, one did not grow. In the eleven which did grow, a 2.5 fold difference in 
the SI production level was observed between transformants (Figure 6.5). As the 
expression  levels  seen  for  individual  SI  clones  were  considerably  higher  than 
those seen for native hA2aR (an increase in fluorescence of 1.2 to 8-fold for the 
same  amount  of  protein  measured)  (compare  Figure  6.5  to  Figure  5.9),  it 
suggested that wild-type SI was more stable than the receptor, and may make a 
good target for structural studies. The transformant making the highest levels of 
SI was retained for subsequent experiments.  
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Figure 6.5 Production of sterol isomerase in different P. pastoris transformants 
Twelve transformants were grown for 24h in BMGY at 30°C followed by another 24h in BMMY at 
22°C. SI expression levels for the eleven colonies that grew were determined by measuring the 
amount  of  LOV  fluorescence  (FU)  (emitted  by  whole  cells)  per  milligram  of  protein  (following 
chemical  cell  lysis).  A  2.5  fold  difference  in  the  SI  production  level  was  observed  between 
transformants. 
Next,  the  SI  clone  that  had  been  selected  was  grown  in  fermenter  culture 
according to the protocol that had been optimised for the hA2aR. Samples were 
taken at selected time-points throughout the fermentation to determine both 
the culture’s biomass (by measuring wet cell weight) and the SI expression level 
(by measuring iLOV fluorescence from whole cells) (Figure 6.6). Biomass levels 
of ca. 300 g wet weight of cells per litre of culture were obtained, similar to 
that observed in hA2aR fermentations. Maximal SI expression levels were in the 
range 1 x 10
7 fluorescence units per milligram of cellular protein (Figure 6.6). 
This compares with 8 x 10
6 FU/mg observed for both Rant21 and Rag23 (Figure 
5.11).   
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Figure 6.6 Time-course of sterol isomerase expression in fermenter culture 
SI-CLBH  was  made  in  fermenter  culture  using  the  optimised  protocol  developed  for  hA2aR 
production.  Wet  cell  weight  and  SI  expression  levels  were  determined  at  regular  intervals. 
Typically, biomass levels of ca. 300g wet weight of cells per litre of culture were obtained with SI 
expression levels in the region of 1 x 10
7 fluorescence units per milligram of protein. 
 
6.4 Purification of SI in DDM using HEPES buffer 
Membranes  containing  SI-CLBH  were  prepared  from  yeast  cells  grown  in 
fermenter culture (Section 3.6.3). The membranes were re-suspended in HEPES-
buffer  pH  7.4  and  then  solubilised  with  DDM.  Following  centrifugation,  the 
supernatant fraction (containing SI) was applied to a Ni
2+ column where the SI 
bound  to  it  via  its  His10  tag.  Contaminant  proteins  were  removed  from  the 
column  by  washing  it  with  HEPES  buffer  containing  500  mM  NaCl  (to  remove 
those contaminant proteins that bound to the Ni
2+ resin via ionic interactions) 
and 75 mM imidazole. SI-CLBH was eluted from the column using an imidazole 
gradient  (Figure  6.7).  Those  fractions  containing  SI-CLBH  (as  determined  by 
measuring  iLOV  fluorescence)  were  analysed  by  SDS-PAGE  to  determine  how 
pure the sample was after this purification step (Figure 6.8). The gel showed 
that the SI-CLBH was largely pure at this stage with a major band clearly visible  
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at ca. 44 kDa (SI-CLBH has a predicted MW of 45 kDa). The SI-CLBH expression 
level was so high that it essentially prevented any contaminant host proteins 
from binding to the Ni
2+ column, explaining why it was largely pure following a 
single chromatographic step.  
 
Figure 6.7 Elution of SI-CLBH from a Ni2+ column using an imidazole gradient 
When detergent-solubilised membranes were passed over a Ni
2+ column the recombinant SI-CLBH 
bound to the Ni
2+ resin via its His10 tag. After the column had been washed, SI-CLBH was eluted 
from the column using a 0-1M imidazole gradient. A single, fluorescent peak corresponding to SI-
CLBH was released by ca. 500 mM imidazole. 
 
Figure 6.8 SDS-PAGE of partially purified SI-CLBH 
Peak fractions eluted from the Ni
2+ column (Figure 6.7) were analysed by SDS-PAGE to determine 
the purity of the SI-CLBH. A major band at ca. 44 kDa (corresponding to SI-CLBH) can be clearly 
observed in all of the fractions. The gel showed that SI-CLBH was largely pure following application 
to the Ni
2+ column.  
The enriched SI-CLBH sample was desalted before it was cleaved overnight with 
C3 protease. The sample was reverse purified the following day using Ni
2+ beads,  
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concentrated  to  a  volume  of  0.5  ml  and  then  applied  to  a  Sepharose  C6  gel 
filtration column. The elution profile only contained a single large symmetrical 
peak (Figure 6.9), demonstrating that SI was both pure and monodisperse in DDM 
making it useful for structural studies. Fractions across the elution peak were 
analysed by SDS-PAGE (Figure 6.10). The gel showed there was a single band 
with a molecular weight of ca. 22 kDa in all of the fractions tested. As SI has a 
predicted MW of 26.2 kDa, it was likely that the band contained SI. To confirm 
this possibility the protein band was excised and analysed by MS-MS. Peptide 
MTTNAGPLHPYWPQHLRL  corresponding  to  αα  1-18  of  SI  was  detected, 
confirming the identity of the purified protein. 
 
Figure 6.9 Elution profile of pure SI in DDM from a Sepharose C6 gel filtration column 
Following  reverse-purification  with  Ni
2+  beads,  the  SI-containing  sample  was  concentrated  and 
applied to the gel-filtration column. The buffer was 10 mM HEPES pH 7.4 containing 10% glycerol 
and  0.05%  DDM.  A  single  symmetric  peak  was  observed  showing  that  the  purified  SI  was 
monodisperse. Fractions across the peak were analysed by SDS-PAGE (Figure 6.10)  
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Figure 6.10 SDS-PAGE analysis of SI-containing gel-filtration fractions 
Aliquots of the fractions from the gel-filtraton peak were analysed by SDS-PAGE. In all of the lanes, 
a strong band of ca. 22 kDa was observed suggesting that it was SI (actual MW 26.2 kDa). This 
band  was  cut-out  and  sent  for  MS-MS  analysis.  A  peptide  of  MTTNAGPLHPYWPQHLRL  was 
identified corresponding to αα 1 - 18  of SI confirming the identify of the purified protein. A further 
faint band could be seen at ca. 40 kDa which appears to be an SDS-induced dimer, as only one 
protein peak was observed by SEC. 
6.5 Secondary structure determination by circular 
dichroism 
Circular dichroism (CD) refers to the differential absorption of left- and right-
handed polarised light by chiral molecules (Kelly et al., 2005). CD signals only 
occur at those wavelengths where the asymmetric molecule absorbs. All proteins 
have  several  chromophores  that  absorb  in  the  ultra-violet  (UV)  region  of  the 
electromagnetic spectrum including peptide bonds (which absorb between 180 
and 240 nm), aromatic amino acids (260 to 320 nm) and disulphide bonds (which 
have weak broad absorption bands around 260 nm).  
The different kinds of secondary structure (e.g. α-helix, β-sheet) that occur in 
proteins have characteristic CD spectra in the far UV (which arise from the chiral 
arrangement of the peptide bonds in each structure). A number of algorithms 
(e.g.  SELCON  (Sreerama  and  Woody,  1993),  VARSLC  (Manavalan  and  Johnson, 
1987), CDSSTR (Johnson, 1999) and CONTIN (Provencher and Glockner, 1981))  
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have  been  developed  that  provide  an  estimation  of  a  protein’s  secondary 
structure composition from its far-UV CD spectra.  
Proteins also have measurable CD in the near-UV (260–320 nm) arising from its 
constituent  aromatic  amino  acids  (Trp,  Tyr,  Phe).  The  actual  shape  and 
magnitude of the near-UV CD spectrum for each protein depends on the number 
of each type of aromatic amino acid present, their mobility, their environment 
(H-bonding, polar groups and polarisability) as well as their position within the 
protein. The near UV-CD spectrum of a protein provides a valuable fingerprint of 
its tertiary structure, and can be used to compare, for example, the structural 
similarity of wild-type and mutant forms of the protein. 
Here, the far- and near-UV CD spectra of SI are presented. 
6.5.1 CD analysis of SI 
The near-UV CD spectrum (region 250-320 nm) of purified SI was recorded and 
found to consist of a series of peaks and troughs with maxima at 256, 265, 277 & 
291 nm and minima at 262, 270, 282 & 296, respectively (Figure 6.11 (A)). The 
secondary structure composition of SI was determined by recording a far-UV CD 
spectrum (region 190–260 nm) (Figure 6.11 (B)), and then fitting it using the 
CDSSTR alogorithm (Johnson, 1999). From this, the secondary structure content 
of SI was estimated to be 31 % α-helix, 26 % β-sheet, 23 % turn with 20 % of the 
protein disordered. This prediction suggests that SI is largely ordered (consistent 
with its catalytic function) and probably has transmembrane α-helices.   
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Figure 6.11 CD spectra of SI in the (A) near- and (B) far-UV 
The near-UV CD spectrum consists of a series of peaks and troughs with maxima at 256, 265, 277 
& 291 nm and minima at 262, 270, 282 & 296, respectively. On fitting the far-UV CD spectrum with 
the CDSSTR alogorithm (Johnson, 1999) the secondary structure content of SI was estimated to 
be 31 % α-helix, 26 % β-sheet, 23 % turn with 20 % of the protein disordered. 
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6.6 Assessing and maximising the thermostability of SI 
in detergent solution 
Removal  of  membrane  proteins  from  their  native  lipid  environment  with 
detergent  confers,  to  a  greater  or  lesser  extent,  instability  on  them. 
Furthermore, as it can take weeks or even months for protein crystals to grow it 
is  essential  that  the  membrane  protein  has  long-term  stability  in  detergent 
solution. The stability of all membrane proteins in aqueous solution are affected 
by  a  range  of  factors  including  the  buffer  type  as  well  as  its  pH,  the  ionic 
composition and strength of the buffer as well as the type of detergent used. 
Therefore, considerable effort needs to be invested for each protein of interest 
to find the conditions in which it is most stable. Through accomplishing this, it 
may be possible to purify the target protein in a short chain detergent increasing 
the probability of getting diffracting protein crystals. In Chapter 5, the effects of 
choice of detergent on hA2aR and hSI stability immediately following membrane 
solubilisation were investigated by FSEC. Although buffer and salt effects on MP 
stability can be assessed by FSEC too, this method is incredibly time consuming. 
An alternative approach involves purifying the target MP to homogeneity in a 
mild-detergent (such as DDM), and then measuring the thermostability of the 
protein in a range of buffer/salt conditions. The stability of any protein can be 
thought of in terms of its resistance to denaturation. Those proteins that are 
unstable  denature  easily  whereas  those  that  are  stable  require  harsher 
conditions  (e.g.  high  temperatures)  before  they  start  to  unfold.  Here,  two 
methods (CD, CPM assay) for studying protein unfolding were explored with a 
view  to  finding  those  conditions  that  gave  maximum  SI  thermostability  in 
detergent solution. 
6.6.1 Investigating SI thermostability by circular dichroism 
CD  can  be  used  to  study  how  a  protein’s  secondary  structure  changes  with 
temperature  giving  insights  into  its  thermostability.  Here,  a  thermal 
denaturation  of  SI  in  10  mM  HEPES  pH  7.5,  150  mM  NaCl,  0.05%  DDM  was 
performed.  The  far-UV  CD  spectrum  of  SI  was  recorded  at  regular  intervals  
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between 5 and 80°C (Figure 6.12 (A)). As the temperature increased, SI became 
partially denatured with a decrease in the minima peak intensities at both 209 
and  222  nm.  This  said,  SI  largely  retained  its  near-UV  CD  profile  even  after 
heating to 80°C showing that even at this high temperature only ca. 30% of the 
total  secondary  structure  had  become  lost  (Figure  6.12  (B-C)).  As  it  was  not 
possible  to  remove  all  of  the  protein’s  secondary  structure  by  thermal 
denaturation, this assay was considered to be too insensitive for screening the 
effects of different buffers and salts on SI stability.  
(A) 
 
(B) 
 
(C) 
 
Figure 6.12 Thermal denaturation of SI assessed by circular dichroism  
(A) Change in the far-UV CD spectrum of SI over the temperature range 5 - 80°C. The extent of SI 
secondary structure remaining following heat denaturation was determined by measuring the size 
of the CD signal at (B) 209 and (C) 222 nm.  
Structural studies on Rag23 and SI     150 
6.6.2 Using the CPM fluorophore to assess SI protein stability 
A sensitive fluorescence-based (CPM) thermal stability assay that can be used 
with  MPs  has  recently  been  described  by  Ray  Stevens  and  co-workers 
(Alexandrov et al., 2008). In this assay, reaction of a protein’s solvent-exposed 
cysteine  residues  with  the  thiol-specific  fluorochrome  N-[4-(7-diethylamino-4-
methyl-3-coumarinyl)phenyl]maleimide  (CPM)  results  in  the  generation  of  a 
fluorescent signal. When a protein is thermally denatured in the presence of 
CPM  as  the  cysteine  residues  located  in  the  protein  interior  became  solvent-
exposed an increase in CPM fluorescence intensity occurs over time. By altering 
the assay conditions (e.g. different buffers - types and pH; salts - types and 
concentrations; addition of specific ligands) in which the thermal denaturations 
are  carried  out  it  is  possible  to  identify  those  reagents  that  confer 
thermostability on the target protein. This assay can be readily-adapted for use 
with 96-well plates allowing numerous conditions to be rapidly assessed. Another 
advantage of this assay is that it consumes relatively small amounts (1-10 µg) of 
protein as compared to CD measurements (which require several 100 µgs).  Here, 
the CPM assay was used to identify the optimal buffer and salt conditions that 
conferred maximal stability on SI. 
The approach of Alexandrov et al. (Alexandrov et al., 2008) was modified so that 
SI was denatured in the presence of SDS (to enhance the rate of unfolding) at a 
constant temperature of 45°C. Initial experiments were performed to determine 
the amount of SI that needed to be added to each assay to give measurable 
amounts  of  fluorescence  (5  µg)  as  well  as  the  length  of  time  necessary  for 
maximal unfolding to occur (2.5 h) (results not shown). Initial experiments were 
performed denaturing SI in the presence of different (50, 100, 150 and 200 mM) 
concentrations of NaCl (Figure 6.13). The amount of fluorescence due to the 
unfolding of SI was determined by subtracting the background fluorescence in a 
buffer  control  from  that  measured  in  the  presence  of  protein.  For  each 
condition, the protein and buffer measurements were made in quadruplicate. 
For all four NaCl conditions, the amount of specific CPM fluorescence increased 
with  time  (Figure  6.13).  The  amount  of  fluorescence  at  t  =  8000  s  for  each  
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condition was plotted in a bar chart (Figure 6.14A). This value is a measure of 
how much SI had become unfolded during the course of the assay. The higher 
the fluorescence, the more SI had become unfolded. The results showed that the 
amount of denatured SI progressively increased with the concentration of NaCl. 
From  this,  it  was  concluded  that  SI  becomes  less  stable  with  increasing 
concentrations of NaCl. 
 
Figure 6.13 The unfolding of SI in the presence of different concentrations of NaCl  
The extent of SI denaturation was determined by reaction with the CPM reagent (which labeled 
solvent-exposed cysteine residues). As the protein unfolded, cysteines from the inner core became 
accessible to the fluorochrome resulting in an increase in fluorescence with time. 
This approach was used with a range of different salts and buffers (Figure 6.14-
16). To compare the effects of Na
+, K
+, Mg
2+, Ca
2+ and NH4
+ ions on SI stability, 
CPM  denaturation  assays  were  performed  in  the  presence  of  four  different 
concentrations (50, 100, 150, 200 mM) of their chloride salt (Figure 6.14 A-C).  
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The trends obtained suggested that in terms of their effect on SI stability NH4
+ > 
Na
+  >  K
+  and  that  Mg
2+  >  Ca
2+.  The  effects  of  anions  on  SI  stability  were 
investigated in a similar way (Figure 6.14 C-D). The results showed that Cl
-, SO4
2- 
and NO3
- have similar effects on SI stability. However, PO4
3- appeared to potently 
stabilise SI (Figure 6.14 D). NH4
+ and PO4
3- are known to promote hydrophobic 
interactions  within  proteins,  and  it  is  likely  that  these  ions  stabilise  SI  by 
strengthening existing hydrophobic contacts (most likely in the transmembrane 
region of the protein) within SI.   
 
Figure 6.14 The effect of a range of salts on SI thermostability 
SI was denatured in the presence of the CPM reagent. The ability of different ions to stabilise SI 
was assessed by measuring the specific increase in CPM fluorescence at the end of the thermal 
unfold. Those ions that gave the smallest rises in fluorescence (e.g. NH4
+ and PO4
3-) over the 
course of the assay had the greatest ability to stabilise SI in detergent solution.   
To  determine  whether  phosphate  itself  was  stabilising  SI  or  was  having  an 
indirect pH effect, further SI thermostability assays were performed in a series 
of phosphate buffers that had different pH (range 4 – 9) (Figure 6.15).  A clear  
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trend was observed with greatest SI thermostability observed at pH 4. As the pH 
of the phosphate buffer increased more SI denaturation occurred. The effect of 
pH on SI stability was further investigated by performing a series of denaturation 
assays in four different buffers (MES, MOPS, HEPES, Tris) over the pH range 5.5 
to  8  (Figure  6.16  (A)).  Similar  to  that  observed  in  phosphate  buffer,  SI  had 
greater thermostability at acidic than alkali pH. Lastly, the effect of selected 
transition metal ions on SI stability was investigated (Figure 6.16 (B)). Zn
2+, Cu
2+, 
Ni
2+ and Co
2+ were all found to stabilise SI.  
 
Figure 6.15 Effect of the pH of phosphate buffer on SI thermostability 
The  thermostability  of  SI  was  pH-dependent.  SI  was  most  stable  at  pH  4.  As  the  pH  of  the 
phosphate buffer increased more SI became denatured.  
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Figure  6.16  The  effect  of  (A)  pH  and  (B)  the  addition  of  transition  metals  on  SI 
thermostability 
Similar to that observed in phosphate buffer (Figure 6.15), SI had greater thermostability at acidic 
than alkali pH. The transition metal ions Zn
2+, Cu
2+, Ni
2+ and Co
2+ were all found to stabilise SI. 
6.7 Purification of SI in DM using a phosphate-based 
buffer 
SI stability in detergent solution is clearly dependent on the choice of buffer 
used as well as its ionic content (Section 6.6). Using the information from the 
CPM denaturation assays, I set-out to develop a purification protocol that would 
give monodisperse SI in the short-chain detergent DM. SI is more stable at acidic 
than  alkali  pH.  However,  the  efficiency  of  SI  release  from  the  membrane  on  
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detergent  solubilisation  decreased  dramatically  at  pH  <7  (results  not  shown). 
Furthermore, His tag binding to a Ni
2+ column is pH-dependent with the strength 
of interaction between the transition metal and the tag increasing as the buffer 
becomes more alkali. Using all of this information, a protocol based on a sodium 
phosphate  buffer  was  devised  in  which  the  Ni
2+  affinity,  C3  cleavage  and 
reverse-purification steps were performed at pH 7.5, and the gel-filtration step 
performed at pH 6. Under these conditions, pure, monodisperse SI in DM could 
be obtained (Figure 6.17). It was hoped that this protein would prove amenable 
to crystallisation.   
 
Figure 6.17 Elution of pure SI from the Sepharose C6 gel-filtration column equilibrated in 
sodium phosphate/DM buffer 
A protocol for purifying SI using a sodium phosphate buffer was devised in which the Ni
2+ affinity, 
C3 cleavage and reverse-purification steps were performed at pH 7.5, and the gel-filtration step 
performed at pH 6. Under these conditions, pure, monodisperse SI in DM could be obtained. 
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6.8 Crystallisation of SI from detergent solution  
As SI could be purified to homogeneity with monodispersity (in both DDM and 
DM),  it  was  thought  that  this  enzyme  would  make  a  good  candidate  for 
crystallisation trials using conventional techniques. Initial screening with SI was 
performed  using  protein  that  had  been  purified  in  HEPES  buffer  pH  7.4 
containing DDM (Section 6.4). 500 nl of 20 mg/ml protein was pipetted into each 
of  the  drops  in  a  96  well  plate  using  a  Cartesian  robot  along  with  an  equal 
volume of the reservoir solution from the Peg/Ion and MemSys/MemStart sparse 
matrix crystallisation screens. The plates were incubated in a Rhombix imager at 
20°C  for  3  months  with  regular  photographs  taken  (daily  for  the  first  week, 
weekly  thereafter)  to  record  crystal  growth  or  precipitation  formation.  In 
several conditions, detergent crystals formed (Figure 6.18 (A)). Disappointingly, 
no protein crystals were observed. A possible explanation for this is that the 
DDM micelle is so big that not enough (and perhaps none) of the polar surface 
area of SI is exposed to form lattice contacts. To address this problem, I set-up a 
crystal  tray  (MemGold)  with  SI  that  had  been  purified  in  sodium  phosphate 
buffer (pH 6) containing DM (Section 6.7). To reduce the number of detergent 
crystals that formed, a micro-dialysis step was introduced immediately prior to 
setting up trays in order to reduce the detergent’s concentration to just above 
its CMC. Although this helped to substantially reduce the number of detergent 
crystals formed (results not shown), no wells were found to contain diffracting 
protein  crystals.  Several  conditions  contained  phosphate  salt  crystals  (Figure 
6.18 (B)). Many wells contained light protein precipitate (Figure 6.18 (C)) which, 
given sufficient time and protein for optimisation, may in the future lead to the 
formation of small protein crystals.   
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(B) 
   
(C) 
 
Figure 6.18 Efforts to crystallise SI in detergent solution 
(A) Initial attempts to crystallise SI in HEPES buffer containing DDM resulted in the formation of 
numerous  detergent  crystals.  This  problem  was  overcome  by  performing  a  micro-dialysis  step 
immediately prior to setting up trays that ensured that the detergent concentration in the SI sample 
was just above its CMC. At a later stage, SI that had been purified in sodium phosphate buffer 
containing  DM  was  used  with  the  MemGold  screen  but  no  diffracting  protein  crystals  were 
obtained. Several conditions did contain phosphate crystals (B). Many wells contained light protein 
precipitate (C) which, given sufficient time and protein for optimisation, may in the future lead to the 
formation of protein crystals.  
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6.9 Development of a cholesterol-doped sparse matrix 
lipidic-sponge phase crystallisation screen 
The recent structures of the human β2-adrenergic and adenosine 2a receptors 
were solved using crystals grown from cholesterol-containing lipidic cubic phases 
(Cherezov et al., 2007; Jaakola et al., 2008). However, due to difficulties in 
handling the cubic phase as well as restrictions on the range of MPs that can be 
used with the cubic phase (due to the relatively small water pores in the lipid 
matrix) the more fluid ‘sponge’ phase has become of interest to the membrane 
protein structural community. While work with lipidic sponge phases is still in its 
infancy they have already been used to obtain diffracting crystals of the purple 
bacterial photosynthetic reaction centre (Wohri et al., 2009). At the outset of 
my  Ph.D.  there  was  not  a  commercially-available  lipidic  sponge  phase 
crystallisation  screen.    Recently,  however,  the  group  of  Richard  Neutze 
(Chalmers University, Sweden) have devised such a screen (in which I played a 
small part in helping to develop) (Wohri et al., 2008). I have shown that up to 
10%  cholesterol  can  be  incorporated  into  lipidic  sponge  phases  (results  not 
shown). Here, I describe my own version of the the Neutze screen consisting of a 
series of cholesterol-doped sponges. 
The  conditions  used  to  make  the  cholesterol  containing  sponge  phase  screen 
were largely the same as that reported in (Wohri et al., 2008), and all contained 
the lipid mono-olein (MO) (Figure 6.19). Cholesterol-containing versions of the 
jeffamine sponges detailed in (Wohri et al., 2008) were not made. Similar to the 
Neutze sponge phase screen, three buffers (HEPES, MES and Tris) and three salts 
(NaCl, MgCl2, and Li2SO4) were used all at a concentration of 100 mM. The pH of 
the buffers ranged between 6.5 and 9. It was not possible to use buffers with 
strongly acidic pH as the MO ester bond is extrememly sensitive to hydrolysis 
(Engstrom  et  al.,  2007).  Cholesterol  was  mixed  with  the  MO  prior  to  sponge 
phase formation to ensure that the sterol was completely incorporated within 
the lipid matrix. Sponge phases were created as described in (Wohri et al., 2008) 
using cholesterol-doped MO for all conditions. Sponge phases were made that 
had two different concentrations of cholesterol (0.5 and 5 % (w/w)) to increase  
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the  diversity  of  the  screen.  The  complete  cholesterol-doped  sponge  phase 
screen is listed in Table 6.1. PEG 400 and PEG 1500 were chosen to form the 
sponge-phases as they both have cryo-protectant properties which means that 
any protein crystals formed in any of the conditions can be directly transfered 
from  the  drop  to  the  X-ray  beam.  Similar  to  that  for  detergent-based 
crystallisation screens, any crystals obtained using the sponge-phase screen will 
likely need optimised to improve their packing before crystals that diffract to 
high-resolution are obtained. 
 
Figure 6.19 Chemical structure of mono-olein 
 
6.10 Crystallisation of SI in the lipidic-sponge phase 
As the cholesterol-doped sponge phases described in Section 6.9 closely mimic 
mammalian membranes they should prove useful for crystallising a wide-range of 
human  MPs.  Here,  I  used  the  lipidic-sponge  screen  with  SI  to  try  to  identify 
conditions that might yield diffracting crystals. 
SI that had been purified in sodium phosphate buffer containing DM was dialysed 
to remove excess detergent and then concentrated to 10 mg/ml. Hanging drop 
crystallisation  trays  were  set-up  in  which  1  µl  of  the  protein  solution  was 
directly added to 1 µl of one of the cholesterol-containing sponges. In addition, 
a buffer control was set-up for each sponge to give confidence that any crystals 
observed in the protein drops did indeed come from the protein and not from 
any of the chemicals present in either the buffer solution or sponge itself. The   
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Condition  PEG  %  % MO  %  pH  Buffer  Salt 1  Salt 2 
        cholesterol    (100 mM)  (100 mM)  (100 mM) 
1  400  40  30  5  6.5  MES     
2  400  40  30  5  6.5  MES  NaCl  Li2SO4 
3  400  40  30  5  6.5  MES  NaCl  MgCl2 
4  400  40  30  5  7.5  HEPES  NaCl  Li2SO4 
5  400  40  30  5  7.5  HEPES     
6  400  40  30  5  7.5  HEPES  NaCl  MgCl2 
7  400  40  30  5  8.5  HEPES     
8  400  40  30  5  8.5  HEPES  NaCl  MgCl2 
9  400  40  30  5  8.5  HEPES  NaCl  Li2SO4 
10  400  40  30  5  9.0  TRIS     
11  400  40  30  5  9.0  TRIS  NaCl  MgCl2 
12  400  40  30  5  9.0  TRIS  NaCl  Li2SO4 
13  400  40  30  0.5  6.5  MES     
14  400  40  30  0.5  6.5  MES  NaCl  Li2SO4 
15  400  30  40  0.5  7.5  HEPES     
16  400  30  40  0.5  7.5  HEPES  NaCl  Li2SO4 
17  400  40  30  0.5  7.5  HEPES     
18  400  40  30  0.5  7.5  HEPES  NaCl  MgCl2 
19  400  40  30  0.5  8.5  HEPES     
20  400  40  30  0.5  8.5  HEPES  NaCl  MgCl2 
21  400  40  30  0.5  8.5  HEPES  NaCl  Li2SO4 
22  400  40  30  0.5  9.0  TRIS     
23  400  40  30  0.5  9.0  TRIS  NaCl  MgCl2 
24  400  40  30  0.5  9.0  TRIS  NaCl  Li2SO4 
25  1500  40  30  5  6.5  MES     
26  1500  40  30  5  6.5  MES  NaCl  Li2SO4 
27  1500  40  30  5  6.5  MES  NaCl  MgCl2 
28  1500  40  30  5  7.5  HEPES     
29  1500  40  30  5  7.5  HEPES  NaCl  Li2SO4 
30  1500  40  30  5  7.5  HEPES  NaCl  MgCl2 
31  1500  40  30  5  8.5  HEPES     
32  1500  40  30  5  8.5  HEPES  NaCl  MgCl2 
33  1500  40  30  5  7.0  TRIS     
34  1500  40  30  5  8.0  TRIS     
35  1500  40  30  5  7.5  TRIS     
36  1500  40  30  5  9.0  TRIS     
37  1500  40  30  0.5  6.5  MES     
38  1500  40  30  0.5  6.5  MES  NaCl  Li2SO4 
39  1500  30  30  0.5  6.5  MES  NaCl  MgCl2 
40  1500  30  30  0.5  7.5  HEPES     
41  1500  40  30  0.5  7.5  HEPES  NaCl  Li2SO4 
42  1500  40  30  0.5  7.5  HEPES  NaCl  MgCl2 
43  1500  40  30  0.5  8.5  HEPES     
44  1500  40  30  0.5  8.5  HEPES  NaCl  MgCl2 
45  1500  40  30  0.5  7.0  TRIS     
46  1500  40  30  0.5  8.0  TRIS     
47  1500  40  30  0.5  7.5  TRIS     
48  1500  40  30  0.5  9.0  TRIS     
Table  6.1  A  cholesterol-containing  sponge  phase  crystallisation  screen  for  use  with 
mammalian membrane proteins 
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trays were sealed and stored at 20°C for one month. Due to the size of the 
crystallisation  trays  and  the  drops  themselves,  all  visualisation  events  were 
performed  manually  using  a  microscope.  Those  conditions  thought  to  be 
interesting  were  photographed.  After  one  month  most  wells  showed  some 
protein precipitation over the sponge background (Figure 6.20 (A)). In certain 
conditions small crystalline material was observed (Figure 6.20 (B)). Due to time 
limitations, however, it was not possible to test the crystalline matter in our in-
house X-ray facility. The preliminary results presented here do suggest that the 
cholesterol-doped sponge-phase screen will prove to be a useful addition to the 
range  of  existing  crystallisation  screens  currently  used  with  mammalian 
membrane proteins.  
 
Figure 6.20 Efforts to crystallise SI using cholesterol-doped lipidic sponges 
(A)  Image  of  sponge  matrix  containing  protein.  (B)  Crystalline  material  in  condition  5  (40% 
PEG400,  30%  mono-olein,  5%  cholesterol,  HEPES  pH  7.5)  of  the  sponge-phase  screen  was 
observed along the perimeter of the sponge drop.  
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6.11 Conclusion 
This chapter shows that CLBH-tagged recombinant mammalian MPs (both Nin and 
Nout)  can  be  purified  to  homogeneity  in  four  simple  steps  (Ni
2+-affinity 
purification; cleavage with C3 protease; desalt and reverse-purification with Ni
2+ 
beads;  gel-filtration).  This  vector  system  should  be  compatible  for  use  with 
other mammalian MPs including type I GPCRs, membrane enzymes, transporters 
and ion channels. 
My work on Rag23 highlights the need to perform thorough functional assays on 
any mutants made for structural studies to ensure that the mutations which have 
been made do not affect the activity of the target protein. The IL3 deletion that 
I made in Rag23 was introduced to reduce the amount of disorder within the 
receptor.  However,  in  making  this  deletion,  I  made  a  mutant  that  had  low-
affinity for agonist most likely by trapping the modified receptor in a closed 
state. This was unfortunate, and prevented me from doing large-scale protein 
preparations for biophysical characterisation and structural studies.  
Sterol isomerase is an incredibly stable enzyme for a wild-type mammalian MP. 
Using information obtained from denaturation assays using the CPM reagent it 
was  possible  to  devise  a  purification  protocol  in  which  monodisperse  SI  was 
obtained in the short-chain detergent DM using sodium phosphate as buffer. The 
power of the CPM assay is the detailed insights it is able to give on the buffer 
(both  type  and  pH)  and  salt  preferences  of  MPs  in  detergent  solution.  The 
approach I used to identify the conditions that gave maximum SI thermostability 
in detergent solution will be useful with other mammalian MPs. Whether or not 
it  is  possible  to  get  diffracting  crystals  of  SI  in  sodium  phosphate/DM  buffer 
remains to be seen.  
Finally,  a  cholesterol-doped  lipidic-sponge  phase  sparse  matrix  crystallisation 
screen was created that was tested with SI. While some crystalline material was 
observed,  time  limitations  prevented  me  from  doing  any  X-ray  analysis  and 
crystal optimisation. However, the preliminary results obtained suggest that the 
screen  may  be  useful  for  growing  diffracting  crystals  of  mammalian  MPs. 
7  Discussion and future perspectives 
Solving the structure of a human membrane protein is a massive challenge as 
evidenced by the small (<20) number of structures that have been deposited in 
the PDB to date. Given the biological and pharmaceutical importance of many 
human MPs, there is currently a substantial effort within the structural biology 
community to find technologies that will overcome the existing bottlenecks in 
solving the structures of mammalian MPs. Unlike their bacterial equivalents (of 
which  there  are  several  hundred  unique  structures  in  the  PDB),  most  human 
membrane proteins are intrinsically unstable in detergent solution. This means 
that there is an urgent need to develop new technologies: i) that allow the most 
stabilising  detergent  for  each  human  MP  to  be  readily  identified,  ii)  for 
optimising buffer conditions to ensure maximal thermostability of each MP in 
detergent  solution,  iii)  such  as  novel  detergents  and  lipids  that  effectively 
stabilise mammalian MPs once they have been removed from the membrane, and 
iv)  that  allow  mammalian  MPs  to  be  crystallised  in  a  lipid  environment. 
Furthermore,  simple  generic  systems  that  allow  the  overproduction  and 
purification of milligram amounts of a range of human MPs for crystallisation 
trials are required. Over the course of my Ph.D., I have developed a series of 
novel technologies that have sought to address some of these bottleneck issues.  
The CLBH vector system developed here allowed the successful over-expression 
and purification of both a conformationally-flexible (hA2aR) and a rigid-bodied 
(hSI)  human  membrane  protein.  Two  versions  of  the  CLBH  expression  vector 
were  made  –  one  with  an  upstream  α-factor  (that  should  be  used  for 
recombinant MPs with a Nout topology (such as the hA2aR)) and one without (that 
should be used with MPs that have a Nin orientation (such as hSI)). The CLBH 
vectors  allowed  both  target  proteins  to  be  purified  to  homogeneity  in  four 
simple  steps  (Ni
2+-affinity  purification;  cleavage  with  C3  protease;  desalt  and 
reverse  purification  with  Ni
2+  beads;  gel-filtration).  Any  recombinant  protein 
made  using  the  CLBH  system  can  be  purified  in  the  same  way.  In  fact,  the 
vectors have already been used in our laboratory to obtain milligram amounts of  
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the plant photoreceptor UVR8, adrenodoxin and the cytochrome p450 enzyme 
aldosterone synthase (Niall Fraser, personal communication).  
The  iLOV  fluorescent  reporter  protein  was  shown  to  be  a  useful  tool  for 
optimising laborious processes such as yeast clonal selection, protein production 
in fermenter culture, detergent and construct screening as well as for tracking 
protein purification, saving both time and energy. iLOV could also be used to 
assess  the  monodispersity  of  MPs  in  detergent  solution  by  FSEC.  Using  this 
approach,  it  was  shown  that  the  cholesterol  derivative  CHS  (which  confers 
radioligand  binding  capacity  on  the  hA2aR  in  detergent  solution)  promotes 
receptor aggregation during purification. Furthermore, iLOV was used to show 
that  monodisperse  Rag23  can  be  obtained  in  the  short-chain  detergent  βOG 
immediately post-solubilisation. Such insights were only realised by measuring 
fluorescence  from  the  iLOV  tag.  In  contrast  to  GFP,  when  iLOV  becomes 
denatured  the  co-factor  flavin  is  released.  This  appears  as  a  “late”  peak  on 
certain of the FSEC profiles. The size of the flavin peak gave a direct measure of 
the amount of target protein denaturation that had occurred on treating the 
membranes  with  detergent.  The  presence  of  a  large  flavin  peak  in  a  FSEC 
experiment (following either detergent-solubilisation or -exchange) shows that 
the target protein is unstable in the chosen detergent whereas the absence of a 
flavin peak suggests that the iLOV-tagged MP is stable. By monitoring the free-
flavin content of iLOV-tagged MPs in detergent solution by FSEC it is possible to 
readily identify those detergents in which the MP is unstable. One disadvantage 
of iLOV compared to GFP is that it is not compatible with in-gel fluorescence 
experiments. As fluorescence from the iLOV chromophore comes from the flavin 
co-factor,  when  iLOV  tagged  receptor  is  treated  with  SDS,  the  iLOV  domain 
denatures rendering it non-fluorescent. This means that iLOV-tagged proteins on 
a  SDS-PAGE  cannot  be  visualised  by  placing  it  under  a  UV-source.  This  is 
different from GFP-tagged proteins which retain their structure and fluorescence 
even after treatment with SDS (Drew et al., 2006). 
Attachment  of  the  biotin  acceptor  domain  to  the  C-terminus  of  the  hA2aR 
increased the receptor’s expression level by ca. 2-4 fold. Similar effects have 
been  observed  previously  when  this  domain  was  fused  to  other  type  I  GPCRs  
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made in P. pastoris (Grunewald et al., 2004; Lundström et al., 2006; Andre et 
al., 2006). It appears likely, therefore, that attachment of this domain to the C-
terminus of other MPs will increase their production levels in P. pastoris also. 
Increased expression helps to reduce the detergent costs associated with making 
large quantities of protein through reducing the volume of membranes required 
for solubilisation. Moreover, fusion of the biotin acceptor domain to MPs that 
express poorly by themselves in P. pastoris may help to make certain projects 
viable that otherwise would remain impossible. The biotin acceptor domain can 
also be biotinylated in vitro by treatment with recombinant biotin ligase. This 
then allows the target MP to be immobilised using (strept)avidin resin. This is an 
elegant  feature  of  the  expression  vector,  and  is  compatible  not  only  with 
purifying  low-abundance  MPs  but  also  with  drug  design  techniques  such  as 
surface  Plasmon  resonance  (SPR)  or  target  immobilized  NMR  screening  (TINS) 
(Vanwetswinkel et al., 2005) where the protein of interest has to be immobilised 
prior to use with molecular and/or fragment libraries. 
A considerable amount of time was spent developing an optimised P. pastoris 
fermentation protocol for make recombinant MPs at an induction temperature of 
22°C. The developed methodology allowed both the hA2aR and hSI to be made 
with a production level >10 mg protein per litre of culture (which is more than 
sufficient  for  structure-determination  experiments  by  way  of  X-ray 
crystallography).  However,  the  protein  produced  could  equally  be  used  in 
nuclear magnetic resonance (NMR) experiments. NMR is an excellent structural 
approach that gives information regarding protein motion at the molecular level 
complementary to that obtained from X-ray crystallography (which gives highly-
detailed information on the three-dimensional structures of proteins trapped in 
particular conformations). Several MPs have had their structures solved by NMR 
most of which have been of bacterial origin (e.g. Arora et al., 2001; Yu et al., 
2005;  van  Horn  et  al.,  2009).  Notably  exceptions  include  archael  sensory 
rhodopsin  II  (Gautier  et  al.,  2010)  and  human  VDAC-1  (Hiller  et  al.,  2008; 
Bayrhuber et al., 2008). One of the major bottlenecks that has prevented the 
wide-spread use of NMR with mammalian MPs lies in the difficulties of obtaining 
labelled, functionally expressed protein for analysis. Traditionally, proteins for  
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NMR experiments are made in E. coli or yeast as these organisms both grow on 
minimal  media  into  which  heavy  atom  labels  can  be  introduced.  At  present, 
however, most academic groups are unable to produce ‘active’ mammalian MPs 
in either bacteria or yeast. The main advantage of the optimised fermentation 
protocol described in this thesis is that it can be readily adapted for labelling 
mammalian MPs with heavy atoms including 
15N, 
13C and 
2H. As the yeast are 
grown on a minimal media, 
15N labelling can be achieved by using 
15N ammonium 
hydroxide (as this is the sole nitrogen source used during fermentations), 
13C 
labelling through feeding with 
13C methanol and 
2H labelling through making up 
the basal media in D2O (not H20). The quantities of hA2aR and hSI that can be 
made per fermentation are more than sufficient for NMR analysis, and this is an 
area of research that I would like to have pursued if there had been sufficient 
time.   
As demonstrated in this thesis, yeasts are powerful hosts for the overproduction 
of mammalian MPs. They are, however, far from being ideal cells for making 
human  MPs  as  they  differ  from  higher  eukaryotes  both  in  the  type  of 
glycosylation that they perform and sterol that they make. Although fungi and 
mammals share the initial steps of protein glycosylation (making the same core 
structure  Man8-GlcNAc2),  the  final  glycans  attached  to  specific  asparagine 
residues in glycoproteins are significantly different (Gemmill and Trimble, 1999). 
In  mammals,  regular,  complex  N-glycans  of  defined  size  are  attached  to  the 
protein.  In  yeast,  however,  numerous  mannose  sugars  are  added  to  the  core 
structure as the glycoprotein passes through the Golgi giving hypermannosylated 
N-glycans (with upto 100 mannose residues sometimes attached). As a result, 
glycoproteins made by yeast are highly-heterogenous in their composition and 
are  incompatible  with  protein  crystallisation.  This  problem  can  be  overcome 
either by using glycosylation-deficient mutants (in which the asparagines that 
are  glycosylated  are  mutated  to  glutamine)  or  by  enzymatic  treatment  of 
purified  glycoproteins  with  glycosidases  in  vitro.  In  recent  years,  however, 
strains  of  P.  pastoris  have  been  engineered  in  such  a  way  that  the  yeast 
performs  uniform  complex  N-glycosylation  adding  defined  glycans  that  are 
terminally  sialylated  (Choi  et  al.,  2003;  Hamilton  et  al.,  2003;  Wildt  and  
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Gerngross, 2005; Hamilton et al., 2006; Hamilton and Gerngross, 2007). Such 
strains  have  been  used  to  make  recombinant  erythropoietin  with  biological 
activity (Hamilton et al., 2006). As yet, these genetically-modified versions of P. 
pastoris have not been used for the recombinant production of human MPs. They 
would, however, make excellent hosts for those human MPs where glycosylation 
is essential for the protein’s activity.  
A  further  drawback  of  using  yeast  for  making  mammalian  MPs  is  that  their 
membranes  do  not  contain  any  cholesterol  –  instead  they  contain  ergosterol. 
Although  cholesterol  and  ergosterol  have  similar  chemical  structures, 
biologically they are non-equivalent (Opekarova and Tanner, 2003). Moreover, it 
is known that cholesterol is essential for maintaining the stability and function 
of many mammalian membrane proteins (e.g. Lagane et al., 2000; Tate, 2001; 
Opekarova and Tanner, 2003). It is likely, therefore, that a strain of yeast that 
synthesises cholesterol instead of ergosterol will be a superior host for making 
human  MPs  compared  to  wild-type.  Currently,  work  is  underway  within  the 
Fraser group to make cholesterol biosynthetic versions of both S. cerevisiae and 
P. pastoris with a view to determining their capacity to make mammalian MPs 
(personal communication, Dr. Niall Fraser).  
Although it is widely recognised that mammalian MPs are considerably less stable 
in detergent solution than ones of bacterial origin, it is poorly understood why. 
There is an emerging body of evidence that strongly suggests that cholesterol is 
a critical determinant of mammalian MP stability in the membrane, detergent 
solution as well as in lipidic crystallisation matrices. It is possible to ‘dope’ both 
cubic and sponge phases with cholesterol. Expression hosts can be chosen that 
have  cholesterol-containing  membranes.  However,  the  issue  of  stabilising 
mammalian  MPs  in  detergent  solution  remains.  One  possible  approach  is  to 
create  mutants  such  as  Rag23  (Magnani  et  al.,  2008)  which  have  sufficient 
thermostability  in  detergent  solution  that  they  do  not  have  any  need  for 
cholesterol.  However,  the  most  direct  approach  to  solving  the  problem  of 
protein instability in detergent solution is to devise novel reagents that mimic 
mammalian membranes more closely than existing commercially-available ones. 
Of  note,  three  recently  described  detergents  (the  maltose-neopentyl  glycol  
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(MNG) amphiphiles (Chae et al., 2010) and two cholesterol based detergents -   
facial amphiphiles (Zhang et al., 2007) and ChoBiMalt (Howell et al., 2010)) -
have been shown to be useful tools for stabilising and crystallising mammalian 
MPs in and from detergent solution (Chae et al. 2010; Annalora et al., 2010; Gay 
et  al.,  2010;  He  et  al.,  2010;  Howell  et  al.,  2010).  I  would  be  particularly 
interested  to  find  out  if  the  cholesterol-detergent  ChoBiMalt  (cholesterol  – 
bimaltoside)  could  stabilise  the  hA2aR  in  the  same  way  as  CHS  does  without 
driving receptor aggregation during protein purification (as was observed in my 
work). 
The CPM assay was an excellent tool for understanding the buffer (type and pH) 
and salt preferences of SI in detergent solution. Using the information obtained 
from  the  denaturation  assays,  it  was  possible  to  purify  SI  in  the  short-chain 
detergent DM without it becoming aggregated using sodium phosphate as buffer. 
Since  I  finished  in  the  lab,  the  Fraser  group  have  since  gone  onto  purify 
monodisperse  SI  in  NM  using  ammonium  phosphate  buffer  (Dr.  Niall  Fraser, 
personal communication). Such thermostability for a wild-type protein is rather 
unusual but suggests that hSI will make a good construct for structural studies 
(both by X-ray crystallography and NMR). When trying to crystallise any protein 
(membrane  or  otherwise),  the  first  step  usually  involves  using  a  range  of 
commercially  available  sparse  matrix  crystallisation  screens  to  try  to  identify 
conditions where the protein of interest comes out of solution to form regular 
crystals.  Once  “hits”  have  been  identified,  the  crystallisation  conditions  are 
optimised  in  an  attempt  to  obtain  crystals  that  diffract  to  high-resolution. 
However, the results from the SI thermostability assays suggests that, at least 
for this enzyme, the probability of getting crystals from a sparse-matrix will be 
low as the protein is only stable in a limited range of conditions (ammonium or 
sodium phosphate, acidic pH). This suggestion was borne out from the limited 
number of crystallisation trays that I set-up. Rather, it seems sensible to try to 
find  crystallisation  conditions  in  which  SI  has  known  stability  around  the 
enzyme’s isoelectric point (pI) – pH 6.3. If time had allowed, I would have used 
the robotic systems in the lab to make a series of screens using either sodium or 
ammomium  phosphate  as  buffer  varing  the  pH  between  5.5  and  7.5  in  
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combination  with  different  types  and  concentrations  of  PEG.  Hopefully,  this 
approach will yield some SI crystal hits.  
Although the CPM assay can be used to devise a purification scheme that yields 
monodisperse mammalian MPs in short-detergents, there are no guarantees that 
it will be possible to obtain protein crystals in the limited range of conditions in 
which the protein of interest is stable. Therefore, it is likely that the best way 
for  getting  crystals  of  mammalian  MPs  will  be  in  either  the  lipidic  cubic-  or 
sponge-phase. It is no surprise then that all but one of the ligand-activated GPCR 
structures that have been solved to date (the human β2 adrenoceptor (Cherezov 
et al., 2007; Hanson et al., 2008); the human adenosine 2a receptor (Jaakola et 
al.,  2008);  the  human  CXCR4  chemokine  receptor  (Wu  et  al.,  2010)  and  the 
dopamine D3 receptor (Chien et al., 2010)) used diffraction data collected from 
crystals grown in the lipidic cubic phase. Recognising the importance of cubic- 
and sponge-phases, I have established a cholesterol-doped version of a sparse-
matrix  lipidic-sponge  phase  crystallisation  screen.  Although  there  was  only 
limited usefullness for this screen with SI, it is likely that cholesterol-sponges 
will become increasing used within the Fraser lab as their attention turns from 
making to trying to crystallise human MPs.  
Lastly, although it was possible to purify a thermostable mutant of the hA2aR 
and hSI to homogeneity, the membrane-enzyme was considerably easier to work 
with. This is not surprising as SI is likely to have a rigid-structure where as the 
hA2aR is likely to have considerable conformational flexibility. This raises the 
issue  of  target-selection  when  setting  out  trying  to  solve  the  structure  of  a 
mammalian MP. Proteins that are similar to SI are likely to be considerably more 
tractable  to  work  than  GPCRs,  and  maybe  amenable  to  a  high-throughput 
structural pipeline approach. In contrast, GPCRs should only be worked on one at 
a  time  by  any  given  person  due  to  the  extra  difficulties  involved  in  getting 
sufficient stable protein for structural studies.    
Over the next 5-10 years, I expect that there is going to be a rapid increase in 
the number of human membrane proteins that have had their structures solved. 
This will in no small part be due to the technologies that have recently been and  
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are  currently  being  developed  (such  as  the  ones  presented  here)  that  allow 
milligram quantities of stable, functional and monodisperse membrane proteins 
to  be  produced.  Furthermore,  the  use  of  lipidic  crystallisation  approaches 
(including  both  the  cubic-  and  sponge-phase)  for  obtaining  MP  crystals  that 
diffract  to  high-resolution  are  likely  to  become  considerably  more  prevalent 
than they are today.  
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